US20240041868A1 - Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors - Google Patents

Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors Download PDF

Info

Publication number
US20240041868A1
US20240041868A1 US18/328,364 US202318328364A US2024041868A1 US 20240041868 A1 US20240041868 A1 US 20240041868A1 US 202318328364 A US202318328364 A US 202318328364A US 2024041868 A1 US2024041868 A1 US 2024041868A1
Authority
US
United States
Prior art keywords
imidazo
pyridyl
pyrazin
phenyl
phenol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US18/328,364
Inventor
Warren C. LAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pathways Neuro Pharma Inc
Original Assignee
Pathways Neuro Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pathways Neuro Pharma Inc filed Critical Pathways Neuro Pharma Inc
Priority to US18/328,364 priority Critical patent/US20240041868A1/en
Assigned to Pathways Neuro Pharma, Inc. reassignment Pathways Neuro Pharma, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Lau, Warren C.
Publication of US20240041868A1 publication Critical patent/US20240041868A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase

Abstract

The present invention provides methods for inhibiting Fyn kinase, using 5-3-pyridin-2-amine, 6-3-imidazo[1,2-a] pyrazine, 6-3-imidazo[1,2-b] pyridazine, N-(5-imidazo [2,1-b][1,3,4] thiadiazol-2-yl)-amine, 4-3-1H-pyrazolo[3,4-b] pyridine, and N-(3-imidazo [1,2-b] pyridazin-6-yl) amine compounds and methods of treatment, prevention, inhibition or amelioration of diseases and conditions associated with Fyn kinase using such compounds.

Description

    CROSS-REFERENCE TO RELATED APPLICATION(S)
  • The present application is a continuation of U.S. patent application Ser. No. 16/896,663, filed Jun. 9, 2020, which is a continuation of U.S. patent application Ser. No. 15/758,274, filed Mar. 7, 2018 (now U.S. Pat. No. 10,688,093), which is a 35 U.S.C. 371 National Stage of International Application Number PCT/US2016/050776, filed Sep. 8, 2016, which claims priority from U.S. Provisional Patent Application No. 62/216,349 filed Sep. 9, 2015, the contents of each of which are incorporated herein by reference.
    • TECHNICAL FIELD
  • The present invention relates to methods for inhibiting, regulating or modulating the activity of Fyn kinase, using compounds or pharmaceutical compositions containing such compounds and methods of treatment using the compounds or compositions to treat diabetes, pre-diabetes, metabolic conditions, immune disorders, cancer and neurodegenerative disorders such as Multiple Sclerosis, Alzheimer's and Parkinson's disease.
    • BACKGROUND
  • Fyn kinase, a cytoplasmic Src family tyrosine kinase, plays an important role in many physiologic processes and is ubiquitous in human cells. Fyn kinase is primarily found on the cytoplasmic face of the plasma membrane where it phosphorylates tyrosine residues of a number of different enzymes involved in the signaling pathways associated with various cell-surface receptors. Fyn kinase is involved in cellular development, apoptosis, and homeostatic regulation, as well as in the development of many different kinds of pathologies. Fyn kinase represents an attractive target for drug therapies designed to control cellular metabolism for management of diabetes, pre-diabetes and general weight loss applications, as an anti-cancer therapeutic and as potential target for the control or prevention of Multiple Sclerosis, Alzheimer's and Parkinson's disease.
  • Fyn knockout mice exhibit increased lipid utilization and increased energy expenditure. Wild-type mice treated with the highly selective Src family kinase inhibitor SU6656, exhibit similar increases in lipid utilization and energy utilization, whereas the Fyn knockout strains show no increase in either parameter upon treatment with SU6656 (WO 2011/119199). Both the Fyn knockout and SU6656 treated mice have significantly reduced fat mass relative to untreated or genetically matched Fyn-competent control mice. Treatment with SU6656 appears to reduce adiposity and promote weight loss, likely through a Fyn-kinase-dependent mechanism.
  • Fyn kinases ability to regulate fatty acid oxidation and increase energy expenditure is thought to result from its affect on sequestration of LKB1 to the nucleus of skeletal muscle cells. Fyn kinase phosphorylates LKB1 present in the cytoplasm of such cells and the phosphorylated LKB1 is preferentially localized to the nucleus where it has little or no access to AMPK, which is found almost exclusively in the cytoplasm. Thus, LKB1 phosphorylated by Fyn kinase cannot activate AMPK (AMP-dependent protein kinase). Activated AMPK serves as a cellular energy sensor directly regulated by alterations in the intracellular AMP/ATP ratio that occurs during prolonged fasting and re-feeding. At high AMP/ATP ratios activation of AMPK results in phosphorylation and inhibition of Acetyl CoA Carboxylase, thereby increasing fatty acid oxidation and decreasing fatty acid biosynthesis. Specific inhibition of Fyn kinase allows LKB1 to constitutively activate AMPK. In this model inhibition of Fyn kinase results in increased cytoplasmic localization of LKB1, resulting in increased levels of activated AMPK.
  • AMPK also regulates glucose metabolism in liver. Hepatic glucose production that is not regulated by insulin is known to play an important role in development of Type 2 diabetes. The asymptomatic insulin resistance phase of Type 2 diabetes is generally followed by defects in insulin secretion that result in severe hyperglycemia if left untreated. Chronic high glucose levels have been shown to result in the death of pancreatic β-cells and loss of insulin production altogether. Activated AMPK reduces insulin secretion and is thought to have a pro-apoptotic effect on pancreatic β-cells.
  • Like many Src family kinases, Fyn plays a role in regulating several physiological processes including cellular growth, proliferation, morphogenesis and motility. Fyn has also been recognized as a potential oncogene and has been shown to be capable of inducing the fully tumorigenic phenotype. Fyn interacts with a number of cancer related pathways. Fyn is a mediator of growth-factor induced anti-apoptotic activity of Akt/PKB, and regulates Rac and Rho GTPases and activates the ERK/MAPK pathways. Fyn also plays a key role in the regulation of matrix formation and degradation, which is important for matrix remodeling and cellular adherence.
  • In addition to metabolic and oncogenic regulation, Fyn is recognized as playing a key role in T-cell development as well as dendritic maturation of cells within the central nervous system. Further, inhibition of Fyn kinase is viewed as an attractive therapeutic target for treatment of Multiple Sclerosis, Alzheimer's and Parkinson's disease. It is the object of this disclosure to describe pharmaceutically effective inhibitors of Fyn kinase with enhanced specificity for therapeutic treatment of one or more of the pathologies in which Fyn kinase plays a role.
  • Structurally, Fyn kinase is relatively well characterized despite the lack of a complete high-resolution structure. The enzyme comprises 537 amino acids in a single polypeptide chain organized into 4 domains, with a molecular weight of 59 kilodaltons. The N-terminal membrane anchoring domain (SH4) possesses myristylated or palmitylated residues essential for proper enzyme trafficking and localization to the cytoplasmic membrane, immediately adjacent to this are the SH3 and SH2 domains, which play critical roles in the interaction of Fyn kinase with its protein targets, followed by a flexible linker connecting the C-terminal tyrosine kinase domain (SH1). Although a complete high-resolution structure of the entire Fyn kinase protein is not available, such structures are available for each of the SH2, 3 and 4 domains, individually.
  • The SH2 domain of Fyn kinase binds phosphotyrosine-containing sequences and functions as a target recognition domain. The SH3 domain promiscuously complexes with polyproline peptides and plays a role in mediating protein-protein interactions between Fyn kinase and other polypeptides. Interaction between the SH3 and SH2 domains enhances the specificity of ligand binding and regulates the activity of the kinase (SH4) domain.
  • The well conserved SH4 domain contains two potential inhibitor binding sites, the first, sensitive to non-specific competitive inhibitors of ATP such as staurosporine, represents the actual ATP binding site of the kinase domain, whereas the second site, immediately adjacent to the ATP binding pocket, is oriented towards the SH2 domain. This second site may be occupied in such a way that ATP binding at the first site is not directly blocked. However, free access to the second site is blocked by the presence of ATP at the first site, and hence, inhibitors targeted to the second site display pseudo-competitive kinetics with respect to the availability of ATP. Although the ATP binding site is highly conserved among Src kinases, the amino acids comprising the hydrophobic pocket typical of the second site are less conserved and may represent the best target for Fyn-specific inhibitors. Regardless, the SH1 domain is essential for the activity of Fyn kinase on any of its protein targets, and has been targeted for the development of potent Fyn kinase inhibitors.
  • Existing Fyn kinase inhibitors all suffer from a lack of specificity and although many Fyn kinase inhibitors have been isolated, most significantly cross-react with other Src family enzymes. Some of the best known Fyn kinase inhibitors include: phenolic compounds such as rosmarinic acid, (−)-epigallocatechin gallate and myricetin; the pyrazolol[3,4-d] pyrimidines PP1, PP2, and various derivatives thereof; as well as other fused pyrimidine compounds such as benzyl 21-methoxy-5,7,19-trioxa-2,13,24,26-tetraazapentacyclo [18.6.2.03,11.04,8.023,27]octacosa-1(26),3(11),4(8),9,20,22,24,27-octaene-13-carboxylate (Janssen Pharmaceuticals, U.S. Pat. No. 8,492,377) and CT5263 and CT5102 (CellTech). The structure of a few of these compounds and their associated IC50 (when known) and logP values are presented in Table 1.
  • TABLE 1
    Known Fyn kinase inhibitors
    IC50 FYN logP Common
    Structure IUPAC name (μM) (consensus) name
    Figure US20240041868A1-20240208-C00001
         		(2R)-3-(3,4-dihydroxy- phenyl)-2-{[(2E)-3-(3, 4-dihydroxyphenyl) prop-2-enoyl]oxy} propanoic acid 1.3 3.00 rosmarinic acid
    Figure US20240041868A1-20240208-C00002
         		(2R,3R)-5,7-dihydroxy- 2-(3,4,5-trihydroxy- phenyl)-3,4-dihydro-2H- 1-benzopyran-3-yl- 3,4,5 unknown 3.08 (−)- epigallocatech in gallate
    Figure US20240041868A1-20240208-C00003
         		5,7-dihydroxy-2-(3,4,5- trihydroxyphenyl)-4H- chromen-4-one unknown 0.65 myricetin
    Figure US20240041868A1-20240208-C00004
         		1-tert-butyl-3-(4- methylphenyl)-1H- pyrazolo[3,4-d] pyrimidin-4-amine 0.006 3.23 PP1 (Pfizer)
    Figure US20240041868A1-20240208-C00005
         		1-tert-butyl-3-(4-chloro- phenyl)-1H- pyrazolo[3,4-d] pyrimidin-4-amine 0.006 3.32 PP2 (Pfizer)
    Figure US20240041868A1-20240208-C00006
         		N-(4-{4-amino-1- [(1r,4r)-4-(4-methyl- piperazin-1-yl)cyclo- hexyl]-1H-pyrazolo [3,4-d]pyrimidin-3-yl}- 2-methoxyphenyl)-1- methyl-1H-indole-2- carboxamide 0.330 3.81 A-420983 (Abbott)
    Figure US20240041868A1-20240208-C00007
         		benzyl- 21-methoxy-5,7,19- trioxa-2,13,24,26- tetraazapentacyclo[18. 6.2.03,11.04,8.023,27]oct- acosa-1(26),3(11),4(8), 9,20,22,24,27- octaene-13-carboxylate 0.00669 5.13 Compound B50 (U.S. Pat. No. 8,492,377) (Janssen Pharmaceuticals)
    Figure US20240041868A1-20240208-C00008
         		9-methoxy-N-{3-me- thoxy-4-[3-(pyrrolidin- 1-yl)propyl]phenyl}- 6,6-dimethyl-5H,6H- benzo[h]quinazolin- 2-amine 0.008 6.12 CT5263 (CellTech)
    Figure US20240041868A1-20240208-C00009
         		N-{4-[2- (dimethylamino) ethoxy]-3,5-dimethyl- phenyl}-9-methoxy- 5H, 6H-benzo[h] quinazolin-2-amine 0.008 5.49 CT5102 (CellTech)
    • SUMMARY
  • Among its many embodiments, the present invention comprises methods for inhibiting Fyn kinase using 5-[R2]-3-[R1] pyridin-2-amine compounds or pharmaceutical compositions comprising such compounds and methods of treatment, prevention, inhibition or amelioration of one or more of the diseases or conditions associated with Fyn kinase.
  • In one aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being 5-[R2]-3-[R1] pyridin-2-amine, wherein R1 and R2 are each individually selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.
  • In another aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being one of the 5-[R2]-3-[R1] pyridin-2-amine derivatives of Tables 3 and 4.
  • In another aspect, the present invention provides a method of treating, or slowing progression of a disease associated with Fyn kinase, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being at least one of the 5-[R2]-3-[R1] pyridin-2-amines described above, or a pharmaceutically acceptable salt or solvate thereof.
  • In another embodiment, the present invention comprises methods for inhibiting Fyn kinase using 6-[R2]-3-[R1] imidazo[1,2-a] pyrazine compounds or pharmaceutical compositions comprising such compounds and methods of treatment, prevention, inhibition or amelioration of one or more of the diseases or conditions associated with Fyn kinase.
  • In one aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being 6-[R2]-3-[R1] imidazo[1,2-a] pyrazine, wherein R1 and R2 are each individually selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.
  • In another aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being one of the 6-[R2]-3-[R1] imidazo[1,2-a]pyrazine derivatives of Tables 3 and 4.
  • In another aspect, the present invention provides a method of treating, or slowing progression of a disease associated with Fyn kinase, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being at least one of the 6-[R2]-3-[R1] imidazo[1,2-a] pyridines described above, or a pharmaceutically acceptable salt or solvate thereof.
  • In another embodiment, the present invention comprises methods for inhibiting Fyn kinase using 6-[R2]-3-[R1] imidazo[1,2-b] pyridazine compounds or pharmaceutical compositions comprising such compounds and methods of treatment, prevention, inhibition or amelioration of one or more of the diseases or conditions associated with Fyn kinase.
  • In one aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being 6-[R2]-3-[R1] imidazo [1,2-b] pyridazine, wherein R1 and R2 are each individually selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.
  • In another aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being one of the 6-[R2]-3-[R1] imidazo [1,2-b]pyridazine derivatives of Tables 3 and 4.
  • In another aspect, the present invention provides a method of treating, or slowing progression of a disease associated with Fyn kinase, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being at least one of the 6-[R2]-3-[R1] imidazo [1,2-b] pyridoxines described above, or a pharmaceutically acceptable salt or solvate thereof.
  • In another embodiments, the present invention comprises methods for inhibiting Fyn kinase using N-(5-[R2] imidazo [2,1-b][1,3,4] thiadiazol-2-yl)[R1]-amine compounds or pharmaceutical compositions comprising such compounds and methods of treatment, prevention, inhibition or amelioration of one or more of the diseases or conditions associated with Fyn kinase.
  • In one aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being N-(5-[R2]imidazo[2,1-b][1,3,4] thiadiazol-2-yl)[R1]-amine, wherein R1 and R2 are each individually selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.
  • In another aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being one of the N-(5-[R2]imidazo[2,1-b][1,3,4]thiadiazol-2-yl)[R1]-amine derivatives of Tables 3 and 4.
  • In another aspect, the present invention provides a method of treating, or slowing progression of a disease associated with Fyn kinase, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being at least one of the N-(5-[R2] imidazo [2,1-b] [1,3,4] thiadiazol-2-yl) [R1]-amines described above, or a pharmaceutically acceptable salt or solvate thereof.
  • In another embodiment, the present invention comprises methods for inhibiting Fyn kinase using 4-[R2]-3[R1]-1H-pyrazolo[3,4-b] pyridine compounds or pharmaceutical compositions comprising such compounds and methods of treatment, prevention, inhibition or amelioration of one or more of the diseases or conditions associated with Fyn kinase.
  • In one aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being 4-[R2]-3[R1]-1H-pyrazolo[3,4-b] pyridine, wherein R1 and R2 are each individually selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.
  • In another aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being one of the 4-[R2]-3[R1]-1H-pyrazolo[3,4-b] pyridine derivatives of Tables 3 and 4.
  • In another aspect, the present invention provides a method of treating, or slowing progression of a disease associated with Fyn kinase, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being at least one of the 4-[R2]-3[R1]-1H-pyrazolo[3,4-b] pyridines described above, or a pharmaceutically acceptable salt or solvate thereof.
  • In another embodiment, the present invention comprises methods for inhibiting Fyn kinase using N-(3-[R2] imidazo [1,2-b] pyridazin-6-yl) [R1] amine compounds or pharmaceutical compositions comprising such compounds and methods of treatment, prevention, inhibition or amelioration of one or more of the diseases or conditions associated with Fyn kinase.
  • In one aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being N-(3-[R2] imidazo [1,2-b] pyridazin-6-yl) [R1]amine, wherein R1 and R2 are each individually selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.
  • In another aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being one of the N-(3-[R2] imidazo [1,2-b]pyridazin-6-yl) [R1] amine derivatives of Tables 3 and 4.
  • In another aspect, the present invention provides a method of treating, or slowing progression of a disease associated with Fyn kinase, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being at least one of the N-(3-[R2] imidazo [1,2-b] pyridazin-6-yl) [R1] amine described above, or a pharmaceutically acceptable salt or solvate thereof.
  • In another aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound selected from the group consisting of N-[3-[6-(2-furylmethylamino)pyrazin-2-yl]phenyl]acetamide, 4-[6-[1-(hydroxymethyl)propylamino]pyrazin-2-yl]phenol, 2-[[6-(5-isopropyl-2-methoxy-phenyl)pyrazin-2-yl]amino]butan-1-ol, 6-(3-aminophenyl)-N-benzyl-pyrazin-2-amine, 2-[[6-(4-aminophenyl)pyrazin-2-yl]amino]butan-1-ol, N-[3-(dimethylamino)propyl]-3-[6-(4-methoxyphenyl)pyrazin-2-yl]benzamide, 2-methoxy-4-[6-(4-methoxyphenyl)pyrazin-2-yl]phenol, N-[3-[6-(4-methoxyphenyl)pyrazin-2-yl]phenyl]acetamide, N-[3-[6-(3-hydroxyphenyl)pyrazin-2-yl]phenyl]acetamide, 3-[5-(3-furylmethylamino)-3-pyridyl]phenol, N-[3-[5-(3,4,5-trimethoxyanilino)-3-pyridyl]phenyl]acetamide, 3-[(3-methoxyphenyl)methyl]-5-(3,4,5-trimethoxyphenyl)-1H-imidazo[4,5-b]pyrazin-2-one, N,N-dimethyl-3-[2-oxo-3-[(1S)-1-phenylethyl]-1H-imidazo[4,5-b]pyrazin-5-yl]benzamide, 5-[3-(dimethylamino)phenyl]-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine, 3-[5-[(6-methoxy-3-pyridyl)amino]pyrazolo[1,5-a]pyrimidin-3-yl]phenol, 3-(3-methoxyphenyl)-N-(6-methoxy-3-pyridyl)pyrazolo[1,5-a]pyrimidin-5-amine, 1-[3-[5-[(6-methoxy-3-pyridyl)amino]pyrazolo[1,5-a]pyrimidin-3-yl]phenyl]ethanone, N-[5-[[3-(3-hydroxyphenyl)pyrazolo[1,5-a]pyrimidin-5-yl]amino]-2-methyl-phenyl]methanesulfonamide, 3-(3,4-dimethoxyphenyl)-N-(3-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-5-amine, N-(3-pyridylmethyl)-3-(3,4,5-trimethoxyphenyl)pyrazolo[1,5-a]pyrimidin-5-amine, N-(4-isopropylphenyl)-3-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-5-amine, 3-(5-methoxy-3-pyridyl)-N-(4-morpholinophenyl)pyrazolo[1,5-a]pyrimidin-5-amine, 3-(3-aminophenyl)-N-(3-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-5-amine, 3-(2-methoxyphenyl)-N-(3-pyridylmethyl) pyrazolo[1,5-a]pyrimidin-5-amine, (E)-3-[3-[5-(3-pyridylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl]phenyl]prop-2-enoic acid, N-[3-(dimethylamino)propyl]-4-[6-(2-fluoro-3-methoxy-phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]benzamide, 6-(1H-indol-5-yl)-N-methyl-pyrazin-2-amine, N-ethyl-2-(3,4,5-trimethoxyanilino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxamide, 6-propyl-N-(3,4,5-trimethoxyphenyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-2-amine, [2-[3-(dimethylamino)anilino]-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl]-(2-methoxyphenyl)methanone, N-[3-(4-fluorophenyl)-6-[4-(morpholine-4-carbonyl)phenyl]imidazo[1,2-a]pyridin-8-yl]formamide, N-[3-(3-acetylphenyl)-6-[4-(morpholine-4-carbonyl)phenyl]imidazo[1,2-a]pyridin-8-yl]formamide, N-[3-(3-chloro-4-fluoro-phenyl)-6-[3-(methanesulfonamido)phenyl]imidazo[1,2-a]pyridin-8-yl]formamide, N-[3-(4-fluorophenyl)-6-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyridin-8-yl]formamide, 1-methyl-N-[4-(4-methylpiperazin-1-yl)phenyl]-2-[3-(trifluoromethyl)phenyl]pyrrolo[3,2-c]pyridin-6-amine, 1-methyl-N-pyrimidin-4-yl-2-[3-(trifluoromethyl)phenyl]pyrrolo[3,2-c]pyridin-6-amine, 2-(3-fluorophenyl)-1-methyl-N-[4-(4-methylpiperazin-1-yl)phenyl]pyrrolo[3,2-c]pyridin-6-amine, 2-(3-fluorophenyl)-1-methyl-N-pyrimidin-4-yl-pyrrolo[3,2-c]pyridin-6-amine, 1-benzyl-N-[4-(4-methylpiperazin-1-yl)phenyl]-2-(3-pyridyl)pyrrolo[3,2-c]pyridin-6-amine, 2-(1H-pyrazol-4-yl)-N-(2-pyridyl)-1H-pyrrolo[3,2-c]pyridin-6-amine, N-(4-methylsulfonylphenyl)-2-(1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridin-6-amine, 1-benzyl-2-(3-pyridyl)-N-pyrimidin-4-yl-pyrrolo[3,2-c]pyridin-6-amine, N-(3-methoxyphenyl)-2-(1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridin-6-amine, N-(3,4-dimethoxyphenyl)-2-(1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridin-6-amine, 1-benzyl-N-[4-(4-methylpiperazin-1-yl)phenyl]-2-phenyl-pyrrolo[3,2-c]pyridin-6-amine, N-[3-[8-acetamido-3-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]acetamide, N-[3-(3-acetylphenyl)-6-(3-methoxyphenyl)imidazo[1,2-a]pyridin-8-yl]acetamide, N-[3-(3-acetylphenyl)-6-(2,4-dimethoxyphenyl)imidazo[1,2-a]pyridin-8-yl]acetamide, N-[3-(3-acetylphenyl)-6-(2-methoxyphenyl)imidazo[1,2-a]pyridin-8-yl]acetamide, N-[6-(4-aminophenyl)-3-(4-fluorophenyl)imidazo[1,2-a]pyridin-8-yl]acetamide, N-[3-(3-acetylphenyl)-6-[4-(morpholine-4-carbonyl)phenyl]imidazo[1,2-a]pyridin-8-yl]acetamide, N,N-dimethyl-4-[4-[4-(4-methylpiperazin-1-yl)anilino]-1H-pyrrolo[3,2-c]pyridin-2-yl]benzamide, 4-[2-(3,5-dimethoxyphenyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]morpholine, N-[4-[[2-(2-methoxyphenyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]amino]phenyl]acetamide, 2-(2-methoxyphenyl)-1-methyl-N-[3-(trifluoromethyl)phenyl]pyrrolo[3,2-c]pyridin-4-amine, 6-(3-chlorophenyl)-3-(3,4-dimethoxyphenyl)pyrazolo[1,5-a]pyrimidin-7-amine, 5-amino-4-(1H-benzimidazol-2-yl)-1-(1,3-benzodioxol-5-yl)-2H-pyrrol-3-one, 8-(2,5-dimethoxyphenyl)-7-(4-fluorophenyl)-1-methyl-3H-imidazo[1,2-g]purine-2,4-dione, methyl 2-amino-1-(3-hydroxyphenyl)pyrrolo[3,2-b]quinoxaline-3-carboxylate, 2-(3,4-dimethoxyphenyl)-6-hydroxy-chromen-4-one, 2-amino-1-(3-methoxyphenyl)pyrrolo[3,2-b]quinoxaline-3-carboxamide.
  • In another aspect, the present invention provides a method of treating, or slowing progression of a disease associated with Fyn kinase, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, wherein the compound is selected from the group consisting of N-[3-[6-(2-furylmethylamino)pyrazin-2-yl]phenyl]acetamide, 4-[6-[1-(hydroxymethyl)propylamino]pyrazin-2-yl]phenol, 2-[[6-(5-isopropyl-2-methoxy-phenyl)pyrazin-2-yl]amino]butan-1-ol, 6-(3-aminophenyl)-N-benzyl-pyrazin-2-amine, 2-[[6-(4-aminophenyl)pyrazin-2-yl]amino]butan-1-ol, N-[3-(dimethylamino)propyl]-3-[6-(4-methoxyphenyl)pyrazin-2-yl]benzamide, 2-methoxy-4-[6-(4-methoxyphenyl)pyrazin-2-yl]phenol, N-[3-[6-(4-methoxyphenyl)pyrazin-2-yl]phenyl]acetamide, N-[3-[6-(3-hydroxyphenyl)pyrazin-2-yl]phenyl]acetamide, 3-[5-(3-furylmethylamino)-3-pyridyl]phenol, N-[3-[5-(3,4,5-trimethoxyanilino)-3-pyridyl]phenyl]acetamide, 3-[(3-methoxyphenyl)methyl]-5-(3,4,5-trimethoxyphenyl)-1H-imidazo[4,5-b]pyrazin-2-one, N,N-dimethyl-3-[2-oxo-3-[(1S)-1-phenylethyl]-1H-imidazo[4,5-b]pyrazin-5-yl]benzamide, 5-[3-(dimethylamino)phenyl]-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine, 3-[5[(6-methoxy-3-pyridyl)amino]pyrazolo[1,5-a]pyrimidin-3-yl]phenol, 3-(3-methoxyphenyl)-N-(6-methoxy-3-pyridyl)pyrazolo [1,5-a]pyrimidin-5-amine, 1-[3-[5-[(6-methoxy-3-pyridyl)amino]pyrazolo[1,5-a]pyrimidin-3-yl]phenyl]ethanone, N-[5-[[3-(3-hydroxyphenyl)pyrazolo[1,5-a]pyrimidin-5-yl]amino]-2-methyl-phenyl]methanesulfonamide, 3-(3,4-dimethoxyphenyl)-N-(3-pyridylmethyl)pyrazolo [1,5-a]pyrimidin-5-amine, N-(3-pyridylmethyl)-3-(3,4,5-trimethoxyphenyl)pyrazolo[1,5-a]pyrimidin-5-amine, N-(4-isopropylphenyl)-3-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-5-amine, 3-(5-methoxy-3-pyridyl)-N-(4-morpholinophenyl)pyrazolo[1,5-a]pyrimidin-5-amine, 3-(3-aminophenyl)-N-(3-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-5-amine, 3-(2-methoxyphenyl)-N-(3-pyridylmethyl)pyrazolo[1,5-a]pyrimidin-5-amine, (E)-3-[3-[5-(3-pyridylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl]phenyl]prop-2-enoic acid, N-[3-(dimethylamino)propyl]-4-[6-(2-fluoro-3-methoxy-phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]benzamide, 6-(1H-indol-5-yl)-N-methyl-pyrazin-2-amine, N-ethyl-2-(3,4,5-trimethoxyanilino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxamide, 6-propyl-N-(3,4,5-trimethoxyphenyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-2-amine, [2-[3-(dimethylamino)anilino]-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl]-(2-methoxyphenyl) methanone, N-[3-(4-fluorophenyl)-6-[4-(morpholine-4-carbonyl)phenyl]imidazo[1,2-a]pyridin-8-yl]formamide, N-[3-(3-acetylphenyl)-6-[4-(morpholine-4-carbonyl)phenyl]imidazo[1,2-a]pyridin-8-yl]formamide, N-[3-(3-chloro-4-fluoro-phenyl)-6-[3-(methanesulfonamido)phenyl]imidazo[1,2-a]pyridin-8-yl]formamide, N-[3-(4-fluorophenyl)-6-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyridin-8-yl]formamide, 1-methyl-N-[4-(4-methylpiperazin-1-yl)phenyl]-2-[3-(trifluoromethyl)phenyl]pyrrolo[3,2-c]pyridin-6-amine, 1-methyl-N-pyrimidin-4-yl-2-[3-(trifluoromethyl)phenyl]pyrrolo[3,2-c]pyridin-6-amine, 2-(3-fluorophenyl)-1-methyl-N-[4-(4-methylpiperazin-1-yl)phenyl]pyrrolo[3,2-c]pyridin-6-amine, 2-(3-fluorophenyl)-1-methyl-N-pyrimidin-4-yl-pyrrolo[3,2-c]pyridin-6-amine, 1-benzyl-N-[4-(4-methylpiperazin-1-yl)phenyl]-2-(3-pyridyl)pyrrolo[3,2-c]pyridin-6-amine, 2-(1H-pyrazol-4-yl)-N-(2-pyridyl)-1H-pyrrolo[3,2-c]pyridin-6-amine, N-(4-methylsulfonylphenyl)-2-(1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridin-6-amine, 1-benzyl-2-(3-pyridyl)-N-pyrimidin-4-yl-pyrrolo[3,2-c]pyridin-6-amine, N-(3-methoxyphenyl)-2-(1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridin-6-amine, N-(3,4-dimethoxyphenyl)-2-(1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridin-6-amine, 1-benzyl-N-[4-(4-methylpiperazin-1-yl)phenyl]-2-phenyl-pyrrolo[3,2-c]pyridin-6-amine, N-[3-[8-acetamido-3-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]acetamide, N-[3-(3-acetylphenyl)-6-(3-methoxyphenyl)imidazo[1,2-a]pyridin-8-yl]acetamide, N-[3-(3-acetylphenyl)-6-(2,4-dimethoxyphenyl)imidazo[1,2-a]pyridin-8-yl]acetamide, N-[3-(3-acetylphenyl)-6-(2-methoxyphenyl)imidazo[1,2-a]pyridin-8-yl]acetamide, N-[6-(4-aminophenyl)-3-(4-fluorophenyl)imidazo[1,2-a]pyridin-8-yl]acetamide, N-[3-(3-acetylphenyl)-6-[4-(morpholine-4-carbonyl)phenyl]imidazo[1,2-a]pyridin-8-yl]acetamide, N,N-dimethyl-4-[4-[4-(4-methylpiperazin-1-yl)anilino]-1H-pyrrolo[3,2-c]pyridin-2-yl]benzamide, 4-[2-(3,5-dimethoxyphenyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]morpholine, N-[4-[[2-(2-methoxyphenyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]amino]phenyl]acetamide, 2-(2-methoxyphenyl)-1-methyl-N-[3-(trifluoromethyl)phenyl]pyrrolo[3,2-c]pyridin-4-amine, 6-(3-chlorophenyl)-3-(3,4-dimethoxyphenyl)pyrazolo[1,5-a]pyrimidin-7-amine, 5-amino-4-(1H-benzimidazol-2-yl)-1-(1,3-benzodioxol-5-yl)-2H-pyrrol-3-one, 8-(2,5-dimethoxyphenyl)-7-(4-fluorophenyl)-1-methyl-3H-imidazo[1,2-g]purine-2,4-dione, methyl 2-amino-1-(3-hydroxyphenyl)pyrrolo[3,2-b]quinoxaline-3-carboxylate, 2-(3,4-dimethoxyphenyl)-6-hydroxy-chromen-4-one, 2-amino-1-(3-methoxyphenyl)pyrrolo[3,2-b]quinoxaline-3-carboxamide.
  • In another aspect, the present invention provides a method of inhibiting Fyn kinase in a patient, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, the compound being any one of those listed in Tables 3 and 4.
  • In another aspect, the present invention provides a method of treating, or slowing progression of a disease associated with Fyn kinase, the method comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, of at least one compound described above, or a pharmaceutically acceptable salt or solvate thereof. Without limitation, the Fyn kinase inhibitors described here may be utilized to treat Types I and II diabetes, pre-diabetes and may prove effective in facilitating overall weight control, extend longevity and improve physical and mental well-being. In addition, such Fyn kinase inhibitors may improve exercise tolerance and increase the human body's ability to endure physical stress, as well as improve recovery from exercise and physical stress.
  • Fyn kinase inhibitors may be effective cancer therapeutics and may, when administered prophylactically, reduce the occurrence of various cancers in an individual. Due to its central role in intracellular regulatory phosphorylation cascades, Fyn kinase can play diverse roles in many common cancers. In breast cancers Fyn kinase regulates phosphorylation of ERB receptors and has been directly implicated in the genesis of tamoxifen and trastuzumab resistant breast cancers. Fyn kinase is also implicated in many forms of prostate cancer and Fyn expression is unusually high in prostate cancer cells. In liver cancers, and hepatocellular cancers generally, Fyn expression also appears to be significantly elevated. Mutant pancreatic cancer cells transfected with highly expressed kinase-dead Fyn genes have been shown to have decreased liver metastases activity in mouse models, suggesting a model by which Fyn kinase activity regulates cell proliferation and apoptosis. Esophageal and gastric cancers also exhibit high levels of Fyn kinase and such cancers are thought to be particularly sensitive to the epidermal growth factor receptor signaling pathway in which Fyn plays a key role. Fyn also plays a role in cervical and ovarian cancers. Elevated levels of Fyn kinase observed in many such cancers appears to be the result of overexpression of NRDG1, which when suppressed by shRNA treatment results in concomitant decrease in Fyn expression and a subsequent decrease in cell adhesion, migration and invasion activity.
  • Existing Fyn kinase inhibitors are also known to mitigate and lessen the severity of neurodegenerative diseases such as Multiple Sclerosis, Alzheimer's and Parkinson's and the Fyn kinase inhibitors described here may exhibit improved therapeutic efficacy in such treatments. The Fyn kinase inhibitors described here may also be effective in improving recovery from head or spinal trauma as well as promoting overall neurological health.
  • The invention described here relate to pharmacophores identified by analysis of specific chemical, physical and biological properties of a large set of chemical combinations based on a limited set of pharmacores. Such pharmacophores define the relevant parameters necessary to specifically modulate Fyn kinase activity and to provide therapeutic treatment for physiologic and pathologic conditions amenable to treatment by regulation of Fyn kinase activity in patients in need of such treatment.
    • Definitions
  • As used herein and throughout this disclosure, the following terms are to be understood to have the following meaning.
  • “Acyl” means an H—C(O)—, alkyl-C(O)— or cycloalkyl-C(O)—, group in which the various groups are as previously described. The bond to the parent moiety is through the carbonyl. Preferred acyls contain a lower alkyl. Non-limiting examples of suitable acyl groups include formyl, acetyl and propanoyl.
  • “Alcohol” means a functional group of the general formula R—OH, wherein R represents and alkane, alkene or any other carbon-containing group.
  • “Alkyl” means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain. More preferred alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain. “Lower alkyl” means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched. “Alkyl” may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, —NH(alkyl), —NH(cycloalkyl), —N(alkyl)2, carboxy and —C(O)O-alkyl. Non-limiting examples of suitable alkyl groups include methyl, ethyl, n-propyl, isopropyl and t-butyl.
  • “Alkenyl” means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 6 carbon atoms in the chain. Branched means that one or more 20 lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkenyl chain. “Lower alkenyl” means about 2 to about 6 carbon atoms in the chain which may be straight or branched. “Alkenyl” may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl. aryl, cycloalkyl, cyano, alkoxy and -5(alkyl). Non-limiting examples of suitable alkenyl groups include ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n-pentenyl, octenyl and decenyl.
  • “Alkoxy” means an alkyl-O-group. Non-limiting examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy. The bond to the parent moiety is through the ether oxygen.
  • “Alkylene” means a difunctional group obtained by removal of a hydrogen atom from an alkyl group that is defined above. Non-limiting examples of alkylene include methylene, ethylene and propylene.
  • “Alkynyl” means an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkynyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkynyl chain. “Lower alkynyl” means about 2 to about 6 carbon atoms in the chain which may be straight or branched. Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, 2-butynyl and 3-methylbutynyl. “Alkynyl” may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of alkyl, aryl and cycloalkyl.
  • “Alkynylalkyl” means an alkynyl-alkyl-group in which the alkynyl and alkyl are as previously described. Preferred alkynylalkyls contain a lower alkynyl and a lower alkyl group. The bond to the parent moiety is through the alkyl. Non-limiting examples of suitable alkynylalkyl groups include propargylmethyl.
  • “Alkylphosphate” means a compound of the general formula ROP(O)3-, wherein the R represents any alkyl group.
  • “Alkylsulfate” means a compound of the general formula ROS(O)3-, wherein the R represents any alkyl group.
  • “Aryl” means an aromatic monocyclic or multicyclic ring system comprising about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms. The aryl group can be optionally substituted with one or more “ring system substituents” which may be the same or different, and are as defined herein. Non-limiting examples of suitable aryl groups include phenyl and naphthyl.
  • “Aroyl” means an aryl-C(O)-group. The bond to the parent moiety is through the carbonyl. Non-limiting examples of suitable groups include benzoyl and 1-naphthoyl.
  • “Arylalkyl” means an aryl-alkyl-group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non-limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.
  • “Alkylaryl” means an alkyl-aryl-group in which the alkyl and aryl are as previously described. Preferred alkylaryls comprise a lower alkyl group. A non-limiting example of a suitable alkylaryl group is tolyl. The bond to the parent moiety is through the aryl.
  • “Alkylthio” means an alkyl-S-group. Non-limiting examples of suitable alkylthio groups include methylthio and ethylthio. The bond to the parent moiety is through the sulfur.
  • “Arylphosphate” means a compound of the general formula ROP(O)3-, wherein the R represents any aryl group.
  • “Arylsulfate” means a compound of the general formula ROS(O)3-, wherein the R represents any aryl group.
  • “Arylthio” means an aryl-S-group. Non-limiting examples of suitable arylthio groups include phenylthio and naphthylthio. The bond to the parent moiety is through the sulfur.
  • “Alkoxycarbonyl” means an alkyl-O—CO-group. Non-limiting examples of suitable alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl. The bond to the parent moiety is through the carbonyl.
  • “Aryloxycarbonyl” means an aryl-O—C(O)-group. Non-limiting examples of suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl. The bond to the parent moiety is through the carbonyl.
  • “Aralkoxycarbonyl” means an aralkyl-O—C(O)— group. Non-limiting example of a suitable aralkoxycarbonyl group is benzyloxycarbonyl. The bond to the parent moiety is through the carbonyl.
  • “Alkylsulfonyl” means an alkyl-S(O2)-group. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfonyl.
  • “Amide” means a functional group comprising (R1)C(O)N(R2)(R3) wherein the R groups refer to H or organic groups and the carbon and nitrogen atoms are covalently linked. Other amides include “sulfonamides” of the general formula (R1)S(O2)N(R2)(R3), wherein the sulfur and nitrogen atoms are covalently linked; and “phosphoramides” of the general formula (R1)(R2)O(O)N(R3)(R4), wherein the phosphate and the nitrogen are covalently linked. A non-limiting example of an amide is acetamide.
  • “Amine” means a functional group comprising: NH2(R1), a “primary amine”; NH(R1)(R2), a “secondary amine”; N(R1)(R2)(R3), a “tertiary amine”, wherein the bond to the parent moiety runs through the nitrogen.
  • “Arylsulfonyl” means an aryl-S(02)-group. The bond to the parent moiety is through the sulfonyl.
  • “Aralkylthio” means an aralkyl-S-group in which the aralkyl group is as previously described. Non-limiting example of a suitable aralkylthio group is benzylthio. The bond to the parent moiety is through the sulfur.
  • “Arylalkenyl” means an alkenyl-aryl-group. Preferred arylalkenyls comprise a lower alkenyl group. A non-limiting example of a suitable arylalkenyl group is phenylacetylene.
  • “Aryloxy” means an aryl-O-group. Non-limiting examples of suitable aryloxy groups include phenoxy and naphthoxy. The bond to the parent moiety is through the ether oxygen.
  • “Aralkyloxy” means an aralkyl-O-group in which the aralkyl group is as previously described. Non-limiting examples of suitable aralkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy. The bond to the parent moiety is through the ether oxygen.
  • “Composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • “Cyano” means a —CN group in which the bond to the parent moiety is through the carbon.
  • “Cycloalkyl” means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms. Preferred cycloalkyl rings contain about 5 to about 7 ring atoms. The cycloalkyl can be optionally substituted with one or more “ring system substituents” which may be the same or different. and are as defined above. Non-limiting examples of suitable monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Non-limiting examples of suitable multicyclic cycloalkyls include 1-decalinyl, norbomyl, adamantyl and the like.
  • “Cycloalkylalkyl” means a cycloalkyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable cycloalkylalkyls include cyclohexylmethyl, adamantylmethyl and the like.
  • “Cycloalkenyl” means a non-aromatic mono or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms which contain at least one carbon-carbon double bond. Preferred cycloalkenyl rings contain about 5 to about 7 ring atoms. The cycloalkenyl can be optionally substituted with one or more “ring system substituents” which may be the same or different, and are as defined above. Non-limiting examples of suitable monocyclic cycloalkenyls include cyclopentenyl, cyclohexenyl, cyclohepta-1,3-dienyl, and the like. Non-limiting example of a suitable multicyclic cycloalkenyl is norbomylenyl.
  • “Cycloalkenylalkyl” means a cycloalkenyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable cycloalkenylalkyls include cyclopentenylmethyl, cyclohexenylmethyl and the like.
  • “Effective amount” or “therapeutically effective amount” is meant to describe an amount of compound or a composition of the present invention effective in inhibiting the above-noted diseases and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect.
  • “Furan” is a heterocyclic aromatic compound of the formula C4H4O. Compounds comprising such structures may be referred to as “furans.”
  • “Halogen” or “halo” means fluorine, chlorine, bromine, or iodine. Preferred are fluorine, chlorine and bromine.
  • “Heteroaryl” means an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. Preferred heteroaryls contain about 5 to about 6 ring atoms. The “heteroaryl” can be optionally substituted by one or more “ring system substituents” which may be the same or different, and are as defined herein. The prefix aza, oxa or thia before the heteroaryl root name means that at least one of a nitrogen, oxygen or sulfur atom respectively, is present as a ring atom. A nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide. Non-limiting examples of suitable heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, oxindolyl, imidazo[1,2-a]pyridinyl, imidazo[2, 1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinolinyl, benzoazaindolyl, 1,2,4-triazinyl, benzothiazolyl and the like. The term “heteroaryl” also refers to partially saturated heteroaryl moieties such as, for example, tetrahydroisoquinolyl, tetrahydroquinolyl and the like.
  • “Heteroarylalkyl” means a heteroaryl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heteroarylalkyls include 2-pyridinylmethyl, quinolinylmethyl and the like.
  • “Heterocyclyl” means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to 30 about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclyls contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. Any —NH in a heterocyclyl ring may exist protected such as, for example, as an —N(Boc), —N(CBz), —N(Tos) group and the like; such protections are also considered part of this invention. The heterocyclyl can be optionally substituted by one or more “ring system substituents” which may be the same or different, and are as defined herein. The nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, lactam, lactone, and the like.
  • “Heterocyclylalkyl” means a heterocyclyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heterocyclylalkyls include piperidinylmethyl, piperazinylmethyl and the like.
  • “Heterocyclenyl” means a non-aromatic monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur atom, alone or in combination, and which contains at least one carbon-carbon double bond or carbon-nitrogen double bond. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclenyl rings contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclenyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. The heterocyclenyl can be optionally substituted by one or more ring system substituents, wherein “ring system substituent” is as defined above. The nitrogen or sulfur atom of the heterocyclenyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable heterocyclenyl groups include 1,2,3,4-tetrahydropyridine, 1,2-dihydropyridyl, 1,4-dihydropyridyl, 1,2,3,6-tetrahydropyridine, 1,4,5,6-tetrahydropyrimidine, 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, dihydroimidazole, dihydrooxazole, dihydrooxadiazole, dihydrothiazole, 3,4-dihydro-2H-pyran, dihydrofuranyl, fluorodihydrofuranyl, 7oxabicyclo[2.2.1]heptenyl, dihydrothiophenyl, dihydrothiopyranyl, and the like.
  • “Hydroxyalkyl” means a HO-alkyl-group in which alkyl is as previously defined. Preferred hydroxyalkyls contain lower alkyl. Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.
  • “Patient” or “Subject” includes both human and animals.
  • “Pharmacore” means a specific chemical structure to which combinations of additional chemical constituents may be added. The combination of pharmacore and additional chemical groups represents the “pharmacophore.”
  • “Pharmacophore” is the ensemble of steric and electronic features of a pharmacore and any additional chemical constituents necessary to ensure supramolecular interactions with a specific biological target structure to trigger or block its biological response. A pharmacophore does not necessarily represent a real molecule or association of functional groups, although it may, but embodies the concept that accounts for the common molecular interaction capacities of a group of compounds towards their target structure. The pharmacophore can be considered the largest common denominator shared by a set of active molecules.
  • “Physiologic function” is the physiological activity of an organ, body part, or pathway within an animal.
  • “Purified”, “in purified form”, “isolated”, or “in isolated and purified form” for a compound refers to the physical state of said compound after being isolated from a synthetic process or natural source or combination thereof. Thus, the term “purified”, “in purified form”, “isolated”, or “in isolated and purified form” for a compound refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan, in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan.
  • “Pyrrole” is a heterocyclic aromatic compound of the formula C4H4N. Compounds comprising such structures may be referred to as “pyrroles.”
  • “Ring system substituent” means a substituent attached to an aromatic or non-aromatic ring system which, for example, replaces an available hydrogen on the ring system. Ring system substituents may be the same or different, each being independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, alkylaryl, heteroaralkyl, heteroarylalkenyl, heteroarylalkynyl, alkylheteroaryl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, heterocyclyl, —C(═N—CN)—NH2, —C(═NH)—NH2, —C(═NH)—NH(alkyl), Y1 Y2N—, Y1Y2N-alkyl-, Y1Y2NC(O)—, Y1Y2NSOr and —SO2NY1Y2, wherein Y1 and Y2 can be the same or different and are independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, and aralkyl. “Ring system substituent” may also mean a single moiety which simultaneously replaces two available hydrogens on two adjacent carbon atoms (one H on each carbon) on a ring system. Examples of such moieties are methylene dioxy, ethylenedioxy, —C(CH3)2- and the like.
  • “Substituted” means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By “stable compound” or “stable structure” is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. The term “optionally substituted” means optional substitution with the specified groups, radicals or moieties.
  • “Thiol” means a functional group of the general formula R—SH, wherein R represents and alkane, alkene or any other carbon-containing group, may also be referred to as a “mercaptan” or “sulfhydryl” group.
  • “Thiophene” is a heterocyclic aromatic compound of the formula C4H4S, may also be referred to as thiofuran.
  • Any carbon as well as heteroatom with unsatisfied valences in the text, examples and Tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.
  • The compounds described herein may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of these compounds as well as mixtures thereof, including racemic mixtures, form part of the present invention. In addition, the present invention embraces all geometric and positional isomers. For example, if a compound incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.
  • Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Enantiomers can also be separated by use of chiral HPLC column.
  • The compounds herein may in some cases form salts which are also within the scope of this invention. Reference to a compound herein is understood to include reference to salts thereof, unless otherwise indicated. The term “salt(s)”, as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases.
  • “Solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. “Hydrate” is a solvate wherein the solvent molecule is water. One or more compounds of the invention may also exist as, or optionally be converted to, a solvate. Preparation of solvates is generally known.
  • The compounds of this invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms.
  • It is also possible that the compounds herein may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.
    • DETAILED DESCRIPTION Identifying FYN Kinase Inhibitors.
  • Individual compounds within a chemical library consisting of 600 potential kinase inhibitors were assayed with the ADP-Glo™ Kinase Assay kit (V9102, Promega UK Ltd., Southhampton, Hampshire, UK) to identify the most potent FYN kinase inhibitors within the collection. The chemical library was comprised of the SoftFocus ATP-competitive hinge binding compounds described by Harris, C. J., Hill, R. D., Sheppard, D. W., et al., The Design and Application of Target-Focused Compound Libraries. Combinatorial Chemistry and High Throughput Screening 14:521-31 (2011). The specific pharmacore chemistries included SFK52 comprising 6-[R2]-3-[R1]imidazo[1,2-b] pyridazine compounds, SFK33 comprising N-(3-[R2] imidazo [1,2-b] pyridazin-6-yl) [R1] amine compounds, SFK49 comprising N-(5-[R2] imidazo [2,1-b][1,3,4] thiadiazol-2-yl)[R1]-amine compounds, SFK 40 comprising 5-[R2]-3-[R1] pyridin-2-amine compounds, SFK43 comprising 6-[R2]-3-[R1]imidazo[1,2-a]pyrazine compounds, and SFK63. The scaffold structure of each pharmacore is shown in Table 2. The chemical structures of the initial 600 potential kinase inhibitors are presented in Table 3, with those chosen for additional analysis presented in Table 4. Comparison of the compounds presented in Table 1 and those of Tables 2, 3 and 4, illustrate the novelty of the chemical structures claimed herein.
  • FYN kinase (10 micrograms) was from the FYN A Kinase Enzyme System (V3571, Promega UK Ltd.), a full-length recombinant human FYN A containing an N-terminal GST tag of about 85 kDa, expressed by bacullovirus in S19 insect cells, supplied at a concentration of 0.1 microgram/microliter in 5× reaction buffer. The FYN substrate, a 12 amino acid peptide of the sequence EFGTYGTLSKKK, containing a single tyrosine phosphorylation site, was custom synthesized (Peptide Synthetics, Peptide Protein Research, Fareham, UK) and supplied as a 4 mg/ml aqueous solution. All other reagents were obtained from Sigma (Sigma-Aldrich, Gillingham, Dorset, UK), with the exception of UltraPure ATP (V9102, Promega UK Ltd.) and the ATP-competitive broad spectrum protein kinase inhibitor staurosporine (569397, Merck Millipore, Watford, Hertfordshire, UK), or as otherwise indicated.
  • The assay procedure determines the IC50 of each potential FYN kinase inhibitor by measuring the enzyme catalyzed ATP-dependent phosphorylation of the FYN substrate peptide. The ADP-Glo™ Kinase Assay is specifically designed to quantify kinase activity by measuring the ADP produced in the reaction The reaction buffer comprises 40 mM Tris-HCl (pH 7.5), 20 mM MgCl2, 0.1 mg/ml BSA and 5 microM DTT. Individual compounds within the chemical library were dissolved in DMSO at known concentrations. Briefly, 2.5 microliters of reaction buffer containing 3 picograms of FYN kinase and serial dilutions of each potential FYN kinase inhibitor (9 3-fold dilutions of a 10 micromolar top sample) are placed into each well of a 384 well microtiter plate and incubated at room temperature for 30 minutes. An additional 2.5 microliters of reaction buffer containing 100 picograms of the FYN substrate and 12.5 picomoles of ATP are then added to each well and the reaction carried out for 90 minutes at room temperature. The reactions are terminated by addition of 5 microliters of the ADP-Glo™ Reagent component of the ADP-Glo™ Kinase Assay kit to each well. The ADP-Glo™ Reagent comprises an ATP-dependent adenylate cyclase, an inorganic pyrophosphatase and an excess of staurosporine. The adenylate cyclase converts the remaining ATP to cAMP and pyrophospahte, the pyrophosphatase converts the pyrophosphate to phosphate and the staurosporine inhibits the activity of the FYN kinase, the net effect is to remove all residual ATP while preserving the ADP produced by FYN kinase. The terminated reactions are incubated for 40 minutes at room temperature, prior to addition of the Kinase Detection Reagent component of the ADP-Glo™ Kinase Assay kit to each well. The Kinase Detection Reagent comprises pyruvate kinase, phosphoenol pyruvate (PEP), luciferin and luciferase. The pyruvate kinase converts PEP to pyruvate and in the process generates ATP from the residual ADP present in the terminated reaction. The ATP is then consumed by the luciferase catalyzed, light emitting conversion of luciferin to oxyluciferin producing AMP, pyrophosphate and CO2. The emitted light was measured on an Envion Luminometer to determine the relative activity of the FYN kinase in each well. A 10 point dose-response curve for each potential FYN kinase inhibitor dilution series was used to determine the IC50, of each compound. Details of the analysis, including assay procedures and representative dilution schema for measuring kinase inhibitors are presented in the Technical Manual accompanying the ADP-Glo™ Kinase Assay kit (Doc. TM313, Promega Corp.) as well as U.S. Pat. Nos. 8,183,007 and 8,802,411, the contents of which are incorporated herein, in their entirety.
  • The results of screening candidate libraries are presented in Table 3, which lists the structure of each compound, the standard IUPAC name of the compound, the observed IC50 and the calculated lipophilicity of the compound. The most potent FYN kinase inhibitors, generally those with the most favorable combination of IC50 and drugability were resynthesized and subjected to further testing and expansion. In general, the best candidate compounds exhibit an IC50 of less than 200 nM and drugability as measured by LLE (Ligand-lipophilicity efficiency) of greater than 2.5. LLE=(pIC50-cLogP) where plC50 is the negative log of the observed IC50 and cLogP is a calculated consensus measure of the lipophilicity of the compound. In practice, this means a cLogP of less than 3.5, based on an average IC50 of less than or equal to 1 μM, represents a favorable level of drugability (LLE>2.5). Candidate compounds selected for additional testing and expansion are listed in Table 4.
    • Cell Based Assay(s) of FYN Kinase Inhibitors
  • Test compounds exhibiting superior IC50 and LLE profiles are further tested for their ability to stimulate T cell proliferation and to inhibit production of Interleukin 2 by stimulated T-cells.
  • T-cell proliferation is analyzed by staining with carboxy-fluorescein diacetate succinimidyl ester (CFSE) at a final concentration 5 μM (Molecular Probes, Invitrogen) according to the manufacturer's instructions. Briefly, cells are resuspended in warm PBS containing 5 μM CFSE and incubated at 37° C. for 10 minutes. Subsequently, cells are washed twice and resuspended in culture media containing 10% FBS before the experimental treatments are initiated. Cells may be analyzed by flow cytometry after 5 days in culture. Alternatively, a 96-well plate is coated with a monoclonal antibody to CD3 (G19-4), the antibody is allowed to bind, and then the plate is washed. Normal human peripheral blood T cells are added to the wells, along with test compound and anti-CD28 antibody to provide co-stimulation. After 3 days, [3H]thymidine is added to the cells and incubated for 6 hours. The cells are harvested and counted in a liquid scintillation counter to measure proliferation.
  • To measure the ability of test compounds to block IL-2 production by Fyn mediated tyrosine phosphorylation induced by anti-CD3 and IL-2 stimulated T-cell proliferation, human T-cells, such as Jurkat cells are preincubated with various concentrations of test compound in serum-free medium at 37° C. for 10 min and then stimulated with plastic-immobilized anti-CD3 mAbs. Cells are cultured in complete media supplemented with 5% fetal bovine serum for 24 h in the presence of 10 μg/ml of anti-human CD25 mAbs to prevent IL-2 autocrine consumption. The supernatants are then harvested and centrifuged, and the IL-2 in the supernatant measured in a bioassay using a murine IL-2-dependent cell line, such as CTLL-4, as described by Trevillyan, et al., J. Immunol. 145:3223-30 (1990). To avoid the influence of residual test compound in the supernatants on proliferation of CTLL-4 cells, the test compound is removed by extensive dialysis against phosphate-buffered saline (0.1 M, pH 7.4). A control supernatant harvested from anti-CD3-stimulated Jurkat cells lacking Lck is spiked with 200 μM test compound is included along with the test compound dilution series to ascertain that all test compound is removed by the dialysis procedure. This “dialysis control” supernatant stimulates CTLL-4 proliferation as well as the positive control supernatant without added test compound, indicating the dialysis procedure has removed the test compound. Alternatively, IL-2 can be directly measured with an in vitro cytokine assays using labeled anti-IL2 mAbs, such as CisBio's Human IL2 Assay Kit (CisBio US, Bedford, MA) without requiring prior removal of test compound.
  • One of skill in the art will recognize that other assays may be devised to measure the efficacy of Fyn kinase inhibition by test compounds and that such assays are conventional in the art and known to those of ordinary skill.
  • TABLE 2
    Representative scaffold structures of SoftFocus library pharmacores
    Figure US20240041868A1-20240208-C00010
         		5-[R2]-3-[R1]pyridin-2-amine Formula I (SFK40 pharmacore)
    Figure US20240041868A1-20240208-C00011
         		6-[R2]-3-[R1]imidazo[1,2-a]pyrazine Formula II (SFK43 pharmacore)
    Figure US20240041868A1-20240208-C00012
         		6-[R2]-3-[R1]imidazo[1,2-b] pyridazine Formula III (SFK52 pharmacore)
    Figure US20240041868A1-20240208-C00013
         		N-(5-[R2]imidazo[2,1-b][1,3,4] thiadiazol-2-yl)[R1]amine Formula IV (SFK49 pharmacore)
    Figure US20240041868A1-20240208-C00014
         		4-[R2]-3-[R1]-1H-pyrazolo[3,4-b] pyridine Formula V (SFK63 pharmacore)
    Figure US20240041868A1-20240208-C00015
         		N-(3-[R2]imidazo[1,2-b]pyridazin-6- yl)[R1]amine Formula VI (SFK33 pharmacore)
  • TABLE 3
    Primary screen-initial compounds.
    IC50 logP
    FYN (con-
    Structure IUPAC name (μM) sensus) Compound ID.
    Figure US20240041868A1-20240208-C00016
         		N-[3-[6-(2- furylmethyl- amino) pyrazin-2- yl]phenyl] acetamide 11.18502 1.66 035_0144_0081
    Figure US20240041868A1-20240208-C00017
         		4-[6-[1- (hydroxy- methyl) propylamino] pyrazin- 2-yl]phenol 15.34591 1.58 035_0153_0080
    Figure US20240041868A1-20240208-C00018
         		2-[[6-(5- isopropyl-2- methoxy- phenyl) pyrazin-2- yl]amino] butan- 1-ol 11.79042 2.97 035_0153_0286
    Figure US20240041868A1-20240208-C00019
         		6-(3- amino- phenyl)-N- benzyl- pyrazin-2- amine 6.67663 2.53 035_0232_0005
    Figure US20240041868A1-20240208-C00020
         		2-[[6-(4- aminophenyl) pyrazin-2- yl]amino]butan- 1-ol 21.05663 1.06 035_0153_0333
    Figure US20240041868A1-20240208-C00021
         		3-[5-(3- furylmethyl- amino)- 3- pyridyl]phenol 10.89609 2.44 081_0284_2069
    Figure US20240041868A1-20240208-C00022
         		N-[3-[5-(3,4,5- trimethoxy- anilino)- 3- pyridyl]phenyl] acetamide 0.3913 2.61 081_0087_0081
    Figure US20240041868A1-20240208-C00023
         		3-[(3- methoxyphenyl) methyl]-5- (3,4,5- trimethoxy- phenyl)-1H- imidazo[4,5- b]pyrazin-2-one 23.44 3.07 170_4313_0087
    Figure US20240041868A1-20240208-C00024
         		N,N-dimethyl-3- [2-oxo-3-[(1S)- 1-phenylethyl]- 1H-imidazo[4,5- b]pyrazin-5- yl]benzamide 1.77669 3.42 170_0148_0349
    Figure US20240041868A1-20240208-C00025
         		5-[3- (dimethylamino) phenyl]-N-(4- morpholino- phenyl) imidazo]1,2- a]pyrazin-8- amine 2.70242 3.14 184_0088_0135
    Figure US20240041868A1-20240208-C00026
         		N-(2- methoxyethyl)- 3-(3- thienyl)imidazo [1,2-b]pyridazin- 6-amine 5.2312 2.02 229_0033_0074
    Figure US20240041868A1-20240208-C00027
         		3-(3,4- dimethoxy- phenyl)- N-(2- methoxyethyl) imidazo[1,2- b]pyridazin-6- amine 1.54534 1.93 229_0033_0079
    Figure US20240041868A1-20240208-C00028
         		3-(4- fluorophenyl)-N- (2- methoxyethyl) imidazo[1,2- b]pyridazin-6- amine 4.00393 2.38 229_0033_0339
    Figure US20240041868A1-20240208-C00029
         		4-[6-(2- furylmethyl- amino) imidazo[1,2- b]pyridazin-3- yl]benzoic acid 3.879 2.73 229_0144_0140
    Figure US20240041868A1-20240208-C00030
         		N-(2- furylmethyl)-3- (4- methoxyphenyl) imidazo[1,2- b]pyridazin-6- amine 3.67644 2.91 229_0144_0280
    Figure US20240041868A1-20240208-C00031
         		[4-[6-(2- furylmethyl- amino) imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 2.20497 2.30 229_0144_0285
    Figure US20240041868A1-20240208-C00032
         		[3-[6-(2- furylmethyl- amino) imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 3.85557 2.30 229_0144_0291
    Figure US20240041868A1-20240208-C00033
         		1-[3-[6-(2- furylmethyl- amino) imidazo[1,2- b]pyridazin-3- yl]phenyl] ethanone 0.99711 2.63 229_0144_4145
    Figure US20240041868A1-20240208-C00034
         		[4-[6-(2- thienylmethyl- amino) imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 1.09479 3.16 229_0146_0285
    Figure US20240041868A1-20240208-C00035
         		3-(4- aminophenyl)- N-(2- thienylmethyl) imidazo[1,2- b]pyridazin-6- amine 5.42153 3.10 229_0146_0333
    Figure US20240041868A1-20240208-C00036
         		3-(4- fluorophenyl)-N- (2- thienylmethyl) imidazo[1,2- b]pyridazin-6- amine 3.28447 4.07 229_0146_0339
    Figure US20240041868A1-20240208-C00037
         		3-(3- methoxyphenyl)- N-(2- thienylmethyl) imidazo[1,2- b]pyridazin-6- amine 2.94644 3.77 229_0146_4140
    Figure US20240041868A1-20240208-C00038
         		1-[3-[6-(2- thienylmethyl amino)imidazo [1,2- b]pyridazin-3- yl]phenyl] ethanone 0.44073 3.48 229_0146_4145
    Figure US20240041868A1-20240208-C00039
         		2-[[3-(3,4,5- trimethoxy- phenyl) imidazo[1,2- b]pyridazin-6- yl]amino]butan- 1-ol 1.2806 2.06 229_0153_0087
    Figure US20240041868A1-20240208-C00040
         		2-[[3-(4- methoxyphenyl) imidazo[1,2- b]pyridazin-6- yl]amino]butan- 1-ol 1.27502 2.38 229_0153_0280
    Figure US20240041868A1-20240208-C00041
         		2-[[3-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6- yl]amino]butan- 1-ol 2.46631 1.77 229_0153_0285
    Figure US20240041868A1-20240208-C00042
         		2-[[3-(6- methoxy-3- pyridyl)imidazo [1,2-b]pyridazin- 6- yl]amino]butan- 1-ol 2.36648 1.76 229_0153_0311
    Figure US20240041868A1-20240208-C00043
         		2-[[3-(3- methoxyphenyl) imidazo[1,2- b]pyridazin-6- yl]amino]butan- 1-ol 1.55019 1.76 229_0153_4140
    Figure US20240041868A1-20240208-C00044
         		[3-[6-[(3- chlorophenyl) methylamino] imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 5.10524 3.85 229_0223_0291
    Figure US20240041868A1-20240208-C00045
         		3-(4- aminophenyl)-N- [(3- chlorophenyl) methyl] imidazo[1,2- b]pyridazin-6- amine 3.41043 3.79 229_0223_0333
    Figure US20240041868A1-20240208-C00046
         		[4-[6-[(4- fluorophenyl) methylamino] imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 2.4449 3.39 229_0224_0285
    Figure US20240041868A1-20240208-C00047
         		N-(1,3- benzodioxol-5- ylmethyl)-3-(4- pyridyl)imidazo [1,2-b]pyridazin- 6-amine 0.37966 2.42 229_0236_0069
    Figure US20240041868A1-20240208-C00048
         		4-[6-(1,3- benzodioxol-5- ylmethylamino) imidazo[1,2- b]pyridazin-3- yl]phenol 5.67256 3.33 229_0236_0080
    Figure US20240041868A1-20240208-C00049
         		3-(benzofuran- 2-yl)-N-(4- pyridylmethyl) imidazo[1,2- b]pyridazin-6- amine 6.44995 2.87 229_0237_0073
    Figure US20240041868A1-20240208-C00050
         		3-(3- aminophenyl)- N- tetrahydropyran- 4-yl- imidazo[1,2- b]pyridazin-6- amine 0.74599 1.42 229_0242_0005
    Figure US20240041868A1-20240208-C00051
         		3-(3,4- dimethoxy- phenyl)-N- tetrahydropyran- 4-yl- imidazo[1,2- b]pyridazin-6- amine 0.54713 1.93 229_0242_0079
    Figure US20240041868A1-20240208-C00052
         		N-[3-[6- (tetrahydropyran- 4- ylamino)imidazo [1,2-b]pyridazin- 3- yl]phenyl] acetamide 0.58811 1.49 229_0242_0081
    Figure US20240041868A1-20240208-C00053
         		N- tetrahydropyran- 4-yl-3-(3,4,5- trimethoxy- phenyl) imidazo[1,2- b]pyridazin-6- amine 0.61737 1.78 229_0242_0087
    Figure US20240041868A1-20240208-C00054
         		3-(1H-indol-5- yl)-N- tetrahydropyran- 4-yl- imidazo[1,2- b]pyridazin-6- amine 1.16563 2.35 229_0242_0204
    Figure US20240041868A1-20240208-C00055
         		3-(3- methoxyphenyl)- N- tetrahydropyran- 4-yl-imidazo[1,2- b]pyridazin-6- amine 0.87042 2.09 229_0242_4140
    Figure US20240041868A1-20240208-C00056
         		2-methoxy-4-[6- [(4- methoxyphenyl) methylamino] imidazo[1,2- b]pyridazin-3- yl]phenol 4.01326 3.39 229_0244_0314
    Figure US20240041868A1-20240208-C00057
         		3-[[3-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-6- yl]amino] propan- 1-ol 0.9286 1.28 229_0248_0068
    Figure US20240041868A1-20240208-C00058
         		3-[[3-(1H-indol- 5- yl)imidazo[1,2- b]pyridazin-6- yl]amino] propan- 1-ol 2.71742 1.76 229_0248_0204
    Figure US20240041868A1-20240208-C00059
         		3-[[3-[3- (trifluoromethyl) phenyl]imidazo [1,2-b]pyridazin- 6- yl]amino] propan- 1-ol 3.41334 2.54 229_0248_0312
    Figure US20240041868A1-20240208-C00060
         		4-[6-(3- hydroxypropyl- amino)imidazo [1,2-b] pyridazin-3- yl]-2-methoxy- phenol 0.32856 1.20 229_0248_0314
    Figure US20240041868A1-20240208-C00061
         		3-[[3-(4- phenoxyphenyl) imidazo[1,2- b]pyridazin-6- yl]amino] propan- 1-ol 5.54336 3.16 229_0248_1029
    Figure US20240041868A1-20240208-C00062
         		(2S)-2-[[3-(3- aminophenyl) imidazo[1,2- b]pyridazin-6- yl]amino]-3- methyl-butan-1- ol 1.80698 2.07 229_0254_0005
    Figure US20240041868A1-20240208-C00063
         		(2S)-2-[[3-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-6- yl]amino]-3- methyl-butan-1- ol 1.82017 2.52 229_0254_0068
    Figure US20240041868A1-20240208-C00064
         		(2S)-2-[[3-(3,4- dimethoxy- phenyl) imidazo[1,2- b]pyridazin-6- yl]amino]-3- methyl-butan-1- ol 0.7782 2.59 229_0254_0079
    Figure US20240041868A1-20240208-C00065
         		N-[3-[6-[[(1S)-1- (hydroxy- methyl)- 2-methyl- propyl]amino] imidazo[1,2- b]pyridazin-3- yl]phenyl] acetamide 0.80076 2.14 229_0254_0081
    Figure US20240041868A1-20240208-C00066
         		4-[6-[[(1S)-1- (hydroxy- methyl)- 2-methyl- propyl]amino] imidazo[1,2- b]pyridazin-3- yl]benzonitrile 3.17911 2.76 229_0254_0086
    Figure US20240041868A1-20240208-C00067
         		(2S)-2-[[3-(4- aminophenyl) imidazo[1,2- b]pyridazin-6- yl]amino]-3- methyl-butan-1- ol 3.05172 2.07 229_0254_0333
    Figure US20240041868A1-20240208-C00068
         		3-(1,3- benzodioxol-5- yl)-N-(2- pyridylmethyl) imidazo[1,2- b]pyridazin-6- amine 0.79705 2.50 229_4007_0068
    Figure US20240041868A1-20240208-C00069
         		N- (cyclopropyl- methyl)-3-(3- methoxyphenyl) imidazo[1,2- b]pyridazin-6- amine 3.29534 2.91 229_4051_4140
    Figure US20240041868A1-20240208-C00070
         		3-[5-[(6- methoxy-3- pyridyl)amino] pyrazolo[1,5- a]pyrimidin-3- yl]phenol 3.39371 3.25 294_0042_0284
    Figure US20240041868A1-20240208-C00071
         		3-(3- methoxyphenyl)- N-(6-methoxy- 3- pyridyl)pyrazolo [1,5-a]pyrimidin- 5-amine 5.3146 3.40 294_0042_4140
    Figure US20240041868A1-20240208-C00072
         		1-[3-[5-[(6- methoxy-3- pyridyl)amino] pyrazolo[1,5- a]pyrimidin-3- yl]phenyl] ethanone 1.63557 3.11 294_0042_4145
    Figure US20240041868A1-20240208-C00073
         		N-[5-[[3-(3- hydroxyphenyl) pyrazolo[1,5- a]pyrimidin-5- yl]amino]-2- methyl- phenyl]methane- sulfonamide 3.17096 2.92 294_0123_0284
    Figure US20240041868A1-20240208-C00074
         		3-(3,4- dimethoxy- phenyl)-N-(3- pyridylmethyl) pyrazolo[1,5- a]pyrimidin-5- amine 1.63605 2.56 294_4003_0079
    Figure US20240041868A1-20240208-C00075
         		N-(3- pyridylmethyl)- 3-(3,4,5- trimethoxy- phenyl) pyrazolo[1,5- a]pyrimidin-5- amine 2.35332 2.40 294_4003_0087
    Figure US20240041868A1-20240208-C00076
         		N-(4- isopropyl- phenyl)- 3-(4- methoxyphenyl) pyrazolo[1,5- a]pyrimidin-5- amine 4.17999 5.42 294_6937_0280
    Figure US20240041868A1-20240208-C00077
         		N-(2- furylmethyl)-3- phenyl- imidazo[1,2- b]pyridazin-6- amine 6.37501 3.07 229_0144_0061
    Figure US20240041868A1-20240208-C00078
         		N-(2- furylmethyl)-3- (3,4,5- trimethoxy- phenyl) imidazo[1,2- b]pyridazin-6- amine 4.89592 2.60 229_0144_0087
    Figure US20240041868A1-20240208-C00079
         		3-(3- aminophenyl)- N-(2- thienylmethyl) imidazo[1,2- b]pyridazin-6- amine 1.79421 3.10 229_0146_0005
    Figure US20240041868A1-20240208-C00080
         		N-(2- thienylmethyl)- 3-(3,4,5- trimethoxy- phenyl) imidazo[1,2- b]pyridazin-6- amine 3.10009 3.45 229_0146_0087
    Figure US20240041868A1-20240208-C00081
         		3-(4- methoxy- phenyl)- N-(2- thienylmethyl) imidazo[1,2- b]pyridazin-6- amine 5.3884 3.77 229_0146_0280
    Figure US20240041868A1-20240208-C00082
         		3-[6-(2- thienylmethyl- amino)imidazo [1,2- b]pyridazin-3- yl]phenol 1.70365 3.62 229_0146_0284
    Figure US20240041868A1-20240208-C00083
         		2-[[3-(2- thienyl)imidazo [1,2-b] pyridazin- 6- yl]amino]butan- 1-ol 3.96823 2.31 229_0153_4147
    Figure US20240041868A1-20240208-C00084
         		N-[(3- chlorophenyl) methyl]-3-(4- methoxyphenyl) imidazo[1,2- b]pyridazin-6- amine 10.74649 4.46 229_0223_0280
    Figure US20240041868A1-20240208-C00085
         		N-[(3- chlorophenyl) methyl]-3-(6- methoxy-3- pyridyl)imidazo [1,2-b]pyridazin- 6-amine 8.33916 3.84 229_0223_0311
    Figure US20240041868A1-20240208-C00086
         		4-[6-[(3- chlorophenyl) methylamino] imidazo[1,2- b]pyridazin-3- yl]-2-methoxy- phenol 3.51753 4.15 229_0223_0314
    Figure US20240041868A1-20240208-C00087
         		3-(3- aminophenyl)- N-propyl- imidazo[1,2- b]pyridazin-6- amine 0.93247 2.34 229_0226_0005
    Figure US20240041868A1-20240208-C00088
         		3-(1,3- benzodioxol-5- yl)-N-propyl- imidazo[1,2- b]pyridazin-6- amine 2.05098 2.79 229_0226_0068
    Figure US20240041868A1-20240208-C00089
         		N-propyl-3-(3- thienyl)imidazo [1,2-b] pyridazin- 6-amine 4.03981 2.95 229_0226_0074
    Figure US20240041868A1-20240208-C00090
         		3-(3,4- dimethoxyphen- yl)-N-propyl- imidazo[1,2- b]pyridazin-6- amine 0.51897 2.85 229_0226_0079
    Figure US20240041868A1-20240208-C00091
         		N-[3-[6- (propylamino) imidazo[1,2- b]pyridazin-3- yl]phenyl] acetamide 0.62919 2.40 229_0226_0081
    Figure US20240041868A1-20240208-C00092
         		4-[6- (propylamino) imidazo[1,2- b]pyridazin-3- yl]benzoic acid 9.76838 2.82 229_0226_0140
    Figure US20240041868A1-20240208-C00093
         		3-(4- methoxyphenyl)- N-propyl- imidazo[1,2- b]pyridazin-6- amine 5.42987 3.01 229_0226_0280
    Figure US20240041868A1-20240208-C00094
         		3-[6- (propylamino) imidazo[1,2- b]pyridazin-3- yl]phenol 0.93003 2.86 229_0226_0284
    Figure US20240041868A1-20240208-C00095
         		3-(3- methoxyphenyl)- N-propyl- imidazo[1,2- b]pyridazin-6- amine 2.21992 3.01 229_0226_4140
    Figure US20240041868A1-20240208-C00096
         		1-[3-[6- (propylamino) imidazo[1,2- b]pyridazin-3- yl]phenyl] ethanone 0.36718 2.72 229_0226_4145
    Figure US20240041868A1-20240208-C00097
         		4-[6-[(3,4- dichlorophenyl) methylamino] imidazo[1,2- b]pyridazin-3- yl]benzoic acid 1.00617 4.88 229_0227_0140
    Figure US20240041868A1-20240208-C00098
         		3-phenyl-N-(4- pyridylmethyl) imidazo[1,2- b]pyridazin-6- amine 4.05638 2.79 229_0237_0061
    Figure US20240041868A1-20240208-C00099
         		3-(4- aminophenyl)- N- tetrahydropyran- 4-yl- imidazo[1,2- b]pyridazin-6- amine 3.12587 1.42 229_0242_0333
    Figure US20240041868A1-20240208-C00100
         		4-[6-[(2,4- dimethylphenyl) methylamino] imidazo[1,2- b]pyridazin-3- yl]-2-methoxy- phenol 5.30595 4.58 229_4319_0314
    Figure US20240041868A1-20240208-C00101
         		3-(5-methoxy-3- pyridyl)-N-(4- morpholinophen- yl)pyrazolo[1,5- a]pyrimidin-5- amine 2.24998 2.85 294_0088_0196
    Figure US20240041868A1-20240208-C00102
         		3-(3- aminophenyl)- N-(3- pyridylmethyl) pyrazolo[1,5- a]pyrimidin-5- amine 2.5122 2.05 294_4003_0005
    Figure US20240041868A1-20240208-C00103
         		3-(2- methoxyphenyl)- N-(3- pyridylmethyl) pyrazolo[1,5- a]pyrimidin-5- amine 1.22114 2.72 294_4003_0083
    Figure US20240041868A1-20240208-C00104
         		N-[3- (dimethylamino) propyl]-3-[6-(4- methoxyphenyl) pyrazin-2- yl]benzamide 9.05883 2.60 035_0280_0302
    Figure US20240041868A1-20240208-C00105
         		2-methoxy-4-[6- (4- methoxyphenyl) pyrazin-2- yl]phenol 5.17907 2.99 035_0280_0314
    Figure US20240041868A1-20240208-C00106
         		N-[3-[6-(4- methoxyphenyl) pyrazin-2- yl]phenyl] acetamide 3.50136 2.68 035_0081_0280
    Figure US20240041868A1-20240208-C00107
         		N-[3-[6-(3- hydroxyphenyl) pyrazin-2- yl]phenyl] acetamide 3.87844 2.54 035_0081_0284
    Figure US20240041868A1-20240208-C00108
         		N-[3- (dimethylamino) propyl]-4-[6-(2- fluoro-3- methoxy- phenyl)-1H- pyrazolo[3,4- b]pyridin-3- yl]benzamide 7.3354 3.65 267_0180_7936
    Figure US20240041868A1-20240208-C00109
         		3-[2-amino-5- (3,4- dimethoxyphen yl)-3- pyridyl]phenol 2.00489 3.20 382_0284_0079
    Figure US20240041868A1-20240208-C00110
         		3-[6-amino-5-[3- (dimethylamino) phenyl]-3- pyridyl]-N-(2- hydroxyethyl) benzamide 3.57159 2.31 382_0135_0192
    Figure US20240041868A1-20240208-C00111
         		5-(3- methoxyphenyl)- 3-(3,4,5- trimethoxyphen- yl)pyridin-2- amine 9.5028 3.18 382_0087_4140
    Figure US20240041868A1-20240208-C00112
         		4-[2-amino-5-(4- methylsulfonyl- phenyl)-3- pyridyl]-2- methoxy-phenol 0.34919 2.19 382_0314_0174
    Figure US20240041868A1-20240208-C00113
         		4-[2-amino-5-(p- tolyl)-3-pyridyl]- 2-methoxy- phenol 4.3442 3.87 382_0314_4139
    Figure US20240041868A1-20240208-C00114
         		4-[2-amino-5-(3- chlorophenyl)-3- pyridyl]-2- methoxy-phenol 3.5107 3.96 382_0314_0279
    Figure US20240041868A1-20240208-C00115
         		4-[2-amino-5-(3- fluorophenyl)-3- pyridyl]-2- methoxy-phenol 2.02739 3.50 382_0314_0313
    Figure US20240041868A1-20240208-C00116
         		4-(2-amino-5- phenyl-3- pyridyl)-2- methoxy-phenol 1.47705 3.35 382_0314_0061
    Figure US20240041868A1-20240208-C00117
         		4-[6-amino-5-(4- hydroxy-3- methoxy- phenyl)-3- pyridyl]-2,6- dimethyl-phenol 0.52648 4.08 382_0314_0315
    Figure US20240041868A1-20240208-C00118
         		4-[2-amino-5-(4- fluorophenyl)-3- pyridyl]-2- methoxy-phenol 3.24026 3.50 382_0314_0339
    Figure US20240041868A1-20240208-C00119
         		4-[2-amino-5- (3,4,5- trimethoxyphen- yl)-3-pyridyl]-2- methoxy-phenol 0.08059 2.88 382_0314_0087
    Figure US20240041868A1-20240208-C00120
         		4-[6-amino-5-[4- (methoxy- methoxy) phenyl]-3- pyridyl] benzamide 3.42268 2.57 382_0341_0346
    Figure US20240041868A1-20240208-C00121
         		[3-[6-amino-5- [4- (methoxy- methoxy) phenyl]-3- pyridyl]phenyl] methanol 4.62016 2.95 382_0341_0291
    Figure US20240041868A1-20240208-C00122
         		3-[6-amino-5-[4- (methoxy- methoxy) phenyl]-3- pyridyl] benzamide 3.02265 2.57 382_0341_0347
    Figure US20240041868A1-20240208-C00123
         		N-[3-[6-amino- 5-[4- (methoxy- methoxy) phenyl]-3- pyridyl]phenyl] acetamide 1.5493 2.96 382_0341_0081
    Figure US20240041868A1-20240208-C00124
         		4-[6-amino-5-[4- (hydroxymethyl) phenyl]-3- pyridyl]-2,6- dimethyl-phenol 4.64395 3.77 382_0285_0315
    Figure US20240041868A1-20240208-C00125
         		3-[4- (methoxy- methoxy) phenyl]-5- (3,4,5- trimethoxy- phenyl) pyridin-2- amine 1.90467 3.25 382_0341_0087
    Figure US20240041868A1-20240208-C00126
         		3-[2-amino-5-(4- morpholinophen- yl)-3- pyridyl]phenol 4.64154 3.40 382_0284_0001
    Figure US20240041868A1-20240208-C00127
         		N-[3-[6-amino- 5-(4- hydroxyphenyl)- 3- pyridyl]phenyl] acetamide 0.83784 2.75 382_7249_0081
    Figure US20240041868A1-20240208-C00128
         		4-[2-amino-5- (3,4,5- trimethoxyphen- yl)-3- pyridyl]phenol 0.20886 3.04 382_7249_0087
    Figure US20240041868A1-20240208-C00129
         		4-[2-amino-5-[3- (dimethylamino) phenyl]-3- pyridyl]phenol 2.19069 3.62 382_7249_0135
    Figure US20240041868A1-20240208-C00130
         		3-[2-amino-5- (3,4,5- trimethoxyphen- yl)-3- pyridyl]phenol 1.01519 3.04 382_0284_0087
    Figure US20240041868A1-20240208-C00131
         		4-[2-amino-5-(4- methylsulfonyl- phenyl)-3- pyridyl]phenol 1.25339 2.35 382_7249_0174
    Figure US20240041868A1-20240208-C00132
         		3-(3- aminophenyl)-5- (3,4,5- trimethoxyphen- yl)pyridin-2- amine 2.96823 2.51 382_0005_0087
    Figure US20240041868A1-20240208-C00133
         		4-[2-amino-5-(3- methoxyphenyl)- 3- pyridyl]phenol 3.49074 3.35 382_7249_4140
    Figure US20240041868A1-20240208-C00134
         		4-[6-amino-5-(4- pyridyl)-3- pyridyl]-2,6- dimethyl-phenol 1.70457 3.32 382_0069_0315
    Figure US20240041868A1-20240208-C00135
         		5-[6-[3- (dimethylamino) propoxy]-3- pyridyl]-3-(3,4,5- trimethoxyphen- yl)pyridin-2- amine 0.5304 2.64 382_0087_0002
    Figure US20240041868A1-20240208-C00136
         		5-(3- fluorophenyl)-3- (3,4,5- trimethoxyphen- yl)pyridin-2- amine 1.5198 3.49 382_0087_0313
    Figure US20240041868A1-20240208-C00137
         		4-[6-amino-5- (3,4,5- trimethoxyphen- yl)-3-pyridyl]- 2,6-dimethyl- phenol 0.71164 4.07 382_0087_0315
    Figure US20240041868A1-20240208-C00138
         		N-[3-[6-amino- 5-(3,4,5- trimethoxyphen- yl)-3- pyridyl]phenyl] methane- sulfonamide 0.5248 1.72 382_0087_6488
    Figure US20240041868A1-20240208-C00139
         		5-phenyl-3- (3,4,5- trimethoxyphen- yl)pyridin-2- amine 0.8934 3.34 382_0087_0061
    Figure US20240041868A1-20240208-C00140
         		3-[6-amino-5- (3,4,5- trimethoxyphen- yl)-3-pyridyl]-N- (2- hydroxyethyl) benzamide 0.48532 1.73 382_0087_0192
    Figure US20240041868A1-20240208-C00141
         		5-(4- aminophenyl)-3- (3,4,5- trimethoxyphen- yl)pyridin-2- amine 0.97087 2.51 382_0087_0333
    Figure US20240041868A1-20240208-C00142
         		4-[6-amino-5- (3,4,5- trimethoxyphen- yl)-3- pyridyl]phenol 1.72584 3.04 382_0087_7249
    Figure US20240041868A1-20240208-C00143
         		5-(4- fluorophenyl)-3- (3,4,5- trimethoxyphen- yl)pyridin-2- amine 2.85921 3.49 382_0087_0339
    Figure US20240041868A1-20240208-C00144
         		4-[6-amino-5- (3,4,5- trimethoxyphen- yl)-3-pyridyl]-N- cyclopropyl- benzamide 0.5072 2.88 382_0087_7489
    Figure US20240041868A1-20240208-C00145
         		5- (benzothiophen- trimethoxyphen- yl)pyridin-2- amine 2.69043 4.22 382_0087_0076
    Figure US20240041868A1-20240208-C00146
         		3-[6-amino-5- (3,4,5- trimethoxyphen- yl)-3- pyridyl]phenol 0.72322 3.04 382_0087_0284
    Figure US20240041868A1-20240208-C00147
         		5-(6-methoxy-3- pyridyl)-3- (3,4,5- trimethoxyphen- yl)pyridin-2- amine 1.06095 2.56 382_0087_0311
    Figure US20240041868A1-20240208-C00148
         		5-[3- (dimethylamino) phenyl]-3- (3,4,5- trimethoxyphen- yl)pyridin-2- amine 0.59506 3.45 382_0087_0135
    Figure US20240041868A1-20240208-C00149
         		[3-[6-amino-5- [3- (dimethylamino) phenyl]-3- pyridyl]phenyl]- (4- methylpiperazin- 1-yl)methanone 4.43871 3.07 382_0135_0200
    Figure US20240041868A1-20240208-C00150
         		4-[6-amino-5-[3- (dimethylamino) phenyl]-3- pyridyl]-2- methoxy-phenol 2.10895 3.46 382_0135_0314
    Figure US20240041868A1-20240208-C00151
         		3-[3- (dimethylamino) phenyl]-5- (3,4,5- trimethoxyphen- yl)pyridin-2- amine 3.13462 3.45 382_0135_0087
    Figure US20240041868A1-20240208-C00152
         		4-[6-amino-5-[3- (dimethylamino) phenyl]-3- pyridyl]-2,6- dimethyl-phenol 4.20127 4.65 382_0135_0315
    Figure US20240041868A1-20240208-C00153
         		3-[3- (dimethylamino) phenyl]-5-(3- pyridyl)pyridin- 2-amine 7.11159 2.71 382_0135_0071
    Figure US20240041868A1-20240208-C00154
         		[3-[6-amino-5- [3- (dimethylamino) phenyl]-3- pyridyl]phenyl] methanol 2.6979 3.16 382_0135_0291
    Figure US20240041868A1-20240208-C00155
         		3-[3- (dimethylamino) phenyl]-5-[6-[3- (dimethylamino) propoxy]-3- pyridyl]pyridin- 2-amine 4.66462 3.22 382_0135_0002
    Figure US20240041868A1-20240208-C00156
         		3-[6-amino-5-[3- (dimethylamino) phenyl]-3- pyridyl] benzamide 3.52109 2.77 382_0135_0347
    Figure US20240041868A1-20240208-C00157
         		5-(3,4- dimethoxyphen- yl)-3-[3- (dimethylamino) phenyl]pyridin- 2-amine 5.04712 3.61 382_0135_0079
    Figure US20240041868A1-20240208-C00158
         		4-[2-amino-5-(3- chloro-4-fluoro- phenyl)-3- pyridyl]-2- methoxy-phenol 11.34048 4.10 382_0314_0164
    Figure US20240041868A1-20240208-C00159
         		5-(4- methoxyphenyl)- 3-(3,4,5- trimethoxyphen- yl)pyridin-2- amine 2.97729 3.18 382_0087_0280
    Figure US20240041868A1-20240208-C00160
         		4-[2-amino-5-(4- methoxyphenyl)- 3-pyridyl]-2- methoxy-phenol 4.15847 3.20 382_0314_0280
    Figure US20240041868A1-20240208-C00161
         		5-(3-furyl)-3- (3,4,5- trimethoxyphen- yl)pyridin-2- amine 12.0965 2.48 382_0087_0343
    Figure US20240041868A1-20240208-C00162
         		5-(2- phenoxyphenyl)- 3-(3,4,5- trimethoxyphen- yl)pyridin-2- amine 9.00592 4.84 382_0087_0063
    Figure US20240041868A1-20240208-C00163
         		4-[6-amino-5- (3,4,5- trimethoxyphen- yl)-3- pyridyl] benzamide 0.40043 2.19 382_0087_0346
    Figure US20240041868A1-20240208-C00164
         		4-[2-amino-5-(3- methoxyphenyl)- 3-pyridyl]-2- methoxy-phenol 1.19944 3.20 382_0314_4140
    Figure US20240041868A1-20240208-C00165
         		[4-[2-amino-5- (3,4- dimethoxyphen- yl)-3- pyridyl]phenyl] methanol 5.13242 2.73 382_0285_0079
    Figure US20240041868A1-20240208-C00166
         		5-[4-(4- methylpiperazin- 1-yl)phenyl]-3- (3,4,5- trimethoxyphen- yl)pyridin-2- amine 0.32234 3.30 382_0087_0218
    Figure US20240041868A1-20240208-C00167
         		3-(4- fluorophenyl)-N- methyl- imidazo[1,2- b]pyridazin-6- amine 3.25909 2.43 437_0339
    Figure US20240041868A1-20240208-C00168
         		3-(4- methoxyphenyl)- N-methyl- imidazo[1,2- b]pyridazin-6- amine 4.15763 2.13 437_0280
    Figure US20240041868A1-20240208-C00169
         		2-[6- (methylamino) imidazo[1,2- b]pyridazin-3- yl]phenol 1.13395 1.98 437_0340
    Figure US20240041868A1-20240208-C00170
         		N-methyl-3-(3- thienyl)imidazo [1,2-b]pyridazin- 6-amine 4.23169 2.07 437_0074
    Figure US20240041868A1-20240208-C00171
         		3-[6- (methylamino) imidazo[1,2- b]pyridazin-3- yl]phenol 2.17588 1.98 437_0284
    Figure US20240041868A1-20240208-C00172
         		3-(3,4- dimethoxyphen- yl)-N-methyl- imidazo[1,2- b]pyridazin-6- amine 1.24313 1.97 437_0079
    Figure US20240041868A1-20240208-C00173
         		N,N-dimethyl-3- [6- (methylamino) imidazo[1,2- b]pyridazin-3- yl]benzamide 2.94156 1.59 437_0349
    Figure US20240041868A1-20240208-C00174
         		N-methyl-3-(1- methylpyrazol- 4- yl)imidazo[1,2- b]pyridazin-6- amine 5.63446 0.72 437_7468
    Figure US20240041868A1-20240208-C00175
         		N-[3-[6- (methylamino) imidazo[1,2- b]pyridazin-3- yl]phenyl] acetamide 1.75426 1.53 437_0081
    Figure US20240041868A1-20240208-C00176
         		3-(6-methoxy-3- pyridyl)-N- methyl- imidazo[1,2- b]pyridazin-6- amine 4.46164 1.51 437_0311
    Figure US20240041868A1-20240208-C00177
         		6-(1H-indol-5- yl)-N-methyl- pyrazin-2-amine 14.9424 1.74 445_0204
    Figure US20240041868A1-20240208-C00178
         		N-ethyl-2-(3,4,5- trimethoxy- anilino)- 7,8-dihydro- 5H-pyrido[4,3- d]pyrimidine-6- carboxamide 4.24682 1.18 582_9377_5725
    Figure US20240041868A1-20240208-C00179
         		6-propyl-N- (3,4,5- trimethoxyphen- yl)-7,8-dihydro- 5H-pyrido[4,3- d]pyrimidin-2- amine 14.67829 2.59 582_9377_5632
    Figure US20240041868A1-20240208-C00180
         		[2-[3- (dimethylamino) anilino]-5,7- dihydropyrrolo [3,4-d] pyrimidin-6- yl]-(2- methoxyphenyl) methanone 10.08397 2.97 585_9372_5053
    Figure US20240041868A1-20240208-C00181
         		N-(2- hydroxyethyl)-4- [3-(4- hydroxyphenyl) imidazo[1,2- a]pyrazin-6- yl+benzamide 0.64093 1.22 388_0080_0328
    Figure US20240041868A1-20240208-C00182
         		3-[3-(4- hydroxyphenyl) imidazo[1,2- a]pyrazin-6-yl]- N,N-dimethyl- benzamide 0.97398 2.14 388_0080_0349
    Figure US20240041868A1-20240208-C00183
         		4-[6-[4-(4- isopropyl- piperazin-1- yl)phenyl] imidazo [1,2-a]pyrazin- 3-yl]phenol 0.63733 3.57 388_0080_0182
    Figure US20240041868A1-20240208-C00184
         		4-[6-(1- benzylpyrazol- 4- yl)imidazo[1,2- a]pyrazin-3- yl]phenol 6.6194 2.99 388_0080_7469
    Figure US20240041868A1-20240208-C00185
         		4-[3-(2- thienyl)imidazo [1,2-a]pyrazin-6- yl]phenol 6.25235 2.62 388_4147_0080
    Figure US20240041868A1-20240208-C00186
         		3,6-bis(2- thienyl)imidazo [1,2-a]pyrazine 5.02752 2.70 388_4147_4147
    Figure US20240041868A1-20240208-C00187
         		N-(2- hydroxyethyl)-3- [3-(4- hydroxyphenyl) imidazo[1,2- a]pyrazin-6- yl]benzamide 1.03081 1.22 388_0080_0192
    Figure US20240041868A1-20240208-C00188
         		N-cyclopropyl-4- [3-(4- hydroxyphenyl) imidazo[1,2- a]pyrazin-6- yl]benzamide 1.95812 2.38 388_0080_7489
    Figure US20240041868A1-20240208-C00189
         		4-[6-[4-(4- methylpiperazin- 1- yl)phenyl] imidazo [1,2-a]pyrazin- 3-yl]phenol 0.67809 2.79 388_0080_0218
    Figure US20240041868A1-20240208-C00190
         		4-[6-(6-amino-3- pyridyl)imidazo [1,2-a]pyrazin-3- yl]phenol 1.9327 1.39 388_0080_7905
    Figure US20240041868A1-20240208-C00191
         		5-[3-(2- thienyl)imidazo [1,2-a]pyrazin-6- yl]pyridin-2- amine 8.16191 1.47 388_4147_7905
    Figure US20240041868A1-20240208-C00192
         		4-[3-(3- acetylphenyl) imidazo[1,2- a]pyrazin-6-yl]- N-(2- dimethylamino- ethyl)benzamide 4.07021 1.79 388_4145_0327
    Figure US20240041868A1-20240208-C00193
         		N-(2- dimethylamino- ethyl)-4-[3-(2- thienyl)imidazo [1,2-a]pyrazin-6- yl]benzamide 8.52139 2.01 388_4147_0327
    Figure US20240041868A1-20240208-C00194
         		4-[3-(3,5- dimethoxyphen yl)imidazo[1,2- a]pyrazin-6-yl]- N-[3- (dimethylamino) propyl] benzamide 6.69112 1.98 388_7492_0180
    Figure US20240041868A1-20240208-C00195
         		N-(2- dimethylamino- ethyl)-4-[3-(4- pyridyl)imidazo [1,2-a]pyrazin-6- yl]benzamide 6.90909 1.02 388_0069_0327
    Figure US20240041868A1-20240208-C00196
         		4-[6-[2- (dimethylamino) phenyl]imidazo [1,2-a]pyrazin-3- yl]-2-methoxy- phenol 1.75434 2.79 388_0314_0006
    Figure US20240041868A1-20240208-C00197
         		N-(2- hydroxyethyl)-3- [3-(4-hydroxy-3- methoxy- phenyl)imidazo [1,2-a]pyrazin-6- yl]benzamide 0.8957 1.07 388_0314_0192
    Figure US20240041868A1-20240208-C00198
         		2-methoxy-4-[6- (3- pyridyl)imidazo [1,2-a]pyrazin-3- yl]phenol 3.06577 1.46 388_0314_0071
    Figure US20240041868A1-20240208-C00199
         		4-[6-(2- chlorophenyl) imidazo[1,2- a]pyrazin-3-yl]- 2-methoxy- phenol 2.53905 3.28 388_0314_4027
    Figure US20240041868A1-20240208-C00200
         		4-[6-(3- ethoxyphenyl) imidazo[1,2- a]pyrazin-3-yl]- 2-methoxy- phenol 1.36347 2.88 388_0314_0205
    Figure US20240041868A1-20240208-C00201
         		N-(2- dimethylamino- ethyl)-4-[3-(4- hydroxy-3- methoxy- phenyl)imidazo [1,2-a]pyrazin-6- yl]benzamide 0.44033 1.77 388_0314_0327
    Figure US20240041868A1-20240208-C00202
         		4-[6-(6-amino-3- pyridyl)imidazo [1,2-a]pyrazin-3- yl]-2-methoxy- phenol 1.41172 1.23 388_0314_7905
    Figure US20240041868A1-20240208-C00203
         		2-methoxy-4-[6- [6-(4- methylpiperazin- 1-yl)-3- pyridyl]imidazo [1,2-a]pyrazin-3- yl]phenol 1.13372 2.01 388 _0314 _0016
    Figure US20240041868A1-20240208-C00204
         		2-methoxy-4-[6- (1- methylpyrazol- 4- yl)imidazo[1,2- a]pyrazin-3- yl]phenol 0.74595 1.11 388_0314_8400
    Figure US20240041868A1-20240208-C00205
         		N-[3-[3-(3,4,5- trimethoxyphen- yl)imidazo[1,2- a]pyrazin-6- yl]phenyl]meth- anesulfonamide 2.79564 1.04 388_0087_6488
    Figure US20240041868A1-20240208-C00206
         		N-[3- (dimethylamino) propyl]-4-[3-(4- hydroxy-3- methoxy- phenyl)imidazo [1,2-a]pyrazin-6- yl]benzamide 0.60574 1.83 388_0314_0180
    Figure US20240041868A1-20240208-C00207
         		2-methoxy-4-[6- [6-(2- morpholinoethyl- amino)-3- pyridyl]imidazo [1,2-a]pyrazin-3- yl]phenol 1.35363 1.33 388 _0314 _0003
    Figure US20240041868A1-20240208-C00208
         		6-(1- methylpyrazol- 4-yl)-3-(3- thienyl)imidazo [1,2-a]pyrazine 6.37648 1.35 388_0074_8400
    Figure US20240041868A1-20240208-C00209
         		6-phenyl-3-(3- thienyl)imidazo [1,2-a]pyrazine 3.94995 2.92 388_0074_0061
    Figure US20240041868A1-20240208-C00210
         		[4-[3-(3- thienyl)imidazo [1,2-a]pyrazin-6- yl]phenyl]metha- nol 2.3518 2.16 388_0074_0285
    Figure US20240041868A1-20240208-C00211
         		4-[3-(4- methoxyphenyl) imidazo[1,2- a]pyrazin-6- yl]phenol 10.45826 2.68 388_0280_0080
    Figure US20240041868A1-20240208-C00212
         		6-(3-pyridyl)-3- (3- thienyl)imidazo [1,2-a]pyrazine 4.33598 1.70 388_0074_0071
    Figure US20240041868A1-20240208-C00213
         		3-(4-pyridyl)-6- (2- thienyl)imidazo [1,2-a]pyrazine 5.68757 1.70 388_0069_4147
    Figure US20240041868A1-20240208-C00214
         		4-[3-(3- thienyl)imidazo [1,2-a]pyrazin-6- yl]phenol 2.70168 2.62 388_0074_0080
    Figure US20240041868A1-20240208-C00215
         		6-(2-thienyl)-3- (3- thienyl)imidazo [1,2-a]pyrazine 2.24904 2.70 388_0074_4147
    Figure US20240041868A1-20240208-C00216
         		N-[3-[3-(3- thienyl)imidazo [1,2-a]pyrazin-6- yl]phenyl] acetamide 2.32941 2.16 388_0074_0081
    Figure US20240041868A1-20240208-C00217
         		N-[3-[3-(3- thienyl)imidazo [1,2-a]pyrazin-6- yl]phenyl]meth- anesulfonamide 3.32047 1.30 388_0074_6488
    Figure US20240041868A1-20240208-C00218
         		6-(2-furyl)-3-(3- thienyl)imidazo [1,2-a]pyrazine 6.25008 1.98 388_0074_0142
    Figure US20240041868A1-20240208-C00219
         		3-(6- phenylimidazo [1,2-a]pyrazin- 3-yl)phenol 6.54588 2.84 388_0284_0061
    Figure US20240041868A1-20240208-C00220
         		3-[3-(3- hydroxyphenyl) imidazo[1,2- a]pyrazin-6- yl]benzamide 1.58014 1.69 388_0284_0347
    Figure US20240041868A1-20240208-C00221
         		4-[6-(3- pyridyl)imidazo [1,2-a]pyrazin-3- yl]phenol 2.72591 1.62 388_0080_0071
    Figure US20240041868A1-20240208-C00222
         		[4-[3-(4- phenoxyphenyl) imidazo[1,2- a]pyrazin-6- yl]phenyl]metha- nol 4.72246 3.88 388_1029_0285
    Figure US20240041868A1-20240208-C00223
         		4-[6-(4- chlorophenyl) imidazo[1,2- a]pyrazin-3- yl]phenol 6.37838 3.44 388_0080_0160
    Figure US20240041868A1-20240208-C00224
         		3-[6-(2- thienyl)imidazo [1,2-a]pyrazin-3- yl]phenol 2.78435 2.62 388_0284_4147
    Figure US20240041868A1-20240208-C00225
         		6-(1- methylpyrazol- 4-yl)-3-(4- phenoxyphenyl) imidazo[1,2- a]pyrazine 1.92958 3.07 388_1029_8400
    Figure US20240041868A1-20240208-C00226
         		3-[6-(2- furyl)imidazo [1,2-a]pyrazin- 3-yl]phenol 6.11196 1.90 388_0284_0142
    Figure US20240041868A1-20240208-C00227
         		4-[6-(6- methoxy-3- pyridyl)imidazo 1,2-a]pyrazin-3- yl]phenol 1.97871 2.06 388_0080_0311
    Figure US20240041868A1-20240208-C00228
         		3-[6-[4- (hydroxymethyl) phenyl]imidazo [1,2-a]pyrazin-3- yl]phenol 3.35687 2.07 388_0284_0285
    Figure US20240041868A1-20240208-C00229
         		3-[6-(1- methylpyrazol- 4- yl)imidazo[1,2- a]pyrazin-3- yl]phenol 2.78229 1.27 388_0284_8400
    Figure US20240041868A1-20240208-C00230
         		4-[6-(1- methylpyrazol- 4- yl)imidazo[1,2- a]pyrazin-3- yl]phenol 1.58926 1.27 388_0080_8400
    Figure US20240041868A1-20240208-C00231
         		6-[6-(4- methylpiperazin- 1-yl)-3-pyridyl]- 3-(4- phenoxyphenyl) imidazo[1,2- a]pyrazine 2.13162 3.97 388_1029_0016
    Figure US20240041868A1-20240208-C00232
         		N-(2- hydroxyethyl)-3- [3-(4- phenoxyphenyl) imidazo[1,2- a]pyrazin-6- yl]benzamide 1.48118 3.03 388_1029_0192
    Figure US20240041868A1-20240208-C00233
         		N-(2- dimethylamino- ethyl)-4-[3-(4- phenoxyphenyl) imidazo[1,2- a]pyrazin-6- yl]benzamide 0.1649 3.74 388_1029_0327
    Figure US20240041868A1-20240208-C00234
         		N-(2- hydroxyethyl)-4- [3-(4- phenoxyphenyl) imidazo[1,2- a]pyrazin-6- yl]benzamide 0.62307 3.03 388_1029_0328
    Figure US20240041868A1-20240208-C00235
         		4-[3-(3- chlorophenyl) imidazo[1,2- a]pyrazin-6-yl]- N-[3- (dimethylamino) propyl] benzamide 8.43215 2.90 388_0279_0180
    Figure US20240041868A1-20240208-C00236
         		5-[3-(4- phenoxyphenyl) imidazo[1,2- a]pyrazin-6- yl]pyridin-2- amine 1.71808 3.19 388_1029_7905
    Figure US20240041868A1-20240208-C00237
         		N-[3- (dimethylamino) propyl]-4-[3-(3- thienyl)imidazo [1,2-a]pyrazin-6- yl]benzamide 3.87213 2.08 388_0074_0180
    Figure US20240041868A1-20240208-C00238
         		3-(4- methoxyphenyl)- 6-[4-(4- methylpiperazin- 1- yl)phenyl] imidazo [1,2-a]pyrazine 5.25112 2.94 388_0280_0218
    Figure US20240041868A1-20240208-C00239
         		N-(2- hydroxyethyl)-3- [3-(3- thienyl)imidazo 1,2-a]pyrazin-6- yl]benzamide 3.67126 1.31 388_0074_0192
    Figure US20240041868A1-20240208-C00240
         		6-[6-(4- methylpiperazin- 1-yl)-3-pyridyl]- 3-(3- thienyl)imidazo [1,2-a]pyrazine 7.04574 2.25 388_0074_0016
    Figure US20240041868A1-20240208-C00241
         		5-[3-(3- thienyl)imidazo [1,2-a]pyrazin-6- yl]pyridin-2- amine 2.45583 1.47 388_0074_7905
    Figure US20240041868A1-20240208-C00242
         		3,6-bis(3- thienyl)imidazo [1,2-a]pyrazine 8.47406 2.70 388_0074_0074
    Figure US20240041868A1-20240208-C00243
         		N-(2- dimethylamino- ethyl)-4-[3-(3- thienyl)imidazo [1,2-a]pyrazin-6- yl]benzamide 1.89752 2.02 388_0074_0327
    Figure US20240041868A1-20240208-C00244
         		3-(1- methylpyrazol- 4-yl)-6-(2- phenoxyphenyl) imidazo[1,2- a]pyrazine 1.81873 3.07 388_8400_0063
    Figure US20240041868A1-20240208-C00245
         		3-[6-[6-(4- methylpiperazin- 1-yl)-3- pyridyl]imidazo [1,2-a]pyrazin-3- yl]phenol 3.14141 2.17 388_0284_0016
    Figure US20240041868A1-20240208-C00246
         		3-[[5-[3-(1,3- benzodioxol-5- yl)imidazo[1,2- a]pyrazin-6-yl]- 2-pyridyl]oxy]- propan-1-amine 9.85132 2.06 388_0068_0002
    Figure US20240041868A1-20240208-C00247
         		3-[6-(3- ethoxyphenyl) imidazo[1,2- a]pyrazin-3- yl]phenol 6.6859 3.04 388_0284 _0205
    Figure US20240041868A1-20240208-C00248
         		3-(1,3- benzodioxol-5- yl)-6-[4-(4- methylpiperazin- 1- yl)phenyl] imidazo [1,2-a]pyrazine 7.93105 2.72 388_0068_0218
    Figure US20240041868A1-20240208-C00249
         		3-[6-(3- thienyl)imidazo [1,2-a]pyrazin-3- yl]phenol 2.51787 2.62 388_0284_0074
    Figure US20240041868A1-20240208-C00250
         		3-[6-[4-(4- methylpiperazin- 1- yl)phenyl] imidazo [1,2-a]pyrazin- 3-yl]phenol 1.58793 2.79 388_0284_0218
    Figure US20240041868A1-20240208-C00251
         		4-[3-(4- chlorophenyl) imidazo[1,2- a]pyrazin-6-yl]- N-[3- (dimethylamino) propyl] benzamide 4.90272 2.90 388_0160_0180
    Figure US20240041868A1-20240208-C00252
         		4-[3-(1,3- benzodioxol-5- yl)imidazo[1,2- a]pyrazin-6-yl]- N-(2- dimethylamino- ethyl) benzamide 3.79881 1.86 388_0068_0327
    Figure US20240041868A1-20240208-C00253
         		3-[6-(6-amino-3- pyridyl)imidazo [1,2-a]pyrazin-3- yl]phenol 2.88877 1.39 388_0284_7905
    Figure US20240041868A1-20240208-C00254
         		N-(2- dimethylamino ethyl)-4-[3-(3- hydroxyphenyl) imidazo[1,2- a]pyrazin-6- yl]benzamide 0.81226 1.93 388_0284_0327
    Figure US20240041868A1-20240208-C00255
         		4-[3-(4- chlorophenyl) imidazo[1,2- a]pyrazin-6-yl]- N-(2- dimethylamino- ethyl) benzamide 4.15862 2.84 388_0160_0327
    Figure US20240041868A1-20240208-C00256
         		3-[6-[6-(2- morpholinoethyl amino)-3- pyridyl]imidazo [1,2-a]pyrazin-3- yl]phenol 2.93938 1.49 388_0284_0003
    Figure US20240041868A1-20240208-C00257
         		N-[3- (dimethylamino) propyl]-4-[3-(3- hydroxyphenyl) imidazo[1,2- a]pyrazin-6- yl]benzamide 1.61113 1.99 388_0284_0180
    Figure US20240041868A1-20240208-C00258
         		N-(2- hydroxyethyl)-4- [3-(3- hydroxyphenyl) imidazo[1,2- a]pyrazin-6- yl]benzamide 1.72336 1.22 388_0284_0328
    Figure US20240041868A1-20240208-C00259
         		4-[3-(1,3- benzodioxol-5- yl)imidazo[1,2- a]pyrazin-6-yl]- N-[3- (dimethylamino) propyl] benzamide 6.03233 1.92 388_0068_0180
    Figure US20240041868A1-20240208-C00260
         		6-[6-(4- methylpiperazin- 1-yl)-3-pyridyl]- 3-phenyl- imidazo[1,2- a]pyrazine 10.85328 2.47 388_0061_0016
    Figure US20240041868A1-20240208-C00261
         		3-[6-[4-(4- isopropylpiper- azin-1- yl)phenyl] imidazo [1,2-a]pyrazin- 3-yl]phenol 2.61352 357 388_0284_0182
    Figure US20240041868A1-20240208-C00262
         		5-[3-(1,3- benzodioxol-5- yl)imidazo[1,2- a]pyrazin-6- yl]pyridin-2- amine 10.2391 1.31 388_0068_7905
    Figure US20240041868A1-20240208-C00263
         		4-[6-[6-[3- (dimethylamino) propoxy]-3- pyridyl]imidazo [1,2-a]pyrazin-3- yl]phenol 1.32178 2.14 388_0080_0002
    Figure US20240041868A1-20240208-C00264
         		4-[6-[6-(2- morpholinoethyl- amino)-3- pyridyl]imidazo [1,2-a]pyrazin-3- yl]phenol 1.31444 1.49 388_0080_0003
    Figure US20240041868A1-20240208-C00265
         		4-[6-[6-(4- methylpiperazin- 1-yl)-3- pyridyl]imidazo [1,2-a]pyrazin-3- yl]phenol 2.21078 2.17 388_0080_0016
    Figure US20240041868A1-20240208-C00266
         		3-[2- (cyclohexyl- amino) imidazo[2,1- b][1,3,4]thia- diazol-5-yl]- N,N- dimethyl- benzamide 0.71795 3.60 699_0052_0349
    Figure US20240041868A1-20240208-C00267
         		N,N-dimethyl-3- [2-[2-(4- sulfamoylphenyl) ethylamino] imidazo[2,1- b][1,3,4]thia- diazol-5- yl]benzamide 0.9091 2.42 699_6182_0349
    Figure US20240041868A1-20240208-C00268
         		3-[2-[(4- hydroxycyclo- hexyl)amino] imidazo[2,1- b][1,3,4]thia- diazol-5-yl]- N,N- dimethyl- benzamide 0.53282 2.22 699_0240_0349
    Figure US20240041868A1-20240208-C00269
         		1-[3-[2-[(4- hydroxycyclo- hexyl)amino] imidazo[2,1- b][1,3,4]thia- diazol-5- yl]phenyl] ethanone 0.48712 2.48 699_0240_4145
    Figure US20240041868A1-20240208-C00270
         		6-(3- chlorophenyl)-3- (3,4- dimethoxyphen- yl)pyrazolo[1,5- a]pyrimidin-7- amine 0.80424 3.50 DT2008- 0028664
    Figure US20240041868A1-20240208-C00271
         		N-[3-[2-(2- furylmethyl- amino) imidazo[2,1- b][1,3,4]thia- diazol-5- yl]phenyl] acetamide 4.56802 2.53 699_0144_0081
    Figure US20240041868A1-20240208-C00272
         		3-[2- (cyclopropyl- methyl- amino)imidazo [2,1- b][1,3,4]thia- diazol-5-yl]- N,N- dimethyl- benzamide 0.97667 2.59 699_4051_0349
    Figure US20240041868A1-20240208-C00273
         		3-[2- (isobutylamino) imidazo[2,1- b][1,3,4]thia- diazol-5-yl]- N,N- dimethyl- benzamide 0.28265 3.05 699_0149_0349
    Figure US20240041868A1-20240208-C00274
         		3-[2-[(4- fluorophenyl) methylamino] imidazo[2,1- b][1,3,4]thia- diazol-5-yl]- N,N- dimethyl- benzamide 2.76099 3.67 699_0224_0349
    Figure US20240041868A1-20240208-C00275
         		N-[3-[2-(2- thienylmethyl- amino)imidazo [2,1- b][1,3,4]thia- diazol-5- yl]phenyl] acetamide 3.92554 3.38 699_0146_0081
    Figure US20240041868A1-20240208-C00276
         		4-[2-[[5-(1- methylpyrazol- 4- yl)imidazo[2,1- b][1,3,4]thia- diazol-2- yl]amino]ethyl] benzenesulfon- amide 2.26191 1.55 699_6182_7468
    Figure US20240041868A1-20240208-C00277
         		4-[[5-[3- (dimethylamino) phenyl]imidazo [2,1- b][1,3,4]thia- diazol-2- yl]amino]cyclo- hexanol 5.79421 3.03 699_0240_0135
    Figure US20240041868A1-20240208-C00278
         		N-[3-[2- (isobutylamino) imidazo[2,1- b][1,3,4]thia- diazol-5- yl]phenyl]meth- anesulfonamide 7.06833 2.12 699_0149_6488
    Figure US20240041868A1-20240208-C00279
         		3-[2-(3- hydroxypropyl amino)imidazo [2,1- b][1,3,4]thia- diazol-5- yl]benzamide 2.87875 0.73 699_0248_0347
    Figure US20240041868A1-20240208-C00280
         		4-[2-[(4- hydroxycyclo- hexyl)amino] imidazo[2,1 b][1,3,4]thia- diazol-5-yl] phenol 3.804 2.62 699_0240_0080
    Figure US20240041868A1-20240208-C00281
         		3-[2-(2- furylmethyl- amino) imidazo[2,1- b][1,3,4]thia- diazol-5- yl]benzamide 1.22619 2.14 699_0144_0347
    Figure US20240041868A1-20240208-C00282
         		4-[2-[[5-(6- methoxy-3- pyridyl)imidazo [2,1- b][1,3,4]thia- diazol-2- yl]amino]ethyl] benzenesulfon- amide 2.61127 2.35 699_6182_0311
    Figure US20240041868A1-20240208-C00283
         		N,N-dimethyl-3- [2- (tetrahydropyran- 4- ylmethylamino) imidazo[2,1- b][1,3,4]thia- diazol-5- yl]benzamide 2.72692 2.23 699_0243_0349
    Figure US20240041868A1-20240208-C00284
         		N,N-dimethyl-3- [2-(o- tolylmethyl- amino) imidazo[2,1- b][1,3,4]thia- diazol-5- yl]benzamide 3.73043 4.04 699_8074_0349
    Figure US20240041868A1-20240208-C00285
         		N-isobutyl-5-(5- methoxy-3- pyridyl)imidazo [2,1- b][1,3,4]thia- diazol-2-amine 5.16693 2.38 699_0149_0196
    Figure US20240041868A1-20240208-C00286
         		N-(1,3- benzodioxol-5- ylmethyl)-5-(5- methoxy-3- pyridyl)imidazo [2,1- b][1,3,4]thia- diazol-2-amine 0.44781 2.48 699_0236_0196
    Figure US20240041868A1-20240208-C00287
         		N-[4-[3-(4- hydroxy-3- methoxy- phenyl)imidazo [1,2-b]pyridazin- 6- yl]phenyl] acetamide 0.16907 3.03 828_0314_0722
    Figure US20240041868A1-20240208-C00288
         		N-[3-[6-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-3- yl]phenyl] acetamide 1.16817 3.11 828_0081_0068
    Figure US20240041868A1-20240208-C00289
         		N-[3-[3-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-6- yl]phenyl] acetamide 1.10979 3.11 828_0068_0081
    Figure US20240041868A1-20240208-C00290
         		N-[3-(3- acetylphenyl)-6- [4-(morpholine- 4- carbonyl)phenyl] imidazo[1,2- a]pyridin-8- yl]acetamide 2.02757 1.85 802_4145_0337
    Figure US20240041868A1-20240208-C00291
         		N-[3-[6-[3- (trifluoro- methoxy) phenyl]imidazo [1,2- b]pyridazin-3- yl]phenyl] acetamide 1.5009 4.92 828_0081_0168
    Figure US20240041868A1-20240208-C00292
         		1-[3-[6-(3,4- dimethoxy- phenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] ethanone 0.65302 3.50 828_4145_0079
    Figure US20240041868A1-20240208-C00293
         		N-[3-[6-(4- methylsulfonyl- phenyl)imidazo [1,2-b] pyridazin-3- yl]phenyl] acetamide 1.08226 2.33 828_0081_0174
    Figure US20240041868A1-20240208-C00294
         		N-[3-[3-(3- acetamido- phenyl) imidazo[1,2- b]pyridazin-6- yl]phenyl] acetamide 0.55312 2.73 828_0081_0081
    Figure US20240041868A1-20240208-C00295
         		3-[2-[(4- methoxyphenyl) methylamino] imidazo[2,1- b][1,3,4]thia- diazol-5-yl]- N,N- dimethyl- benzamide 2.33054 3.37 699_0244_0349
    Figure US20240041868A1-20240208-C00296
         		N-[3-[3-(3- acetylphenyl) imidazo[1,2- b]pyridazin-6- yl]phenyl] acetamide 0.6205 3.05 828_4145_0081
    Figure US20240041868A1-20240208-C00297
         		4-[3-(3- acetamido- phenyl) imidazo[1,2- b]pyridazin-6- yl]benzamide 0.22155 2.34 828_0081_0346
    Figure US20240041868A1-20240208-C00298
         		N-[4-[3-(3- hydroxyphenyl) imidazo[1,2- b]pyridazin-6- yl]phenyl] acetamide 0.51873 3.19 828_0284_0722
    Figure US20240041868A1-20240208-C00299
         		N-[2-(4- pyridyl)ethyl]-5- (3,4,5- trimethoxyphen- yl)imidazo[2,1- b][1,3,4]thia- diazol-2-amine 1.77014 2.83 699_0039_0087
    Figure US20240041868A1-20240208-C00300
         		N-[3-(4- fluorophenyl)-6- [4-(morpholine- 4- carbonyl)phenyl] imidazo[1,2- a]pyridin-8- yl]formamide 3.59432 2.39 788_0339_0337
    Figure US20240041868A1-20240208-C00301
         		3-[2- (benzylamino) imidazo[2,1- b][1,3,4]thia- diazol-5-yl]- N,N- dimethyl- benzamide 1.50507 3.53 699_0232_0349
    Figure US20240041868A1-20240208-C00302
         		5-(6-methoxy-3- pyridyl)-N-(4- pyridylmethyl) imidazo[2,1- b][1,3,4]thia- diazol-2-amine 2.58601 2.23 699_0237_0311
    Figure US20240041868A1-20240208-C00303
         		N-[3-[3-[3- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6- yl]phenyl] acetamide 1.63929 2.72 828_0291_0081
    Figure US20240041868A1-20240208-C00304
         		3-[2-(2- furylmethyl- amino) imidazo[2,1- b][1,3,4]thia- diazol-5-yl]- N,N- dimethyl- benzamide 2.46273 2.59 699_0144_0349
    Figure US20240041868A1-20240208-C00305
         		N-[3-[6-(4- dimethylamino- phenyl)imidazo [1,2-b] pyridazin-3- yl]phenyl] acetamide 1.09863 3.60 828_0081_0004
    Figure US20240041868A1-20240208-C00306
         		N-[3-(3- acetylphenyl)-6- [4-(morpholine- 4- carbonyl)phenyl] imidazo[1,2- a]pyridin-8- yl]formamide 2.99487 1.80 788_4145_0337
    Figure US20240041868A1-20240208-C00307
         		N-[3-[3-(4- hydroxy-3- methoxy- phenyl)imidazo [1,2-b] pyridazin- 6- yl]phenyl] acetamide 0.10208 3.03 828_0314_0081
    Figure US20240041868A1-20240208-C00308
         		N-[3-[3-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6- yl]phenyl]meth- anesulfonamide 0.83024 1.86 828_0285_6488
    Figure US20240041868A1-20240208-C00309
         		1-[3-[6-(3- hydroxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] ethanone 0.99396 3.51 828_4145_0284
    Figure US20240041868A1-20240208-C00310
         		[4-[3-[3- (hydroxymethyl) phenyl]imidazo [1,2-b] pyridazin- 6- yl]phenyl] methanol 2.22994 2.72 828_0291_0285
    Figure US20240041868A1-20240208-C00311
         		4-[3-[3- (hydroxymethyl) phenyl]imidazo [1,2-b] pyridazin- 6-yl]benzamide 1.89185 2.34 828_0291_0346
    Figure US20240041868A1-20240208-C00312
         		N-(2- dimethylamino- ethyl)-3-[6-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 3-yl]benzamide 1.47637 2.58 828_0176_0285
    Figure US20240041868A1-20240208-C00313
         		3-[3-(3- hydroxyphenyl) imidazo[1,2- b]pyridazin-6- yl]benzamide 0.31104 2.80 828_0284_0347
    Figure US20240041868A1-20240208-C00314
         		4-[3-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]-2-methoxy- phenol 0.22297 3.02 828_0285_0314
    Figure US20240041868A1-20240208-C00315
         		2-(3,4- dimethoxyphen- yl)-6-hydroxy- chromen-4-one 8.95228 2.35 DT2012- 0347380
    Figure US20240041868A1-20240208-C00316
         		[3-[6-(3- pyridyl)imidazo [1,2-b]pyridazin- 3- yl]phenyl]metha- nol 2.03689 2.27 828_0291_0071
    Figure US20240041868A1-20240208-C00317
         		[3-[6-[(4- fluorophenyl) methyl]imidazo [1,2- b]pyridazin-3- yl]phenyl]metha- nol 3.9747 3.56 828_0291_6370
    Figure US20240041868A1-20240208-C00318
         		[3-[6-(3- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl]metha- nol 2.74495 3.33 828_0291_4140
    Figure US20240041868A1-20240208-C00319
         		N-[3-[3-(4- pyridyl)imidazo [1,2-b]pyridazin- 6- yl]phenyl]meth- anesulfonamide 0.29796 1.41 828_0069_6488
    Figure US20240041868A1-20240208-C00320
         		1-benzyl-N-[4- (4- methylpiperazin- 1-yl)phenyl]-2- (3- pyridyl)pyrrolo [3,2-c] pyridin-6- amine 13.73604 5.14 809_2675_6001_ 0091
    Figure US20240041868A1-20240208-C00321
         		2-(1H-pyrazol-4- yl)-N-(2-pyridyl)- 1H-pyrrolo[3,2- c]pyridin-6- amine 7.566 2.14 809_2678_0263_ 0259
    Figure US20240041868A1-20240208-C00322
         		N-(4- methylsulfonyl- phenyl)-2-(1H- pyrazol-4-yl)- 1H-pyrrolo[3,2- c]pyridin-6- amine 4.77594 1.60 809_2678_0263_ 9248
    Figure US20240041868A1-20240208-C00323
         		1-benzyl-2-(3- pyridyl)-N- pyrimidin-4-yl- pyrrolo[3,2- c]pyridin-6- amine 6.84653 3.86 809_2675_6001_ 6410
    Figure US20240041868A1-20240208-C00324
         		N-(3- methoxyphenyl)- 2-(1H-pyrazol- 4-yl)-1H- pyrrolo[3,2- c]pyridin-6- amine 16.58236 2.60 809_2678_0263_ 0026
    Figure US20240041868A1-20240208-C00325
         		N-(3,4- dimethoxyphen- yl)-2-(1H- pyrazol-4-yl)- 1H-pyrrolo[3,2- c]pyridin-6- amine 12.71137 2.44 809_2678_0263_ 0036
    Figure US20240041868A1-20240208-C00326
         		1-benzyl-N-[4- (4- methylpiperazin- 1-yl)phenyl]-2- phenyl- pyrrolo[3,2- c]pyridin-6- amine 15.018 6.36 809_9960_6001_ 0091
    Figure US20240041868A1-20240208-C00327
         		6-(2- methoxyphenyl)- 3-(4- pyridyl)imidazo [1,2-b]pyridazine 0.58491 2.88 828_0069_0083
    Figure US20240041868A1-20240208-C00328
         		3-[3-(4- pyridyl)imidazo [1,2-b]pyridazin- 6-yl]benzamide 1.2024 1.89 828_0069_0347
    Figure US20240041868A1-20240208-C00329
         		N-[3-(6- phenylimidazo [1,2-b] pyridazin-3- yl)phenyl] acetamide 0.77278 3.49 828_0081_0061
    Figure US20240041868A1-20240208-C00330
         		N-[3-[6-(3- hydroxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] acetamide 1.0711 3.19 828_0081_0284
    Figure US20240041868A1-20240208-C00331
         		3-(3,4- dimethoxyphen- yl)-6-(3- fluorophenyl) imidazo[1,2- b]pyridazine 1.0392 4.08 828_0079_0313
    Figure US20240041868A1-20240208-C00332
         		N-[3-[6-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 3- yl]phenyl] acetamide 0.49363 2.72 828_0081_0285
    Figure US20240041868A1-20240208-C00333
         		[3-(6- phenylimidazo [1,2-b] pyridazin-3- yl)phenyl]metha- nol 1.74526 3.49 828_0291_0061
    Figure US20240041868A1-20240208-C00334
         		6-(3- chlorophenyl)-3- (4- pyridyl)imidazo [1,2-b]pyridazine 0.25819 3.64 828_0069_0279
    Figure US20240041868A1-20240208-C00335
         		4-[3-(3,4- dimethoxyphen- yl)imidazo[1,2- b]pyridazin-6- yl]-2-methoxy- phenol 0.22231 3.48 828_0079_0314
    Figure US20240041868A1-20240208-C00336
         		N-[3-[6-(2- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] acetamide 2.85447 3.33 828_0081_0083
    Figure US20240041868A1-20240208-C00337
         		N-[3-[6-[3- (trifluoromethyl) phenyl]imidazo [1,2-b]pyridazin- 3- yl]phenyl] acetamide 1.6027 4.37 828_0081_0312
    Figure US20240041868A1-20240208-C00338
         		[3-[6-(2- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl]metha- nol 1.06972 3.33 828_0291_0083
    Figure US20240041868A1-20240208-C00339
         		4-[3-[3- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]-2-methoxy- phenol 0.15309 3.02 828_0291_0314
    Figure US20240041868A1-20240208-C00340
         		3-phenyl-6-(4- pyridyl)imidazo [1,2-b]pyridazine 6.92543 3.04 828_0061_0069
    Figure US20240041868A1-20240208-C00341
         		3-[3-(4- pyridyl)imidazo [1,2-b]pyridazin- 6-yl]phenol 0.22268 2.73 828_0069_0284
    Figure US20240041868A1-20240208-C00342
         		3-(3,4- dimethoxyphen- yl)-6-phenyl- imidazo[1,2- b]pyridazine 0.42017 3.94 828_0079_0061
    Figure US20240041868A1-20240208-C00343
         		3-(3,4- dimethoxyphen- yl)-6-(4- fluorophenyl) imidazo[1,2- b]pyridazine 1.33171 4.08 828_0079_0339
    Figure US20240041868A1-20240208-C00344
         		N-[3-[6-(3,4,5- trimethoxyphen- yl)imidazo[1,2- b]pyridazin-3- yl]phenyl] acetamide 3.13438 3.02 828_0081_0087
    Figure US20240041868A1-20240208-C00345
         		N-[3-[6-(4- hydroxy-3- methoxy- phenyl)imidazo [1,2-b]pyridazin- 3- yl]phenyl] acetamide 0.09296 3.03 828_0081_0314
    Figure US20240041868A1-20240208-C00346
         		3-phenyl-6-(3- pyridyl)imidazo [1,2-b]pyridazine 3.84274 3.04 828_0061_0071
    Figure US20240041868A1-20240208-C00347
         		[4-[3-(4- pyridyl)imidazo [1,2-b]pyridazin- 6- yl]phenyl]metha- nol 0.2553 2.27 828_0069_0285
    Figure US20240041868A1-20240208-C00348
         		3-(3,4- dimethoxyphen- yl)-6-(2- methoxyphenyl) imidazo[1,2- b]pyridazine 3.12222 3.78 828_0079_0083
    Figure US20240041868A1-20240208-C00349
         		3-(3,4- dimethoxyphen- yl)-6-(3- furyl)imidazo [1,2-b] pyridazine 0.98263 3.08 828_0079_0343
    Figure US20240041868A1-20240208-C00350
         		N-[3-[6-(3- furyl)imidazo [1,2-b] pyridazin-3- yl]phenyl] acetamide 1.2569 2.63 828_0081_0343
    Figure US20240041868A1-20240208-C00351
         		[3-[6-(3- furyl)imidazo [1,2-b] pyridazin-3- yl]phenyl] methanol 3.99398 2.63 828_0291_0343
    Figure US20240041868A1-20240208-C00352
         		N,N-dimethyl-4- [3-(4- pyridyl)imidazo [1,2-b]pyridazin- 6-yl]aniline 0.39834 3.14 828_0069_0004
    Figure US20240041868A1-20240208-C00353
         		[3-[6-(4- methylsulfonyl- phenyl)imidazo [1,2-b] pyridazin-3- yl]phenyl]metha- nol 3.03776 2.33 828_0291_0174
    Figure US20240041868A1-20240208-C00354
         		N-[3-(3- phenylimidazo [1,2-b] pyridazin-6- yl)phenyl] acetamide 3.66176 3.49 828_0061_0081
    Figure US20240041868A1-20240208-C00355
         		6-phenyl-3-(4- pyridyl)imidazo [1,2-b]pyridazine 0.22894 3.04 828_0069_0061
    Figure US20240041868A1-20240208-C00356
         		6-(3- fluorophenyl)-3- (4- pyridyl)imidazo [1,2-b]pyridazine 0.35611 3.18 828_0069_0313
    Figure US20240041868A1-20240208-C00357
         		3-(3,4- dimethoxyphen- yl)-6-(3- methoxyphenyl) imidazo[1,2- b]pyridazine 0.95169 3.78 828_0079_4140
    Figure US20240041868A1-20240208-C00358
         		N-[3-[6-(5- methoxy-3- pyridyl)imidazo [1,2-b]pyridazin- 3- yl]phenyl] acetamide 0.614 2.12 828_0081_0196
    Figure US20240041868A1-20240208-C00359
         		[3-[6-(5- methoxy-3- pyridyl)imidazo [1,2-b]pyridazin- 3- yl]phenyl] methanol 2.14052 2.11 828_0291_0196
    Figure US20240041868A1-20240208-C00360
         		6-(1,3- benzodioxol-5- yl)-3-(4- pyridyl)imidazo [1,2-b]pyridazine 0.21745 2.66 828_0069_0068
    Figure US20240041868A1-20240208-C00361
         		6-(3-furyl)-3-(4- pyridyl)imidazo [1,2-b]pyridazine 1.02049 2.18 828_0069_0343
    Figure US20240041868A1-20240208-C00362
         		N-[3-[6-(3- chlorophenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] acetamide 0.3705 4.10 828_0081_0279
    Figure US20240041868A1-20240208-C00363
         		N-[3-[6-(3- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] acetamide 0.40863 3.33 828_0081_4140
    Figure US20240041868A1-20240208-C00364
         		3-[3-[3- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]phenol 0.95381 3.18 828_0291_0284
    Figure US20240041868A1-20240208-C00365
         		4-(3- phenylimidazo [1,2-b] pyridazin-6- yl)benzamide 2.14265 3.10 828_0061_0346
    Figure US20240041868A1-20240208-C00366
         		3-[3-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-6- yl]phenol 0.91497 3.57 828_0068_0284
    Figure US20240041868A1-20240208-C00367
         		6-phenyl-3-(3- pyridyl)imidazo [1,2-b]pyridazine 1.94131 3.04 828_0071_0061
    Figure US20240041868A1-20240208-C00368
         		3-(3-pyridyl)-6- (2- thienyl)imidazo [1,2-b]pyridazine 0.34617 2.81 828_0071_4147
    Figure US20240041868A1-20240208-C00369
         		N-[3-[6-(3- acetylphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] acetamide 0.46574 3.05 828_0081_4145
    Figure US20240041868A1-20240208-C00370
         		3-[6-(3- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenol 1.2357 3.79 828_0284_4140
    Figure US20240041868A1-20240208-C00371
         		4-[6-(3,4- dimethoxyphen- yl)imidazo[1,2- b]pyridazin-3- yl]-2-methoxy- phenol 0.04451 3.48 828_0314_0079
    Figure US20240041868A1-20240208-C00372
         		1-[3-[6-(2- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] ethanone 2.3343 3.65 828_4145_0083
    Figure US20240041868A1-20240208-C00373
         		1-[3-[6-(1- methylpyrazol- 4- yl)imidazo[1,2- b]pyridazin-3- yl]phenyl] ethanone 0.37322 2.24 828_4145_7468
    Figure US20240041868A1-20240208-C00374
         		N-[3-[3-(2- thienyl)imidazo [1,2-b]pyridazin- 6- yl]phenyl]meth- anesulfonamide 1.20815 2.40 828_4147_6488
    Figure US20240041868A1-20240208-C00375
         		3-(1,3- benzodioxol-5- yl)-6-(3- pyridyl)imidazo [1,2-b]pyridazine 0.68757 2.66 828_0068_0071
    Figure US20240041868A1-20240208-C00376
         		[4-[3-(3- pyridyl)imidazo [1,2-b]pyridazin- 6- yl]phenyl] methanol 2.9094 2.27 828_0071_0285
    Figure US20240041868A1-20240208-C00377
         		6-benzyl-3-(3,4- dimethoxyphen- yl)imidazo[1,2- b]pyridazine 0.97448 3.87 828_0079_6001
    Figure US20240041868A1-20240208-C00378
         		3-[6-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 3-yl]phenol 0.28545 3.18 828_0284_0285
    Figure US20240041868A1-20240208-C00379
         		[4-[6-(2- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 3.90029 3.33 828_0285_0083
    Figure US20240041868A1-20240208-C00380
         		[4-[6-(3- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 1.55838 3.33 828_0285_4140
    Figure US20240041868A1-20240208-C00381
         		2-methoxy-4-[6- (3- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenol 0.22071 3.63 828_0314_4140
    Figure US20240041868A1-20240208-C00382
         		1-[3-[6-(3- furyl)imidazo [1,2-b] pyridazin-3- yl]phenyl] ethanone 3.4398 2.95 828_4145_0343
    Figure US20240041868A1-20240208-C00383
         		4-[3-(2- thienyl)imidazo [1,2-b]pyridazin- 6-yl]benzamide 0.95101 2.88 828_4147_0346
    Figure US20240041868A1-20240208-C00384
         		3-[3-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-6- yl]-N-(2- hydroxyethyl) benzamide 0.36748 2.26 828_0068_0192
    Figure US20240041868A1-20240208-C00385
         		[3-[3-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-6- yl]phenyl] methanol 0.33166 3.11 828_0068_0291
    Figure US20240041868A1-20240208-C00386
         		N-[3-[6-(2- thienyl)imidazo [1,2-b]pyridazin- 3- yl]phenyl] acetamide 0.20995 3.27 828_0081_4147
    Figure US20240041868A1-20240208-C00387
         		3-(6- phenylimidazo [1,2-b] pyridazin-3- yl)phenol 0.89352 3.95 828_0284_0061
    Figure US20240041868A1-20240208-C00388
         		1-[3-[3-(3- hydroxyphenyl) imidazo[1,2- b]pyridazin-6- yl]phenyl]NL ethanone 1.60026 3.51 828_0284_4145
    Figure US20240041868A1-20240208-C00389
         		[4-[6-(3- fluorophenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 2.95859 3.63 828_0285_0313
    Figure US20240041868A1-20240208-C00390
         		1-[3-[3-[3- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6- yl]phenyl] ethanone 2.16824 3.04 828_0291_4145
    Figure US20240041868A1-20240208-C00391
         		1-[3-[6-[3- (dimethylamino) phenyl]imidazo [1,2-b]pyridazin- 3- yl]phenyl] ethanone 0.88623 3.92 828_4145_0135
    Figure US20240041868A1-20240208-C00392
         		1-[3-[6-(6- amino-3- pyridyl)imidazo [1,2-b]pyridazin- 3- yl]phenyl] ethanone 0.28267 2.36 828_4145_7905
    Figure US20240041868A1-20240208-C00393
         		[4-[3-(2- thienyl)imidazo [1,2-b]pyridazin- 6- yl]phenyl] methanol 2.35649 3.26 828_4147_0285
    Figure US20240041868A1-20240208-C00394
         		N-[3-[3-(3,4- dimethoxyphen- yl)imidazo[1,2- b]pyridazin-6- yl]phenyl]meth- anesulfonamide 0.70252 2.31 828_0079_6488
    Figure US20240041868A1-20240208-C00395
         		3-[3-(3- acetylphenyl) imidazo[1,2- b]pyridazin-6- yl]benzamide 0.51895 2.66 828_4145_0347
    Figure US20240041868A1-20240208-C00396
         		N-[3-[3-(3- pyridyl)imidazo [1,2-b]pyridazin- 6- yl]phenyl]meth- anesulfonamide 1.41022 1.41 828_0071_6488
    Figure US20240041868A1-20240208-C00397
         		3-[6-(4- pyridyl)imidazo [1,2-b]pyridazin- 3-yl]phenol 0.20283 2.73 828_0284_0069
    Figure US20240041868A1-20240208-C00398
         		3-[6-(5- quinolyl)imidazo [1,2-b]pyridazin- 3-yl]phenol 14.63638 4.11 828_0284_6831
    Figure US20240041868A1-20240208-C00399
         		N-[3-[3-[3- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6- yl]phenyl]meth- anesulfonamide 1.15032 1.86 828_0291_6488
    Figure US20240041868A1-20240208-C00400
         		2-methoxy-4-[6- (2- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenol 0.95886 3.63 828_0314_0083
    Figure US20240041868A1-20240208-C00401
         		3-[3-(3- acetylphenyl) imidazo[1,2- b]pyridazin-6- yl]-N-methyl- benzamide 1.71793 2.89 828_4145_7965
    Figure US20240041868A1-20240208-C00402
         		[3-[3-(2- thienyl)imidazo [1,2-b]pyridazin- 6- yl]phenyl]metha- nol 1.68324 3.26 828_4147_0291
    Figure US20240041868A1-20240208-C00403
         		6-(1- methylpyrazol- 4-yl)-3-(2- thienyl)imidazo [1,2-b]pyridazine 1.3135 2.46 828_4147_7468
    Figure US20240041868A1-20240208-C00404
         		3-[3-(3,4- dimethoxyphen- yl)imidazo[1,2- b]pyridazin-6- yl]-N-(2- hydroxyethyl) benzamide 0.3666 2.32 828_0079_0192
    Figure US20240041868A1-20240208-C00405
         		3-(1,3- benzodioxol-5- yl)-6-(1- methylpyrazol- 4- yl)imidazo[1,2- b]pyridazine 0.95557 2.30 828_0068_7468
    Figure US20240041868A1-20240208-C00406
         		3-(3,4- dimethoxyphen- yl)-6-(1- methylpyrazol- 4- yl)imidazo[1,2- b]pyridazine 0.36693 2.37 828_0079_7468
    Figure US20240041868A1-20240208-C00407
         		3-[6-(3- fluorophenyl) imidazo[1,2- b]pyridazin-3- yl]phenol 2.26441 4.09 828_0284_0313
    Figure US20240041868A1-20240208-C00408
         		1-[3-[6-(3- aminophenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] ethanone 1.12246 2.98 828_4145_0005
    Figure US20240041868A1-20240208-C00409
         		6-(2- methoxyphenyl)- 3-(3- pyridyl)imidazo [1,2-b]pyridazine 2.3503 2.88 828_0071_0083
    Figure US20240041868A1-20240208-C00410
         		3-(3,4- dimethoxyphen- yl)-6-(4- pyridyl)imidazo [1,2-b]pyridazine 0.40386 2.72 828_0079_0069
    Figure US20240041868A1-20240208-C00411
         		3-[6-(3- pyridyl)imidazo [1,2-b]pyridazin- 3-yl]phenol 0.58643 2.73 828_0284_0071
    Figure US20240041868A1-20240208-C00412
         		3-[6-(1- methylpyrazol- 4- yl)imidazo[1,2- b]pyridazin-3- yl]phenol 0.38762 2.38 828_0284_7468
    Figure US20240041868A1-20240208-C00413
         		[4-[6-(4- fluorophenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 2.94383 3.63 828_0285_0339
    Figure US20240041868A1-20240208-C00414
         		4-[6-(3- hydroxyphenyl) imidazo[1,2- b]pyridazin-3- yl]-2-methoxy- phenol 0.29478 3.49 828_0314_0284
    Figure US20240041868A1-20240208-C00415
         		6-(3,4- dimethoxyphen- yl)-3-(4- pyridyl)imidazo [1,2-b]pyridazine 0.28231 2.72 828_0069_0079
    Figure US20240041868A1-20240208-C00416
         		6-(4- fluorophenyl)-3- (3- pyridyl)imidazo [1,2-b]pyridazine 2.77876 3.18 828_0071_0339
    Figure US20240041868A1-20240208-C00417
         		[3-[3-(3- chlorophenyl) imidazo[1,2- b]pyridazin-6- yl]phenyl] methanol 9.81893 4.09 828_0279_0291
    Figure US20240041868A1-20240208-C00418
         		3-[6-(4- fluorophenyl) imidazo[1,2- b]pyridazin-3- yl]phenol 11.87843 4.09 828_0284_0339
    Figure US20240041868A1-20240208-C00419
         		3-phenyl-6-(2- thienyl)imidazo [1,2-b]pyridazine 1.9697 4.03 828_0061_4147
    Figure US20240041868A1-20240208-C00420
         		3-(3,4- dimethoxyphen- yl)-6-(3- pyridyl)imidazo [1,2-b]pyridazine 0.54944 2.72 828_0079_0071
    Figure US20240041868A1-20240208-C00421
         		N-[3-[3-(3- hydroxyphenyl) imidazo[1,2- b]pyridazin-6- yl]phenyl] acetamide 1.64512 3.19 828_0284_0081
    Figure US20240041868A1-20240208-C00422
         		4-[6-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 3-yl]-2-methoxy- phenol 0.12455 3.02 828_0314_0285
    Figure US20240041868A1-20240208-C00423
         		3-[3-(3,4- dimethoxyphen- yl)imidazo[1,2- b]pyridazin-6- yl]-N-methyl- benzamide 3.49397 3.01 828_0079_7965
    Figure US20240041868A1-20240208-C00424
         		N-[3-[3-(4- pyridyl)imidazo [1,2-b]pyridazin- 6- yl]phenyl] acetamide 0.59778 2.27 828_0069_0081
    Figure US20240041868A1-20240208-C00425
         		6-(3-furyl)-3-(3- pyridyl)imidazo [1,2-b]pyridazine 2.34906 2.18 828_0071_0343
    Figure US20240041868A1-20240208-C00426
         		N-[3-[6-(3,4- dimethoxyphen- yl)imidazo[1,2- b]pyridazin-3- yl]phenyl] acetamide 0.25932 3.18 828_0081_0079
    Figure US20240041868A1-20240208-C00427
         		3-[6-(3- furyl)imidazo [1,2-b] pyridazin-3- yl]phenol 1.05684 3.09 828_0284_0343
    Figure US20240041868A1-20240208-C00428
         		1-[3-[6-(4- pyridyl)imidazo [1,2-b]pyridazin- 3- yl]phenyl] ethanone 0.37149 2.59 828_4145_0069
    Figure US20240041868A1-20240208-C00429
         		6-(m- tolylmethyl)-3- (4- pyridyl)imidazo [1,2-b]pyridazine 0.97706 3.48 828_0069_6291
    Figure US20240041868A1-20240208-C00430
         		3-(1,3- benzodioxol-5- yl)-6-(4- fluorophenyl) imidazo[1,2- b]pyridazine 7.60066 4.02 828_0068_0339
    Figure US20240041868A1-20240208-C00431
         		3,6-bis(3,4- dimethoxyphen- yl)imidazo[1,2- b]pyridazine 0.53841 3.62 828_0079_0079
    Figure US20240041868A1-20240208-C00432
         		3-[6-(2- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenol 2.73595 3.79 828_0284_0083
    Figure US20240041868A1-20240208-C00433
         		[4-(6- phenylimidazo [1,2-b] pyridazin-3- yl)phenyl] methanol 1.45898 3.49 828_0285_0061
    Figure US20240041868A1-20240208-C00434
         		N-[4-[3-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6- yl]phenyl] acetamide 21.45348 2.72 828 _0285_0722
    Figure US20240041868A1-20240208-C00435
         		4-[6-[3- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 3-yl]-2-methoxy- phenol 0.10235 3.02 828_0314_0291
    Figure US20240041868A1-20240208-C00436
         		1-[3-[6-[3- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 3- yl]phenyl] ethanone 0.17883 3.04 828_4145_0291
    Figure US20240041868A1-20240208-C00437
         		6-(4-pyridyl)-3- (2- thienyl)imidazo [1,2-b]pyridazine 0.49696 2.81 828_4147_0069
    Figure US20240041868A1-20240208-C00438
         		2-methoxy-4-[3- (2- thienyl)imidazo [1,2-b]pyridazin- 6-yl]phenol 0.69396 3.57 828_4147_0314
    Figure US20240041868A1-20240208-C00439
         		N-(2- hydroxyethyl)-3- (3- phenylimidazo [1,2-b] pyridazin-6- yl)benzamide 13.8636 2.64 828_0061_0192
    Figure US20240041868A1-20240208-C00440
         		6-benzyl-3-(4- pyridyl)imidazo [1,2-b]pyridazine 0.6243 2.97 828_0069_6001
    Figure US20240041868A1-20240208-C00441
         		4-[3-(3- pyridyl)imidazo [1,2-b]pyridazin- 6-yl]benzamide 11.24348 1.89 828_0071_0346
    Figure US20240041868A1-20240208-C00442
         		1-[3-[6-(3- pyridyl)imidazo [1,2-b]pyridazin- 3- yl]phenyl] ethanone 1.23395 2.59 828_4145_0071
    Figure US20240041868A1-20240208-C00443
         		1-[3-[6-(3- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] ethanone 1.78495 3.65 828_4145_4140
    Figure US20240041868A1-20240208-C00444
         		6-[(4- fluorophenyl) methyl]-3-(4- pyridyl)imidazo [1,2-b] pyridazine 1.44642 3.11 828_0069_6370
    Figure US20240041868A1-20240208-C00445
         		3-[3-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-6- yl]aniline 0.84313 3.05 828_0068_0005
    Figure US20240041868A1-20240208-C00446
         		3-(1,3- benzodioxol-5- yl)-6-(3- furyl)imidazo [1,2-b] pyridazine 1.60154 3.02 828_0068_0343
    Figure US20240041868A1-20240208-C00447
         		[4-[6-(3,4- dimethoxyphen- yl)imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 3.9402 3.17 828_0285_0079
    Figure US20240041868A1-20240208-C00448
         		3-[3-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-6- yl]-N-(2- dimethylamino- ethyl)benzamide 0.39289 2.97 828_0068_0176
    Figure US20240041868A1-20240208-C00449
         		N-[3-[6-(3- chloro-4-fluoro- phenyl)imidazo [1,2-b]pyridazin- 3- yl]phenyl] acetamide 0.52521 4.24 828_0081_0164
    Figure US20240041868A1-20240208-C00450
         		3-[3-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]phenol 1.13696 3.18 828_0285_0284
    Figure US20240041868A1-20240208-C00451
         		[3-[6-(3,4- dimethoxyphen- yl)imidazo[1,2- b]pyridazin-3- yl]phenyl] methanol 0.74933 6.29 828_0291_0079
    Figure US20240041868A1-20240208-C00452
         		1-[3-[3-(3- acetylphenyl) imidazo[1,2- b]pyridazin-6- yl]phenyl] ethanone 0.58173 3.37 828_4145_4145
    Figure US20240041868A1-20240208-C00453
         		N-(2- dimethylamino- ethyl)-3-[3-(2- thienyl)imidazo [1,2-b]pyridazin- 6-yl]benzamide 1.1611 3.12 828_4147_0176
    Figure US20240041868A1-20240208-C00454
         		3-(1,3- benzodioxol-5- yl)-6-phenyl- imidazo[1,2- b]pyridazine 3.08798 3.88 828_0068_0061
    Figure US20240041868A1-20240208-C00455
         		3-[3-(3- pyridyl)imidazo [1,2-b]pyridazin- 6-yl]phenol 1.81461 2.73 828_0071_0284
    Figure US20240041868A1-20240208-C00456
         		3-(3,4- dimethoxyphen- yl)-6-(2- thienyl)imidazo [1,2-b] pyridazine 0.21139 3.72 828_0079_4147
    Figure US20240041868A1-20240208-C00457
         		3-[3-(3- hydroxyphenyl) imidazo[1,2- b]pyridazin-6- yl]phenol 0.98714 3.65 828_0284_0284
    Figure US20240041868A1-20240208-C00458
         		N-[3-[3-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6- yl]phenyl] acetamide 2.2389 2.72 828_0285_0081
    Figure US20240041868A1-20240208-C00459
         		1-[3-[6-(4- fluorophenyl) imidazo[1,2- b]pyridazin-3- yl]phenyl] ethanone 4.81048 3.95 828_4145_0339
    Figure US20240041868A1-20240208-C00460
         		3-[3-(3- acetamidophen- yl)imidazo[1,2- b]pyridazin-6- yl]-N-methyl- benzamide 1.3298 2.57 828_0081_7965
    Figure US20240041868A1-20240208-C00461
         		[3-(3- phenylimidazo [1,2-b] pyridazin-6- yl)phenyl] methanol 1.92857 3.49 828_0061_0291
    Figure US20240041868A1-20240208-C00462
         		6-(1- methylpyrazol- 4-yl)-3-(4- pyridyl)imidazo [1,2-b] pyridazine 30 1.46 828_0069_7468
    Figure US20240041868A1-20240208-C00463
         		N-(2- dimethylamino- ethyl)-3-[3-[3- (trifluoro- methoxy) phenyl]imidazo [1,2- b]pyridazin-6- yl]benzamide 3.93108 4.78 828_0168_0176
    Figure US20240041868A1-20240208-C00464
         		[4-[3-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6- yl]phenyl] methanol 1.03522 2.72 828_0285_0285
    Figure US20240041868A1-20240208-C00465
         		4-[6-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-3- yl]-2-methoxy- phenol 0.1999 3.42 828_0314_0068
    Figure US20240041868A1-20240208-C00466
         		1-[3-[6-(2- thienyl)imidazo [1,2-b]pyridazin- 3- yl]phenyl] ethanone 0.41575 3.59 828_4145_4147
    Figure US20240041868A1-20240208-C00467
         		6-(5-methoxy-3- pyridyl)-3-(2- thienyl)imidazo [1,2-b]pyridazine 2.86231 2.66 828_4147_0196
    Figure US20240041868A1-20240208-C00468
         		3,6-bis(2- thienyl)imidazo [1,2-b] pyridazine 4.89416 3.81 828_4147_4147
    Figure US20240041868A1-20240208-C00469
         		N-(2- dimethylamino- ethyl)-3-[6-(1- methylpyrazol- 4- yl)imidazo[1,2- b]pyridazin-3- yl]benzamide 1.76458 1.77 828_0176_7468
    Figure US20240041868A1-20240208-C00470
         		3-[6-(1,3- benzodioxol-5- yl)imidazo[1,2- b]pyridazin-3- yl]-N-(2- dimethylamino- ethyl)benzamide 2.01862 2.97 828_0176_0068
    Figure US20240041868A1-20240208-C00471
         		3-[3-[3-(2- dimethylamino- ethylcarbamoyl) phenyl]imidazo [1,2-b] pyridazin-6- yl]benzamide 4.14881 2.20 828_0176_0347
    Figure US20240041868A1-20240208-C00472
         		N-(2- hydroxyethyl)-3- [3-(3- hydroxyphenyl) imidazo[1,2- b]pyridazin-6- yl]benzamide 0.35163 2.33 828_0284_0192
    Figure US20240041868A1-20240208-C00473
         		2-methoxy-4-[6- (3,4,5- trimethoxyphen- yl)imidazo[1,2- b]pyridazin-3- yl]phenol 1.81139 3.32 828_0314_0087
    Figure US20240041868A1-20240208-C00474
         		[3-[3-(3- furyl)imidazo [1,2-b] pyridazin-6- yl]phenyl] methanol 7.32807 2.63 828_0343_0291
    Figure US20240041868A1-20240208-C00475
         		4-(6- benzylimidazo [1,2-b] pyridazin-3- yl)benzamide 0.71127 3.04 828_0346_6001
    Figure US20240041868A1-20240208-C00476
         		3-[6-(4- acetamidophen- yl)imidazo[1,2- b]pyridazin-3- yl]-N-(2- dimethylamino- ethyl)benzamide 0.98309 2.58 828_0176_0722
    Figure US20240041868A1-20240208-C00477
         		2-methoxy-4-[6- [3- (trifluoro- methoxy) phenyl]imidazo [1,2- b]pyridazin-3- yl]phenol 0.83451 5.22 828_0314_0168
    Figure US20240041868A1-20240208-C00478
         		N-(2- dimethylamino- ethyl)-3-[6-[3- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 3-yl]benzamide 0.81608 2.58 828_0176_0291
    Figure US20240041868A1-20240208-C00479
         		4-[6-[(3,4- difluorophenyl) methyl]imidazo [1,2-b]pyridazin- 3-yl]benzamide 3.07271 3.52 828_0346_6007
    Figure US20240041868A1-20240208-C00480
         		3-[6-(3- acetamidophen- yl)imidazo[1,2- b]pyridazin-3- yl]-N-(2- dimethylamino- ethyl)benzamide 3.16865 2.58 828_0176_0081
    Figure US20240041868A1-20240208-C00481
         		2-methoxy-4-[6- [3- (trifluoromethyl) phenyl]imidazo [1,2-b]pyridazin- 3-yl]phenol 1.08271 4.67 828_0314_0312
    Figure US20240041868A1-20240208-C00482
         		6-benzyl-3-(5- methoxy-3- pyridyl)imidazo [1,2-b]pyridazine 2.67306 2.81 828_0196_6001
    Figure US20240041868A1-20240208-C00483
         		4-[6-(m- tolylmethyl) imidazo[1,2- b]pyridazin-3- yl]benzamide 3.10262 3.55 828_0346_6291
    Figure US20240041868A1-20240208-C00484
         		N-(2- dimethylamino- ethyl)-3-[6-(2- methoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]benzamide 2.13745 3.19 828_0176_0083
    Figure US20240041868A1-20240208-C00485
         		N-(2- dimethylamino- ethyl)-3-[6-(3- phenoxyphenyl) imidazo[1,2- b]pyridazin-3- yl]benzamide 19.18297 4.85 828_0176_4032
    Figure US20240041868A1-20240208-C00486
         		3-(6- cyclopropyl- imidazo[1,2- b]pyridazin-3- yl)phenol 1.88565 2.83 828_0284_7494
    Figure US20240041868A1-20240208-C00487
         		4-[6-(3- fluorophenyl) imidazo[1,2- b]pyridazin-3- yl]-2-methoxy- phenol 0.28065 3.93 828_0314_0313
    Figure US20240041868A1-20240208-C00488
         		6-[(4- fluorophenyl) methyl]-3-(5- methoxy-3- pyridyl)imidazo [1,2-b]pyridazine 4.41614 2.95 828_0196_6370
    Figure US20240041868A1-20240208-C00489
         		4-[6-[(4- fluorophenyl) methyl]imidazo [1,2- b]pyridazin-3- yl]benzamide 1.30064 3.18 828_0346_6370
    Figure US20240041868A1-20240208-C00490
         		N-(2- hydroxyethyl)-3- [3-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]benzamide 2.14389 1.87 828_0285_0192
    Figure US20240041868A1-20240208-C00491
         		3-[3-(4-hydroxy- 3-methoxy- phenyl)imidazo [1,2-b]pyridazin- 6-yl]benzamide 0.22316 2.64 828_0314_0347
    Figure US20240041868A1-20240208-C00492
         		3-(1- methylpyrazol- 4-yl)-6-(m- tolylmethyl) imidazo[1,2- b]pyridazine 1.79534 3.13 828_7468_6291
    Figure US20240041868A1-20240208-C00493
         		3-[3-(3- acetylphenyl) imidazo[1,2- b]pyridazin-6- yl]-N-(2- hydroxyethyl) benzamide 0.6293 2.20 828_4145_0192
    Figure US20240041868A1-20240208-C00494
         		[4-(6- benzylimidazo [1,2-b] pyridazin-3- yl)phenyl] methanol 3.22675 3.42 828_0285_6001
    Figure US20240041868A1-20240208-C00495
         		4-[6-[(4- fluorophenyl) methyl]imidazo [1,2- b]pyridazin-3- yl]-2-methoxy- phenol 2.08974 3.87 828_0314_6370
    Figure US20240041868A1-20240208-C00496
         		6-[(4- fluorophenyl) methyl]-3-(1- methylpyrazol- 4- yl)imidazo[1,2- b]pyridazine 1.29697 2.76 828_7468_6370
    Figure US20240041868A1-20240208-C00497
         		N-(2- dimethylamino- ethyl)-3-[6-(4- fluorophenyl) imidazo[1,2- b]pyridazin-3- yl]benzamide 2.23882 3.49 828_0176_0339
    Figure US20240041868A1-20240208-C00498
         		3-[3-(3- chlorophenyl) imidazo[1,2- b]pyridazin-6- hydroxyethyl) benzamide 30 3.24 828_0279_0192
    Figure US20240041868A1-20240208-C00499
         		3-[6-(m- tolylmethyl) imidazo[1,2- b]pyridazin-3- yl]benzamide 2.16636 3.55 828_0347_6291
    Figure US20240041868A1-20240208-C00500
         		1-[3-(6- benzylimidazo [1,2-b] pyridazin-3- yl)phenyl] ethanone 3.9717 3.74 828_4145_6001
    Figure US20240041868A1-20240208-C00501
         		5-(6- benzylimidazo [1,2-b] pyridazin-3- yl)pyridin-2- amine 3.63637 2.73 828_7905_6001
    Figure US20240041868A1-20240208-C00502
         		N-(2- dimethylamino- ethyl)-3-[6-(3- furyl)imidazo [1,2-b] pyridazin-3- yl]benzamide 3.88391 2.49 828_0176_0343
    Figure US20240041868A1-20240208-C00503
         		3-[3-[4- (hydroxymethyl) phenyl]imidazo [1,2-b]pyridazin- 6-yl]-N-methyl- benzamide 14.94149 2.56 828_0285_7965
    Figure US20240041868A1-20240208-C00504
         		4-[4-[3-(2- methoxyphenyl)- 1H- pyrazolo[3,4- b]pyridin-4- yl]phenyl] morpholine 1.38698 3.86 932_2105_0001
    Figure US20240041868A1-20240208-C00505
         		4-(3-chloro-4- fluoro-phenyl)- 3-(2- methoxyphenyl)- 1H- pyrazolo[3,4- b]pyridine 1.28108 4.72 932_2105_0164
    Figure US20240041868A1-20240208-C00506
         		3-(2- methoxyphenyl)- 4-(6-methoxy- 3-pyridyl)-1H- pyrazolo[3,4- b]pyridine 2.93037 3.19 932_2105_0311
    Figure US20240041868A1-20240208-C00507
         		3-(2- methoxyphenyl)- 4-(2- methoxy- pyrimidin- 5-yl)-1H- pyrazolo[3,4- b]pyridine 6.43118 2.57 932_2105_7628
    Figure US20240041868A1-20240208-C00508
         		4-[3-(3- fluorophenyl)- 1H- pyrazolo[3,4- b]pyridin-4-yl]- N,N-dimethyl- benzamide 3.86464 3.57 932_5640_7464
    Figure US20240041868A1-20240208-C00509
         		N,N-dimethyl-4- [3-(3-thienyl)- 1H- pyrazolo[3,4- b]pyridin-4- yl]benzamide 11.19371 3.20 932_2055_7464
    Figure US20240041868A1-20240208-C00510
         		N-[4-(3- cyclopropyl-1H- pyrazolo[3,4- b]pyridin-4- yl)phenyl] acetamide 8.88989 2.24 932_2070_0722
    Figure US20240041868A1-20240208-C00511
         		3-[3-(4-pyridyl)- 1H- pyrazolo[3,4- b]pyridin-4- yl]aniline 18.00668 2.08 932_5650_0005
    Figure US20240041868A1-20240208-C00512
         		[4-[3-(3- fluorophenyl)- 1H- pyrazolo[3,4- b+9pyridin-4- yl]phenyl] methanol 3.87681 3.50 932_5640_0285
    Figure US20240041868A1-20240208-C00513
         		3-(2- methoxyphenyl)- 4-(3-thienyl)- 1H- pyrazolo[3,4- b]pyridine 2.66842 3.75 932_2105_0074
    Figure US20240041868A1-20240208-C00514
         		N-[4-[3-(3,4,5- trimethoxyphen- yl)-1H- pyrazolo[3,4- b]pyridin-4- yl]phenyl] acetamide 2.02053 2.89 932_4516_0722
    Figure US20240041868A1-20240208-C00515
         		3-(2- methoxyphenyl)- 4-[(E)-styryl]- 1H- pyrazolo[3,4- b]pyridine 1.12832 4.66 932_2105_0170
    Figure US20240041868A1-20240208-C00516
         		4-(3- fluorophenyl)-3- (2- methoxyphenyl)- 1H- pyrazolo[3,4- b]pyridine 1.35112 4.11 932_2105_0313
    Figure US20240041868A1-20240208-C00517
         		4-[3-(2- methoxyphenyl)- 1H- pyrazolo[3,4- b]pyridin-4- yl]benzamide 1.47616 2.82 932_2105_0346
    Figure US20240041868A1-20240208-C00518
         		[4-(3-phenyl-1H- pyrazolo[3,4- b]pyridin-4- yl)phenyl] methanol 7.10693 3.36 932_2047_0285
    Figure US20240041868A1-20240208-C00519
         		3-phenyl-4-(1H- pyrazol-4-yl)- 1H- pyrazolo[3,4- b]pyridine 0.8524 2.43 932_2047_7467
    Figure US20240041868A1-20240208-C00520
         		4-(4- isopropyl- phenyl)- 3-(3,4,5- trimethophen- yl)-1H- pyrazolo[3,4- b]pyridine 20.88874 4.90 932_4516_0283
    Figure US20240041868A1-20240208-C00521
         		4-(3- chlorophenyl)-3- cyclopropyl-1H- pyrazolo[3,4- b]pyridine 30 3.61 932_2070_0279
    Figure US20240041868A1-20240208-C00522
         		N-(2- dimethylamino- ethyl)-3-[3-(2- methoxyphenyl)- 1H- pyrazolo[3,4- b]pyridin-4- yl]benzamide 4.85182 3.06 932_2105_0176
    Figure US20240041868A1-20240208-C00523
         		[3-[3-(2- methoxyphenyl)- 1H- pyrazolo[3,4- b]pyridin-4- yl]phenyl] methanol 1.66776 3.20 932_2105_0291
    Figure US20240041868A1-20240208-C00524
         		4-[3-(3- fluorophenyl)- 1H- pyrazolo[3,4- b]pyridin-4- yl]benzamide 2.04666 3.12 932_5640_0346
    Figure US20240041868A1-20240208-C00525
         		4-[3-(4- chlorophenyl)- 1H- pyrazolo[3,4- b]pyridin-4- yl]benzamide 5.71214 3.58 932_5666_0346
    Figure US20240041868A1-20240208-C00526
         		3-[3-(3,4,5- trimethoxyphen- yl)-1H- pyrazolo[3,4- b]pyridin-4- yl]phenol 5.02812 3.35 932_4516_0284
    Figure US20240041868A1-20240208-C00527
         		1-[3-[3-(4- piperidyl)-1H- pyrazolo[3,4- b]pyridin-4- yl]phenyl] ethanone 19.65771 1.89 932_2802_4145
    Figure US20240041868A1-20240208-C00528
         		N-[4-[3-(3- thienyl)-1H- pyrazolo[3,4- b]pyridin-4- yl]phenyl] acetamide 4.86579 3.14 932_2055_0722
    Figure US20240041868A1-20240208-C00529
         		2-methoxy-4-[3- (4-piperidyl)- 1H- pyrazolo[3,4- b]pyridin-4- yl]phenol 11.88451 1.87 932_2802_0314
    Figure US20240041868A1-20240208-C00530
         		N-[3-[3-(3,4,5- trimethoxyphen- yl)-1H- pyrazolo[3,4- b]pyridin-4- yl]phenyl] methane- sulfonamide 12.76436 2.03 932_4516_6488
    Figure US20240041868A1-20240208-C00531
         		4-(3-furyl)-3-(2- methoxyphenyl)- 1H- pyrazolo[3,4- b]pyridine 4.89672 3.11 932_2105_0343
    Figure US20240041868A1-20240208-C00532
         		3-[3-(1,3- benzodioxol-5- yl)-1H- pyrazolo[3,4- b]pyridin-4- yl]phenol 6.24902 3.45 932_5654_0284
    Figure US20240041868A1-20240208-C00533
         		4-(3-furyl)-3-(3- pyridyl)-1H- pyrazolo[3,4- b]pyridine 14.29835 2.05 932_2094_0343
    Figure US20240041868A1-20240208-C00534
         		[4-[3-(3,4,5- trimethoxyphen- yl)-1H- pyrazolo[3,4- b]pyridin-4- yl]phenyl] methanol 5.38048 2.89 932_4516_0285
    Figure US20240041868A1-20240208-C00535
         		4-(3- methoxyphenyl)- 3-(4-piperidyl)- 1H- pyrazolo[3,4- b]pyridine 17.59629 2.17 932_2802_4140
    Figure US20240041868A1-20240208-C00536
         		4-[3-(2- methoxyphenyl)- 1H- pyrazolo[3,4- b]pyridin-4- yl]benzonitrile 1.58329 3.82 932_2105_0086
    Figure US20240041868A1-20240208-C00537
         		N,N-dimethyl-4- [3-(3,4,5- trimethoxyphen- yl)-1H- pyrazolo[3,4- b]pyridin-4- yl]benzamide 11.14532 2.95 932_4516_7464
    Figure US20240041868A1-20240208-C00538
         		[4-[3-(1,3- benzodioxol-5- yl)-1H- pyrazolo[3,4- b]pyridin-4- yl]phenyl] methanol 4.64328 2.98 932_5654_0285
    Figure US20240041868A1-20240208-C00539
         		4-(5-fluoro-2- methoxy- phenyl)-3-(4- piperidyl)-1H- pyrazolo[3,4- b]pyridine 11.69312 2.31 932_2802_8363
    Figure US20240041868A1-20240208-C00540
         		4-(4- methylsulfonyl- phenyl)-3-(3,4,5- trimethoxyphen- yl)-1H- pyrazolo[3,4- b]pyridine 11.16027 2.49 932_4516_0174
    Figure US20240041868A1-20240208-C00541
         		[4-[3-(3- chlorophenyl)- 1H- pyrazolo[3,4- b]pyridin-4- yl]phenyl] methanol 6.49611 3.96 932_2049_0285
    Figure US20240041868A1-20240208-C00542
         		[3-[3-(1,3- benzodioxol-5- yl)-1H- pyrazolo[3,4- b]pyridin-4- yl]phenyl] methanol 3.09057 2.98 932_5654_0291
    Figure US20240041868A1-20240208-C00543
         		4-(3-furyl)-3- phenyl-1H- pyrazolo[3,4- b]pyridine 8.62504 3.27 932_2047_0343
    Figure US20240041868A1-20240208-C00544
         		4-(6-methoxy-3- pyridyl)-3- (3,4,5- trimethoxyphen- yl)-1H- pyrazolo[3,4- b]pyridine 16.92312 2.87 932_4516_0311
    Figure US20240041868A1-20240208-C00545
         		3-cyclopropyl-4- (2-furyl)-1H- pyrazolo[3,4- b]pyridine 12.61441 2.06 932_2070_0142
    Figure US20240041868A1-20240208-C00546
         		4-(2-furyl)-3-(2- methoxyphenyl)- 1H- pyrazolo[3,4- b]pyridine 2.27665 3.03 932_2105_0142
    Figure US20240041868A1-20240208-C00547
         		[4-[3-(2- methoxyphenyl)- 1H- pyrazolo[3,4- b]pyridin-4- yl]phenyl] methanol 1.10049 3.20 932_2105_0285
    Figure US20240041868A1-20240208-C00548
         		1-[3-[3-(2- methoxyphenyl)- 1H- pyrazolo[3,4- b]pyridin-4- yl]phenyl] ethanone 6.60309 3.53 932_2105_4145
    Figure US20240041868A1-20240208-C00549
         		4-(3-furyl)-3-(4- pyridyl)-1H- pyrazolo[3,4- b]pyridine 20.24336 2.05 932_5650_0343
    Figure US20240041868A1-20240208-C00550
         		3-[3-(3- fluorophenyl)- 1H- pyrazolo[3,4- b]pyridin-4- yl]aniline 15.07442 3.44 932_5640_0005
    Figure US20240041868A1-20240208-C00551
         		3-(3-phenyl-1H- pyrazolo[3,4- b]pyridin-4- yl)benzamide 11.71738 2.98 932_2047_0347
    Figure US20240041868A1-20240208-C00552
         		3-[3-(3,4,5- trimethoxyphen- yl)-1H- pyrazolo[3,4- b]pyridin-4- yl]aniline 14.80741 2.82 932_4516_0005
    Figure US20240041868A1-20240208-C00553
         		4-(3- fluorophenyl)-3- (3,4,5- trimethoxyphen- yl)-1H- pyrazolo[3,4- b]pyridine 5.22838 3.80 932_4516_0313
    Figure US20240041868A1-20240208-C00554
         		(E)-3-[3-[5-(3- pyridylmethyl- amino)pyrazolo [1,5- a]pyrimidin-3- yl]phenyl]prop- 2-enoic acid 2.27421 3.04 294_4003_0289
    Figure US20240041868A1-20240208-C00555
         		3-[6-amino-5- (3,4,5- trimethoxyphen- yl)-3- pyridyl] benzamide 0.44196 2.19 382_0087_0347
    Figure US20240041868A1-20240208-C00556
         		1-[5-[6-amino-5- [3- (dimethylamino) phenyl]-3- pyridyl]-2- thienyl] ethanone 3.41528 3.39 382_0135_0066
    Figure US20240041868A1-20240208-C00557
         		(Z)-5-[6- (methylamino) imidazo[1,2- b]pyridazin-3- yl]pent-4- en-1-ol 31.48029 1.22 437_0299
    Figure US20240041868A1-20240208-C00558
         		2-methoxy-4-[2- (tetrahydropyran- 4- ylmethylamino) imidazo[2,1- b][1,3,4]thia- diazol-5-yl] phenol 2.16407 2.47 699_0243_0314
    Figure US20240041868A1-20240208-C00559
         		N-[3-[8- acetamido-3- (3,4- dimethoxyphen- yl)imidazo[1,2- a]pyridin-6- yl]phenyl] acetamide 1.59766 2.13 802_0079_0081
    Figure US20240041868A1-20240208-C00560
         		N-[3-(3- acetylphenyl)-6- (3- methoxyphenyl) imidazo[1,2- a]pyridin-8- yl]acetamide 3.05101 2.61 802_4145_4140
    Figure US20240041868A1-20240208-C00561
         		5-(5-methoxy-3- pyridyl)-N-(4- pyridylmethyl) imidazo[2,1- b][1,3,4]thia- diazol-2-amine 0.93173 1.64 699_0237_0196
    Figure US20240041868A1-20240208-C00562
         		4-[[5-(3-chloro- 4-fluoro- phenyl)imidazo [2,1- b][1,3,4]thia- diazol-2- yl]amino] cyclohexanol 4.05722 3.67 699_0240_0164
    Figure US20240041868A1-20240208-C00563
         		4-[2-[[5-(3,4- dimethoxyphen- yl)imidazo[2,1- b][1,3,4]thia- diazol-2- yl]amino]ethyl] benzene- sulfonamide 5.11606 2.81 699_6182_0079
    Figure US20240041868A1-20240208-C00564
         		N-[3-(3- acetylphenyl)-6- (2,4- dimethoxyphen- yl)imidazo[1,2- a]pyridin-8- yl]acetamide 2.50187 2.45 802_4145_4141
    Figure US20240041868A1-20240208-C00565
         		5-(3,4- dimethoxyphen- yl)-N-[2-(4- pyridyl)ethyl] imidazo[2,1- b][1,3,4]thia- diazol-2-amine 3.1387 2.99 699_0039_0079
    Figure US20240041868A1-20240208-C00566
         		5-(4-pyridyl)-N- (4- pyridylmethyl) imidazo[2,1- b][1,3,4]thia- diazol-2-amine 2.64747 1.80 699_0237_0069
    Figure US20240041868A1-20240208-C00567
         		5-(6-methoxy-3- pyridyl)-N-[2-(4- pyridyl)ethyl] imidazo[2,1- b][1,3,4]thia- diazol-2-amine 2.03015 2.52 699_0039_0311
    Figure US20240041868A1-20240208-C00568
         		4-[2-[[5-(3- pyridyl)imidazo [2,1- b][1,3,4]thia- diazol-2- yl]amino]ethyl] benzene- sulfonamide 1.87926 1.91 699_6182_0071
    Figure US20240041868A1-20240208-C00569
         		5-(4- morpholinophen- yl)-N-(2- thienylmethyl) imidazo[2,1- b][1,3,4]thia- diazol-2-amine 3.82253 4.03 699_0146_0001
    Figure US20240041868A1-20240208-C00570
         		[4-[2-[(4- methoxyphenyl) methylamino] imidazo[2,1- b][1,3,4]thia- diazol-5- yl]phenyl] methanol 2.8094 3.31 699_0244_0285
    Figure US20240041868A1-20240208-C00571
         		5-(4- chlorophenyl)- N-(3- pyridylmethyl) imidazo[2,1- b][1,3,4]thia- diazol-2-amine 3.65935 3.62 699_4003_0160
    Figure US20240041868A1-20240208-C00572
         		N-[3-[2-[2-(4- pyridyl)ethyl- amino] imidazo[2,1- b][1,3,4]thia- diazol-5- yl]phenyl] acetamide 1.31627 2.54 699_0039_0081
    Figure US20240041868A1-20240208-C00573
         		N,N-dimethyl-3- [2-[2-(4- pyridyl)ethyl- amino] imidazo[2,1- b][1,3,4]thia- diazol-5- yl]benzamide 0.72142 2.60 699_0039_0349
    Figure US20240041868A1-20240208-C00574
         		2-methoxy-4-[2- [(4- methoxyphenyl) methylamino] imidazo[2,1- b][1,3,4]thia- diazol-5-yl] phenol 1.77761 3.61 699_0244_0314
    Figure US20240041868A1-20240208-C00575
         		5-(6-methoxy-3- pyridyl)-N-(3- pyridylmethyl) imidazo[2,1- b][1,3,4]thia- diazol-2-amine 2.93804 2.23 699_4003_0311
    Figure US20240041868A1-20240208-C00576
         		5-(3-chloro-4- fluoro-phenyl)- N-(2- morpholino- ethyl) imidazo[2,1- b][1,3,4]thia- diazol-2-amine 4.81646 3.05 699_0252_0164
    Figure US20240041868A1-20240208-C00577
         		5-(4-pyridyl)-N- [2-(4- pyridyl)ethyl] imidazo[2,1- b][1,3,4]thia- diazol-2-amine 2.42663 2.08 699_0039_0069
    Figure US20240041868A1-20240208-C00578
         		4-[[5-(6- methoxy-3- pyridyl)imidazo [2,1- b][1,3,4]thia- diazol-2- yl]amino] cyclohexanol 1.61261 2.14 699_0240_0311
    Figure US20240041868A1-20240208-C00579
         		1-[5-[2-(2- morpholinoethyl- amino)imidazo [2,1- b][1,3,4]thia- diazol-5-yl]-2- thienyl] ethanone 3 1.77 699_0252_0066
    Figure US20240041868A1-20240208-C00580
         		N-[3-(3- acetylphenyl)-6- (2- methoxyphenyl) imidazo[1,2- a]pyridin-8- yl]acetamide 1.58352 2.61 802_4145_0083
    Figure US20240041868A1-20240208-C00581
         		N-[3-(3-chloro- 4-fluoro- phenyl)-6-[3- (methanesulfon- amido)phenyl] imidazo[1,2- a]pyridin-8- yl]formamide 2.85911 2.28 788_0164_6488
    Figure US20240041868A1-20240208-C00582
         		5-(4-pyridyl)-N- (2- thienylmethyl) imidazo[2,1- b][1,3,4]thia- diazol-2-amine 3.61591 2.93 699_0146_0069
    Figure US20240041868A1-20240208-C00583
         		N-[3-[2- (cyclohexyl- amino) imidazo[2,1- b][1,3,4]thia- diazol-5- yl]phenyl] methane- sulfonamide 4.33348 2.68 699_0052_6488
    Figure US20240041868A1-20240208-C00584
         		3-[2- (isobutylamino) imidazo[2,1- b][1,3,4]thia- diazol-5- yl]benzamide 1.13221 2.60 699_0149_0347
    Figure US20240041868A1-20240208-C00585
         		3-[2- (cyclopropyl- methyl- amino)imidazo [2,1- b][1,3,4]thia- diazol-5- yl]benzamide 1.94081 2.14 699_4051_0347
    Figure US20240041868A1-20240208-C00586
         		4-[[5-(3- fluorophenyl) imidazo[2,1- b][1,3,4]thia- diazol-2- yl]amino]cyclo- hexanol 2.92063 3.06 699_0240_0313
    Figure US20240041868A1-20240208-C00587
         		4-[[5-(3,4- dimethoxyphen- yl)imidazo[2,1- b][1,3,4]thia- diazol-2- yl]amino]cyclo- hexanol 0.48307 2.60 699_0240_0079
    Figure US20240041868A1-20240208-C00588
         		5-(3-pyridyl)-N- (2- thienylmethyl) imidazo[2,1- b][1,3,4]thia- diazol-2-amine 1.94173 2.93 699_0146_0071
    Figure US20240041868A1-20240208-C00589
         		5-(3,4- dimethoxyphen- yl)-N-(4- pyridylmethyl) imidazo[2,1- b][1,3,4]thia- diazol-2-amine 2.1285 2.70 699_0237_0079
    Figure US20240041868A1-20240208-C00590
         		N-[6-(4- aminophenyl)-3- (4- fluorophenyl) imidazo[1,2- a]pyridin-8- yl]acetamide 5.25032 2.53 802_0339_7917
    Figure US20240041868A1-20240208-C00591
         		N-[3-(4- fluorophenyl)-6- (1- methylpyrazol- 4- yl)imidazo[1,2- a]pyridin-8- yl]formamide 8.08703 1.73 788_0339_8400
    Figure US20240041868A1-20240208-C00592
         		2-amino-1-(3- methoxyphenyl) pyrrolo[3,2- b]quinoxaline-3- carboxamide 1.18486 2.64 DT2012- 0375412
    Figure US20240041868A1-20240208-C00593
         		N-cyclohexyl-5- (3- fluorophenyl) imidazo[2,1- b][1,3,4]thia- diazol-2-amine 4.07753 4.45 699_0052_0313
    Figure US20240041868A1-20240208-C00594
         		N-(2- furylmethyl)-5- (3- pyridyl)imidazo [2,1- b][1,3,4]thia- diazol-2-amine 3.16405 2.07 699_0144_0071
    Figure US20240041868A1-20240208-C00595
         		N-(2- furylmethyl)-5- (1- methylpyrazol- 4- yl)imidazo[2,1- b][1,3,4]thia- diazol-2-amine 5.63578 1.72 699_0144_7468
    Figure US20240041868A1-20240208-C00596
         		5-(5-methoxy-3- pyridyl)-N-(2- thienylmethyl) imidazo[2,1- b][1,3,4]thia- diazol-2-amine 0.72859 2.77 699_0146_0196
    Figure US20240041868A1-20240208-C00597
         		5-(3,4- dimethoxyphen- yl)-N-isobutyl- imidazo[2,1- b][1,3,4]thia- diazol-2-amine 2.74508 3.44 699_0149_0079
    Figure US20240041868A1-20240208-C00598
         		1-[3-[2- (isobutylamino) imidazo[2,1- b][1,3,4]thia- diazol-5- yl]phenyl] ethanone 15.11833 3.31 699_0149_4145
    Figure US20240041868A1-20240208-C00599
         		N-benzyl-5-(3- pyridyl)imidazo 2,1- b][1,3,4]thia- diazol-2-amine 0.8393 3.01 699_0232_0071
    Figure US20240041868A1-20240208-C00600
         		N-benzyl-5-(5- methoxy-3- pyridyl)imidazo [2,1- b][1,3,4]thia- diazol-2-amine 0.34323 2.86 699_0232_0196
    Figure US20240041868A1-20240208-C00601
         		5-(3-pyridyl)-N- (tetrahydropyran- 4- ylmethyl)imidazo [2,1- b][1,3,4]thia- diazol-2-amine 4.84876 1.71 699_0243_0071
    Figure US20240041868A1-20240208-C00602
         		5-(5-methoxy-3- pyridyl)-N- (tetrahydropyran- 4- ylmethyl)imidazo [2,1- b][1,3,4]thia- diazol-2-amine 0.38423 1.55 699_0243_0196
    Figure US20240041868A1-20240208-C00603
         		N-[(4- methoxyphenyl) methyl]-5-(5- methoxy-3- pyridyl)imidazo [2,1 b][1,3,4]thia- diazol-2-amine 9.65333 2.70 699_0244_0196
    Figure US20240041868A1-20240208-C00604
         		N-(o- tolylmethyl)-5- (3- pyridyl)imidazo [2,1- b][1,3,4]thia- diazol-2-amine 1.07729 3.53 699_8074_0071
    Figure US20240041868A1-20240208-C00605
         		1-methyl-N- (4- methylpiperazin- 1-yl)phenyl]-2- [3- (trifluoro- methyl) phenyl]pyrrolo [3,2-c] pyridin-6- amine 30 5.51 809_2669_5837_ 0091
    Figure US20240041868A1-20240208-C00606
         		1-methyl-N- pyrimidin-4-yl- 2-[3-(trifluoro- methyl) phenyl]pyrrolo [3,2-c] pyridin-6- amine 16.77669 4.23 809_2669_5837_ 6410
    Figure US20240041868A1-20240208-C00607
         		2-(3- fluorophenyl)- 1-methyl-N- [4-(4- methylpiperazin- 1-yl)phenyl] pyrrolo [3,2-c]pyridin- 6-amine 12.86554 4.78 809_2670_5837_ 0091
    Figure US20240041868A1-20240208-C00608
         		2-(3- fluorophenyl)-1- methyl-N- pyrimidin-4-yl- pyrrolo[3,2- c]pyridin-6- amine 9.08728 3.49 809_2670_5837_ 6410
    Figure US20240041868A1-20240208-C00609
         		5-amino-4-(1H- benzimidazol-2- yl)-1-(1,3- benzodioxol-5- yl)-2H-pyrrol-3- one 4.06818 2.64 DT2009- 0160159
    Figure US20240041868A1-20240208-C00610
         		N,N-dimethyl-4- [4-[4-(4- methylpiperazin- 1-yl)anilino]- 1H-pyrrolo[3,2- c]pyridin-2- yl]benzamide 7.04339 3.71 838_2671_0263_ 0091
    Figure US20240041868A1-20240208-C00611
         		4-[2-(3,5- dimethoxyphen- yl)-1H- pyrrolo[3,2- c]pyridin-4- yl]morpholine 30 2.59 838_2728_0263_ 4009
    Figure US20240041868A1-20240208-C00612
         		N-[4-[[2-(2- methoxyphenyl)- 1H-pyrrolo[3,2- c]pyridin-4- yl]amino] phenyl] acetamide 30 3.54 838_2729_0263_ 0023
    Figure US20240041868A1-20240208-C00613
         		2-(2- methoxyphenyl)- 1-methyl-N-[3- (trifluoro- methyl) phenyl]pyrrolo [3,2-c] pyridin-4- amine 30 5.40 838_2729_5837_ 0235
    Figure US20240041868A1-20240208-C00614
         		8-(2,5- dimethoxyphen- yl)-7-(4- fluorophenyl)-1- methyl-3H- imidazo[1,2- g]purine-2,4- dione [Also listed as: 6-(2,5- dimethoxyphen- yl)-7-(4- fluorophenyl)- 4-methyl- purino[7,8- a]imidazole- 1,3-dione: 18.44433 2.44 DT2012- 0296118
    Figure US20240041868A1-20240208-C00615
         		methyl 2-amino- 1-(3- hydroxphenyl) pyrrolo[3,2- b]quinoxaline-3- carboxylate 2.25787 3.64 DT2012- 0351552
  • TABLE 4
    Secondary screen- initial candidate compounds re-synthesized and expanded.
    logP Compound ID.
    IC50 FYN (con- (prior ID
    Structure IUPAC name (μM) sensus) No. if any)
    Figure US20240041868A1-20240208-C00616
         		5-phenyl-3- (3,4,5- trimethoxy- phenyl)pyridin- 2-amine 1.306193248 3.34 BF000312489 (382_0087_0061)
    Figure US20240041868A1-20240208-C00617
         		5-[4-(4- methylpiper- azin-1- yl)phenyl]- 3-(3,4,5- trimethoxy- phenyl)pyridin- 2-amine 0.232041699 3.30 BF000312520 (382_0087_0218)
    Figure US20240041868A1-20240208-C00618
         		3-[6-amino- 5-(3,4,5- trimethoxy- phenyl)-3- pyridyl]phe- nol 0.52870963 3.04 BF000312527 (382_0087_0284)
    Figure US20240041868A1-20240208-C00619
         		3-[6-amino- 5-(3,4,5- trimethoxy- phenyl)-3- pyridyl]benz- amide 0.4942965 2.19 BF000312539 (382_0087_0347)
    Figure US20240041868A1-20240208-C00620
         		4-[6-amino- 5-(3,4,5- trimethoxy- phenyl)-3- pyridyl]benz- amide 0.4578952 2.19 BF000312540 (382_0087_0346)
    Figure US20240041868A1-20240208-C00621
         		3-[6-amino- 5-(3,4,5- trimethoxy- phenyl)-3- pyridyl]-N-(2- hydroxyethyl) benzamide 1.001189887 1.73 BF000312542 (382_0087_0192)
    Figure US20240041868A1-20240208-C00622
         		5-(4- methylsulfo- nylphenyl)- 3-(3,4,5- trimethoxy- phenyl)pyridin- 2-amine 0.674160478 2.18 BF000312544
    Figure US20240041868A1-20240208-C00623
         		N-[3-[6- amino-5- (3,4,5- trimethoxy- phenyl)-3- pyridyl]phe- nyl]methane- sulfonamide 0.561599306 1.72 BF000312545 (382_0087_6488)
    Figure US20240041868A1-20240208-C00624
         		4-[2-amino- 5-(3,4,5- trimethoxy- phenyl)-3- pyridyl]phe- nol 0.2885 3.04 BF000313556 (382_7249_0087)
    Figure US20240041868A1-20240208-C00625
         		4-[6-amino- 5-(4- hydroxyphe- nyl)-3- pyridyl]benz- amide 1.085653826 2.36 BF000313559
    Figure US20240041868A1-20240208-C00626
         		N-[3-[6- amino-5-(4- hydroxy- phenyl)-3- pyridyl]phe- nyl]acetamide 0.898083782 2.75 BF000313562 (382_7249_0081)
    Figure US20240041868A1-20240208-C00627
         		4-[2-amino- 5-(4- methylsulfo- nylphenyl)-3- pyridyl]phe- nol 1.551309576 2.35 BF000313563 (382_7249_0174)
    Figure US20240041868A1-20240208-C00628
         		N-[3- (dimethyl- amino)propyl]- 4-[3-(4- hydroxyphe- nyl)imidazo [1,2-a]pyrazin- 6-yl]benzamide 0.705417706 1.99 BF000333874
    Figure US20240041868A1-20240208-C00629
         		4-[6-[4-(4- methylpiper- azin-1- yl)phenyl]imi- dazo[1,2- a]pyrazin-3- yl]phenol 0.464568962 2.79 BF000333878 (388_0080_0218)
    Figure US20240041868A1-20240208-C00630
         		N-[2- (dimethyl- amino)ethyl]- 4-[3-(4- hydroxyphe- nyl)imidazo[1,2- a]pyrazin-6- yl]benzamide 0.486180008 1.93 BF000333881
    Figure US20240041868A1-20240208-C00631
         		N-(2- hydroxyethyl)- 4-[3-(4- hydroxyphe- nyl)imidazo[1,2- a]pyrazin-6- yl]benzamide 0.739736615 1.22 BF000333882 (388_0080_0328)
    Figure US20240041868A1-20240208-C00632
         		N-[3- (dimethyl- amino)propyl]- 4-[3-(4- hydroxy-3- methoxy- phenyl)imi- dazo[1,2- a]pyrazin-6- yl]benzamide 0.647432877 1.83 BF000334019 (388_0314_0180)
    Figure US20240041868A1-20240208-C00633
         		N-(2- hydroxyeth- yl)-3-[3-(4- hydroxy-3- methoxy- phenyl)imi- dazo[1,2- a]pyrazin-6- yl]benzamide 1.275657607 1.07 BF000334020 (388_0314_0192)
    Figure US20240041868A1-20240208-C00634
         		4-[2-amino- 5-[4-(4- methylpiper- azin-1- yl)phenyl]- 3- pyridyl]phe- nol 0.520622627 3.47 BF000710044
    Figure US20240041868A1-20240208-C00635
         		3-[2- (cyclopropyl- methylamino) imidazo[2,1- b][1,3,4]thia- diazol-5-yl]- N,N- dimethyl- benzamide 0.884088514 2.59 BF000714798 (699_4051_0349)
    Figure US20240041868A1-20240208-C00636
         		5-(5- methoxy-3- pyridyl)-N- (2- thienylmeth- yl)imidazo[2,1- b][1,3,4]thia- diazol-2- amine 0.437195357 2.77 BF000714968 (699_0146_0196)
    Figure US20240041868A1-20240208-C00637
         		4-[[5-(3,4- dimethoxy- phenyl)imi- dazo[2,1- b][1,3,4]thia- diazol-2- yl]amino]cy- clohexanol 0.439583985 2.60 BF000717406 (699_0240_0079)
    Figure US20240041868A1-20240208-C00638
         		3-[2-[(4- hydroxycyclo- hexyl)amino] imidazo[2,1- b][1,3,4]thia- diazol-5-yl]- N,N- dimethyl- benzamide 0.288412517 2.22 BF000717418 (699_0240_0349)
    Figure US20240041868A1-20240208-C00639
         		4-[[5-(4- methoxy-3- pyridyl)imi- dazo[2,1- b][1,3,4]thia- diazol-2- yl]amino]cy- clohexanol 0.300821259 1.54 BF000802724
    Figure US20240041868A1-20240208-C00640
         		2-methoxy- 4-[6- (propylamino) imidazo[1,2- b]pyridazin- 3-yl]phenol 0.081593995 2.71 BF000147080
    Figure US20240041868A1-20240208-C00641
         		3-(4- pyridyl)-N- (2- thienylmeth- yl)imidazo[1,2- b]pyridazin- 6-amine 0.104821372 2.71 BF000145941
    Figure US20240041868A1-20240208-C00642
         		2-methoxy- 4-[6- (tetrahydro- pyran-4- ylamino)imi- dazo[1,2- b]pyridazin- 3-yl]phenol 0.112523997 1.79 BF000147168
    Figure US20240041868A1-20240208-C00643
         		4-[2-amino- 5-(3,4,5- trimethoxy- phenyl)-3- pyridyl]-2- methoxy- phenol 0.115507056 2.88 BF000313035 (382_0314−0087)
    Figure US20240041868A1-20240208-C00644
         		4-[2-amino- 5-[4-(4- methylpiper- azin-1- yl)phenyl]- 3-pyridyl]-2- methoxy- phenol 0.121074357 3.31 BF000313028
    Figure US20240041868A1-20240208-C00645
         		2-methoxy- 4-[6-(2- thienylmeth- ylamino)imi- dazo[1,2- b]pyridazin- 3-yl]phenol 0.166284575 3.46 BF000145954
    Figure US20240041868A1-20240208-C00646
         		N-[3-[6-(4- hydroxy-3- methoxy- phenyl)imi- dazo[1,2- b]pyridazin- 3-yl]phe- nyl]acetamide 0.166802816 3.03 BF000726183 (828_0081_0314)
    Figure US20240041868A1-20240208-C00647
         		4-[6-(3- hydroxypro- pylamino)imi- dazo[1,2- b]pyridazin- 3-yl]-2- methoxy- phenol 0.205976791 1.20 BF000146250 (229_0248_0314)
    Figure US20240041868A1-20240208-C00648
         		4-[6-amino- 5-(4- hydroxy-3- methoxy- phenyl)-3- pyridyl]benz- amide 0.214088697 2.20 BF000313038
    Figure US20240041868A1-20240208-C00649
         		N-propyl-3- (4- pyridyl)imi- dazo[1,2- b]pyridazin- 6-amine 0.217345163 1.95 BF000147056
    Figure US20240041868A1-20240208-C00650
         		N-[2- (dimethyl- amino)ethyl]- 4-[3-(4- phenoxyphe- nyl)imidazo[1,2- a]pyrazin-6- yl]benzamide 0.22160528 3.74 BF000334031
    Figure US20240041868A1-20240208-C00651
         		2-methoxy- 4-[6-(2- pyridylmeth- ylamino)imi- dazo[1,2- b]pyridazin- 3-yl]phenol 0.233047949 2.41 BF000817095
    Figure US20240041868A1-20240208-C00652
         		N-[3- (dimethyl- amino)propyl]- 4-[3-(4- phenoxyphe- nyl)imidazo[1,2- a]pyrazin-6- yl]benzamide 0.247391087 3.80 BF000816927
    Figure US20240041868A1-20240208-C00653
         		3-(4- pyridyl)-N- tetrahydro- pyran-4-yl- imidazo[1,2- b]pyridazin- 6-amine 0.270083246 1.03 BF000817099
    Figure US20240041868A1-20240208-C00654
         		3-(3,4- dimethoxy- phenyl)-N- propyl- imidazo[1,2- b]pyridazin- 6-amine 0.285138703 2.85 BF000147061 (229_0226_0079)
    Figure US20240041868A1-20240208-C00655
         		N-(1,3- benzodioxol- 5- ylmethyl)-3- (4- pyridyl)imi- dazo[1,2- b]pyridazin- 6-amine 0.297126173 2.42 BF000146108 (229_0236_0069)
    Figure US20240041868A1-20240208-C00656
         		N-[3-[6-(3,4- dimethoxy- phenyl)imida- zo[1,2- b]pyridazin- 3- yl]phenyl]acet- amide 0.313364743 3.18 BF000726345 (828_0081_0079)
    Figure US20240041868A1-20240208-C00657
         		4-[2-amino- 5-(4- methylsulfo- nylphenyl)- 3-pyridyl]-2- methoxy- phenol 0.315744691 2.19 BF000313040 (382_0314_0174)
    Figure US20240041868A1-20240208-C00658
         		N-[2- (dimethyl- amino)ethyl]- 4-[3-(4- hydroxy-3- methoxy- phenyl)imi- dazo[1,2- a]pyrazin-6- yl]benzamide 0.336758519 1.77 BF000334023
    Figure US20240041868A1-20240208-C00659
         		3-(1,3- benzodioxol- 5-yl)-N-(2- pyridylmeth- yl)imidazo[1,2- b]pyridazin- 6-amine 0.354989794 2.50 BF000146330 (229_4007_0068)
    Figure US20240041868A1-20240208-C00660
         		4-[6-amino- 5-(3,4,5- trimethoxy- phenyl)-3- pyridyl]-N- cyclopropyl- benzamide 0.376810127 2.88 BF000312541 (382_0087_7489)
    Figure US20240041868A1-20240208-C00661
         		N-[3-[6- (tetrahydro- pyran-4- ylamino)imi- dazo[1,2- b]pyridazin- 3- yl]phenyl]acet- amide 0.396885185 1.49 BF000146155 (229_0242_0081)
    Figure US20240041868A1-20240208-C00662
         		1-[3-[6- (propylamino) imidazo[1,2- b]pyridazin- 3- yl]phenyl]eth- anone 0.405532058 2.72 BF000147088 (229_0226_4145)
    Figure US20240041868A1-20240208-C00663
         		4-[6-[[(1S)- 1- (hydroxy- methyl)-2- methyl- propyl]amino] imidazo[1,2- b]pyridazin- 3-yl]-2- methoxy- phenol 0.44318569 2.44 BF000146319
    Figure US20240041868A1-20240208-C00664
         		1-[3-[6-(2- thienylmeth- ylamino)imi- dazo[1,2- b]pyridazin- 3- yl]phenyl]eth- anone 0.450916544 3.48 BF000145962 (229_0146_4145)
    Figure US20240041868A1-20240208-C00665
         		N-(2- hydroxyeth- yl)-4-[3-(4- phenoxy- phenyl)imi- dazo[1,2- a]pyrazin-6- yl]benzamide 0.463504693 3.03 BF000334032 (388_1029_0328)
    Figure US20240041868A1-20240208-C00666
         		3-(3,4- dimethoxy- phenyl)-N- tetrahydro- pyran-4-yl- imidazo[1,2- b]pyridazin- 6-amine 0.479948935 1.93 BF000146153 (229_0242_0079)
    Figure US20240041868A1-20240208-C00667
         		3-(3,4- dimethoxy- phenyl)-N-(2- pyridylmeth- yl)imidazo[1,2- b]pyridazin- 6-amine 0.494462769 2.56 BF000147233
    Figure US20240041868A1-20240208-C00668
         		N- tetrahydro- pyran-4-yl-3- (3,4,5- trimethoxy- phenyl)imi- dazo[1,2- b]pyridazin- 6-amine 0.503383229 1.78 BF000147394 (229_0242_0087)
    Figure US20240041868A1-20240208-C00669
         		3-[[3-(4- pyridyl)imi- dazo[1,2- b]pyridazin- 6- yl]amino]pro- pan-1-ol 0.538085737 0.44 BF000722253
    Figure US20240041868A1-20240208-C00670
         		3-[6- (propylamino) imidazo[1,2- b]pyridazin- 3-yl]phenol 0.59230731 2.86 BF000147075 (229_0226_0284)
    Figure US20240041868A1-20240208-C00671
         		2-methoxy- 4-[6-(1- methyl- pyrazol-4- yl)imidazo[1,2- a]pyrazin-3- yl]phenol 0.624331939 1.11 BF000333452 (388_0314_8400)
    Figure US20240041868A1-20240208-C00672
         		(2S)-3- methyl-2- [[3-(4- pyridyl)imi- dazo[1,2- b]pyridazin- 6- yl]amino]bu- tan-1-ol 0.630941398 1.68 BF000817097
    Figure US20240041868A1-20240208-C00673
         		1-[3-[6-(3- hydroxypro- pylamino)imi- dazo[1,2- b]pyridazin- 3- yl]phenyl]eth- anone 0.64498853 1.21 BF000817098
    Figure US20240041868A1-20240208-C00674
         		3-[[3-(1,3- benzodioxol- 5- yl)imidazo[1,2- b]pyridazin- 6- yl]amino]pro- pan-1-ol 0.707789559 1.28 BF000146218 (229_0248_0068)
    Figure US20240041868A1-20240208-C00675
         		5-[6-[3- (dimethyl- amino)pro- poxy]- 3-pyridyl]- 3-(3,4,5- trimethoxy- phenyl)pyridin- 2-amine 0.709144298 2.64 BF000312521 (382_0087_0002)
    Figure US20240041868A1-20240208-C00676
         		3-(3,4- dimethoxy- phenyl)-N-(2- thienylmeth- yl)imidazo[1,2- b]pyridazin- 6-amine 0.721406376 3.61 BF000146992
    Figure US20240041868A1-20240208-C00677
         		3-[[3-(3,4- dimethoxy- phenyl)imi- dazo[1,2- b]pyridazin- 6- yl]amino]pro- pan-1-ol 0.72516936 1.34 BF000146224
    Figure US20240041868A1-20240208-C00678
         		N-[3-[6-(4- pyridyl)imi- dazo[1,2- b]pyridazin- 3- yl]phenyl]acet- amide 0.740677454 2.27 BF000817142
    Figure US20240041868A1-20240208-C00679
         		(2S)-2-[[3- (3,4- dimethoxy- phenyl)imi- dazo[1,2- b]pyridazin- 6-yl]amino]- 3-methyl- butan-1-ol 0.742215008 2.59 BF000147413 (229_0254_0079)
    Figure US20240041868A1-20240208-C00680
         		N-[3-[6- [[(1S)-1- (hydroxy- methyl)-2- methyl- propyl]amino] imidazo[1,2- b]pyridazin- 3- yl]phenyl]acet- amide 0.791967537 2.14 BF000146300 (229_0254_0081)
    Figure US20240041868A1-20240208-C00681
         		3-(3- methoxy- phenyl)-N- tetrahydro- pyran-4-yl- imidazo[1,2- b]pyridazin- 6-amine 0.828721524 2.09 BF000146183 (229_0242_4140)
    Figure US20240041868A1-20240208-C00682
         		3-[3-(4- hydroxy- phenyl)imi- dazo[1,2- a]pyrazin-6- yl]-N,N- dimethyl- benzamide 0.870676961 2.14 BF000333343 (388_0080_0349)
    Figure US20240041868A1-20240208-C00683
         		4-[6-(1,3- benzodioxol- 5- ylmethyl- amino)imi- dazo[1,2- b]pyridazin- 3-yl]-2- methoxy- phenol 1.308570599 3.17 BF000146126
    Figure US20240041868A1-20240208-C00684
         		3-(3- aminophenyl)- N- tetrahydro- pyran-4-yl- imidazo[1,2- b]pyridazin- 6-amine 1.423322773 1.42 BF000146142 (229_0242_0005)
    Figure US20240041868A1-20240208-C00685
         		1-[3-[6-(1,3- benzodioxol- 5- ylmethyl- amino)imi- dazo[1,2- b]pyridazin- 3- yl]phenyl]eth- anone 3.189566346 3.19 BF000147140
    Figure US20240041868A1-20240208-C00686
         		N-(1,3- benzodioxol- 5- ylmethyl)-3- (3,4- dimethoxy- phenyl)imi- dazo[1,2- b]pyridazin- 6-amine 6.216010093 3.32 BF000146114
    Figure US20240041868A1-20240208-C00687
         		4-[2-amino- 5-(4- piperazin-1- ylphenyl)-3- pyridyl]-2- methoxy- phenol 0.060908784 2.93 BF000707279
    Figure US20240041868A1-20240208-C00688
         		N-benzyl-5- (3- pyridyl)imi- dazo[2,1- b][1,3,4]thia- diazol-2- amine 0.633579663 3.01 BF000714845 (699_0232_0071)
    Figure US20240041868A1-20240208-C00689
         		3-[2- (benzyl- amino)imi- dazo[2,1- b][1,3,4]thia- diazol-5-yl]- N,N- dimethyl- benzamide 1.233285044 3.53 BF000714847 (699_0232_0349)
    Figure US20240041868A1-20240208-C00690
         		N-benzyl-5- (5-methoxy- 3- pyridyl)imi- dazo[2,1- b][1,3,4]thia- diazol-2- amine 0.217465905 2.86 BF000714862 (699_0232_0196)
    Figure US20240041868A1-20240208-C00691
         		5-(5- methoxy-3- pyridyl)-N- (tetrahydro- pyran-4- ylmethyl)imi- dazo[2,1- b][1,3,4]thia- diazol-2- amine 0.292588141 1.55 BF000714923 (699_0243_0196)
    Figure US20240041868A1-20240208-C00692
         		N-(1,3- benzodioxol- 5- ylmethyl)-5- (5-methoxy- 3- pyridyl)imi- dazo[2,1- b][1,3,4]thia- diazol-2- 0.289073347 2.48 BF000714981 (699_0236_0196)
    amine
    Figure US20240041868A1-20240208-C00693
         		N,N- dimethyl-3- [2- (tetrahydro- pyran-4- ylmethyl- amino)imi- dazo[2,1- b][1,3,4]thia- diazol-5- yl]benzamide 1.363919415 2.23 BF000715802 (699_0243_0349)
    Figure US20240041868A1-20240208-C00694
         		3-[2-(1,3- benzodioxol- 5- ylmethyl- amino)imi- dazo[2,1- b][1,3,4]thia- diazol-5-yl]- N,N- dimethyl- 1.925583132 3.15 BF000717214
    benzamide
    Figure US20240041868A1-20240208-C00695
         		2-methoxy- 4-[2- (tetrahydro- pyran-4- ylmethyl- amino)imi- dazo[2,1- b][1,3,4]thia- diazol-5- yl]phenol 0.710456332 2.47 BF000717555 (699_0243_0314)
    Figure US20240041868A1-20240208-C00696
         		3-[3-[3- (hydroxy- methyl)phenyl] imidazo[1,2- b]pyridazin- 6-yl]phenol 1.166257347 3.18 BF000726195 (828_0291_0284)
    Figure US20240041868A1-20240208-C00697
         		N-[3-[3-(3- acetamido- phenyl)imi- dazo[1,2- b]pyridazin- 6- yl]phenyl]acet- amide 0.647620035 2.73 BF000726346 (828_0081_0081)
    Figure US20240041868A1-20240208-C00698
         		3-[6-(4- pyridyl)imi- dazo[1,2- b]pyridazin- 3-yl]phenol 0.342140497 2.73 BF000726352 (828_0284_0069)
    Figure US20240041868A1-20240208-C00699
         		[3-[6-(4- pyridyl)imi- dazo[1,2- b]pyridazin- 3- yl]phenyl]meth- anol 0.972914631 2.27 BF000726364
    Figure US20240041868A1-20240208-C00700
         		[3-[6-(3,4- dimethoxy- phenyl)imi- dazo[1,2- b]pyridazin- 3- yl]phenyl]meth- anol 0.892824216 3.17 BF000726366 (828_0291_0079)
    Figure US20240041868A1-20240208-C00701
         		N-[3-[3-[3- (hydroxy- methyl)phenyl] imidazo[1,2- b]pyridazin- 6- yl]phenyl]acet- amide 1.516622765 2.72 BF000726367 (828_0291_0081)
    Figure US20240041868A1-20240208-C00702
         		4-[6-(3,4- dimethoxy- phenyl)imi- dazo[1,2- b]pyridazin- 3-yl]-2- methoxy- phenol 0.039407867 3.48 BF000726453 (828_0314_0079)
    Figure US20240041868A1-20240208-C00703
         		N-[3-[3-(4- hydroxy-3- methoxy- phenyl)imi- dazo[1,2- b]pyridazin- 6- yl]phenyl]acet- amide 0.103548636 3.03 BF000726454 (828_0314_0081)
    Figure US20240041868A1-20240208-C00704
         		1-[3-[6-[3- (hydroxy- methyl)phenyl] imidazo[1,2- b]pyridazin- 3- yl]phenyl]eth- anone 0.290543095 3.04 BF000726471 (828_4145_0291)
    Figure US20240041868A1-20240208-C00705
         		4-[6-[4- (hydroxy- methyl)phenyl] imidazo[1,2- b]pyridazin- 3-yl]-2- methoxy- phenol 0.061804045 3.02 BF000726486 828_0314_0285)
    Figure US20240041868A1-20240208-C00706
         		4-[6-[3- (hydroxy- methyl)phenyl] imidazo[1,2- b]pyridazin- 3-yl]-2- methoxy- phenol 0.062959987 3.02 BF000726487 (828_0314_0291)
    Figure US20240041868A1-20240208-C00707
         		2-methoxy- 4-[6-(4- pyridyl)imi- dazo[1,2- b]pyridazin- 3-yl]phenol 0.079413853 2.57 BF000817169
    Figure US20240041868A1-20240208-C00708
         		3-(4- pyridyl)-N- (2- pyridylmeth- yl)imidazo[1,2- b]pyridazin- 6-amine 0.170100794 1.66 BF000817170
    Figure US20240041868A1-20240208-C00709
         		3,5- bis(3,4,5- trimethoxy- phenyl)pyridin- 2-amine 0.08540726 2.87 BF000817175
    Figure US20240041868A1-20240208-C00710
         		4-[2-amino- 5-[4-(4- isopropylpiper- azin-1- yl)phenyl]-3- pyridyl]-2- methoxy- phenol 0.078146017 4.08 BF000817185
    Figure US20240041868A1-20240208-C00711
         		4-[3-(4- hydroxy-3- methoxy- phenyl)imi- dazo[1,2- b]pyridazin- 6-yl]-2- methoxy- phenol 0.02944792 3.33 BF000817186
    Figure US20240041868A1-20240208-C00712
         		[3-[3-[3- (hydroxymeth- yl)phenyl]imi- dazo[1,2- b]pyridazin- 6- yl]phenyl]meth- anol 0.828494158 2.72 BF000817188
    Figure US20240041868A1-20240208-C00713
         		5-(3,4- dimethoxy- phenyl)-N- (tetrahydro- pyran-4- ylmethyl)imi- dazo[2,1- b][1,3,4]thia- diazol-2- amine 1.026007749 2.61 BF000817208
    Figure US20240041868A1-20240208-C00714
         		N-[3-[6-[3- (hydroxy- methyl)phe- nyl]imidazo[1,2- b]pyridazin- 3- yl]phenyl]acet- amide 0.435155145 2.72 BF000817329
    Figure US20240041868A1-20240208-C00715
         		4-[2-amino- 5-(4- morpholino- phenyl)-3- pyridyl]-2- methoxy- phenol 0.212232208 3.24 BF000817413
    Figure US20240041868A1-20240208-C00716
         		5-[6-amino- 5-[4-(4- methylpiper- azin-1- yl)phenyl]- 3-pyridyl]-2- methoxy- phenol 9.65 3.31 BF000817418

Claims (11)

1. A compound of formula (I):
Figure US20240041868A1-20240208-C00717
wherein:
R1 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate, and
R2 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.
2. A method of treating, or slowing progression of, a disease associated with Fyn kinase, said method comprising administering a therapeutically effective amount of at least one compound according to claim 1, or pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof.
Figure US20240041868A1-20240208-C00718
3. The compound of claim 1, wherein the compound is selected from the group consisting of 3-[2-amino-5-(3,4-dimethoxyphenyl-3 pyridyl]phenol, 3-[6-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]-N-(2-hydroxyethyl)benzamide, 5-(3-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[2-amino-5-(4-methylsulfonylphenyl)-3-pyridyl]-2-methoxy-phenol, 4-[2-amino-5-(p-tolyl)-3-pyridyl]-2-methoxy-phenol, 4-[2-amino-5-(3-chlorophenyl)-3-pyridyl]-2-methoxy-phenol, 4-[2-amino-5-(3-fluorophenyl)-3-pyridyl]-2-methoxy-phenol, 4-(2-amino-5-phenyl-3-pyridyl)-2-methoxy-phenol, 4-[6-amino-5-(4-hydroxy-3-methoxy-phenyl)-3-pyridyl]-2,6-dimethyl-phenol, 4-[2-amino-5-(4-fluorophenyl)-3-pyridyl]-2-methoxy-phenol, 4-[2-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]-2-methoxy-phenol, 4-[6-amino-5-[4-(methoxymethoxy)phenyl]-3-pyridyl] benzamide, 3-[6-amino-5-[4-(methoxymethoxy)phenyl]-3-pyridyl]phenyl]methanol, 3-[6-amino-5-[4-(methoxymethoxy)phenyl]-3-pyridyl]benzamide, N-[3-[6-amino-5-[4-(methoxymethoxy)phenyl]-3-pyridyl]phenyl]acetamide, 4-[6-amino-5-[4-(hydroxymethyl)phenyl]-3-pyridyl]-2,6-dimethyl-phenol, 3-[4-(methoxymethoxy)phenyl]-5-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 3-[2-amino-5-(4-morpholinophenyl)-3-pyridyl]phenol, N-[3-[6-amino-5-(4-hydroxyphenyl)-3-pyridyl]phenyl]acetamide, 4-[2-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]phenol, 4-[2-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]phenol, 3-[2-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]phenol, 4-[2-amino-5-(4-methylsulfonylphenyl)-3-pyridyl]phenol, 3-(3-aminophenyl)-5-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[2-amino-5-(3-methoxyphenyl)-3-pyridyl]phenol, 4-[6-amino-5-(4-pyridyl)-3-pyridyl]-2,6-dimethyl-phenol, 5-[6-[3-(dimethylamino)propoxy]-3-pyridyl]-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 5-(3-fluorophenyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]-2,6-dimethyl-phenol, N-[3-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]phenyl]methanesulfonamide, 5-phenyl-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 3-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]-N-(2-hydroxyethyl)benzamide, 5-(4-aminophenyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]phenol, 5-(4-fluorophenyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]-N-cyclopropyl-benzamide, 5-(benzothiophen-2-yl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 3-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]phenol, 5-(6-methoxy-3-pyridyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 5-[3-(dimethylamino)phenyl]-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, [3-[6-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]phenyl]-(4-methylpiperazin-1-yl)methanone, 4-[6-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]-2-methoxy-phenol, 3-[3-(dimethylamino)phenyl]-5-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[6-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]-2,6-dimethyl-phenol, 3-[3-(dimethylamino)phenyl]-5-(3-pyridyl)pyridin-2-amine, [3-[6-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]phenyl]methanol, 3-[3-(dimethylamino)phenyl]-5-[6-[3-(dimethylamino)propoxy]-3-pyridyl]pyridin-2-amine, 3-[6-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]benzamide, 5-(3,4-dimethoxyphenyl)-3-[3-(dimethylamino)phenyl]pyridin-2-amine, 4-[2-amino-5-(3-chloro-4-fluoro-phenyl)-3-pyridyl]-2-methoxy-phenol, 5-(4-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[2-amino-5-(4-methoxyphenyl)-3-pyridyl]-2-methoxy-phenol, 5-(3-furyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 5-(2-phenoxyphenyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]benzamide, 4-[2-amino-5-(3-methoxyphenyl)-3-pyridyl]-2-methoxy-phenol, [4-[2-amino-5-(3,4-dimethoxyphenyl)-3-pyridyl]phenyl]methanol, 5-[4-(4-methylpiperazin-1-yl)phenyl]-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 3-[6-amino-5-(3,4,5-trimethoxyphenyl)-3-pyridyl]benzamide, 1-[5-[6-amino-5-[3-(dimethylamino)phenyl]-3-pyridyl]-2-thienyl]ethanone, 5-(4-methylsulfonylphenyl)-3-(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[6-amino-5-(4-hydroxyphenyl)-3-pyridyl]benzamide, 4-[2-amino-5-[4-(4-methylpiperazin-1-yl)phenyl]-3-pyridyl]phenol, 4-[2-amino-5-[4-(4-methylpiperazin-1-yl)phenyl]-3-pyridyl]-2-methoxy-phenol, 4-[6-amino-5-(4-hydroxy-3-methoxy-phenyl)-3-pyridyl]benzamide, 4-[2-amino-5-(4-piperazin-1-ylphenyl)-3-pyridyl]-2-methoxy-phenol, 3,5-bis(3,4,5-trimethoxyphenyl)pyridin-2-amine, 4-[2-amino-5-[4-(4-isopropylpiperazin-1-yl)phenyl]-3-pyridyl]-2-methoxy-phenol, 4-[2-amino-5-(4-morpholinophenyl)-3-pyridyl]-2-methoxy-phenol, and 5-[6-amino-5-[4-(4-methylpiperazin-1-yl)phenyl]-3-pyridyl]-2-methoxy-phenol.
4. A compound of formula (II):
Figure US20240041868A1-20240208-C00719
wherein:
R1 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate, and
R2 is selected from the group consisting of H, alkyl, alkenyl, alkylene, alkynyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclenyl, wherein each of the alkyl, alkenyl, alkylene, alkynyl, alkynylalkyl, aryl, arylalkyl, alkylaryl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclic moieties can be substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of acyl, alcohol, alkyl, aryl, aroyl, alkoxy, aryloxy, arylalkyloxy, alkylthio, arylthio, aralkylthio, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, cyano, hydroxyalkyl, amide, amine, thiol, thiophene, pyrrole, furan, alkylsulfate, arylsulfate, alkylphosphate and arylphosphate.
5. A method of treating, or slowing progression of, a disease associated with Fyn kinase, said method comprising administering a therapeutically effective amount of at least one compound according to claim 4, or pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof.
Figure US20240041868A1-20240208-C00720
6. The compound of claim 4, wherein the compound is selected from the group consisting of N-(2-hydroxyethyl)-4-[3-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 3-[3-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]-N,N-dimethyl-benzamide, 4-[6-[4-(4-isopropylpiperazin-1-yl)phenyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[6-(1-benzylpyrazol-4-yl)imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[3-(2-thienyl)imidazo[1,2-a] pyrazin-6-yl]phenol, 3,6-bis(2-thienyl)imidazo[1,2-a]pyrazine, N-(2-hydroxyethyl)-3-[3-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, N-cyclopropyl-4-[3-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[6-[4-(4-methylpiperazin-1-yl)phenyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[6-(6-amino-3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 5-[3-(2-thienyl)imidazo[1,2-a]pyrazin-6-yl]pyridin-2-amine, 4-[3-(3-acetylphenyl)imidazo[1,2-a]pyrazin-6-yl]-N-(2-dimethylaminoethyl)benzamide, N-(2-dimethylaminoethyl)-4-[3-(2-thienyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[3-(3,5-dimethoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]-N-[3-(dimethylamino)propyl]benzamide, N-(2-dimethylaminoethyl)-4-[3-(4-pyridyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[6-[2-(dimethylamino)phenyl]imidazo[1,2-a]pyrazin-3-yl]-2-methoxy-phenol, N-(2-hydroxyethyl)-3-[3-(4-hydroxy-3-methoxy-phenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 2-methoxy-4-[6-(3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[6-(2-chlorophenyl)imidazo[1,2-a]pyrazin-3-yl]-2-methoxy-phenol, 4-[6-(3-ethoxyphenyl)imidazo[1,2-a]pyrazin-3-yl]-2-methoxy-phenol, N-(2-dimethylaminoethyl)-4-[3-(4-hydroxy-3-methoxy-phenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[6-(6-amino-3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]-2-methoxy-phenol, 2-methoxy-4-[6-[6-(4-methylpiperazin-1-yl)-3-pyridyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 2-methoxy-4-[6-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyrazin-3-yl]phenol, N-[3-[3-(3,4,5-trimethoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]phenyl]methanesulfonamide, N-[3-(dimethylamino)propyl]-4-[3-(4-hydroxy-3-methoxy-phenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 2-methoxy-4-[6-[6-(2-morpholinoethylamino)-3-pyridyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 6-(1-methylpyrazol-4-yl)-3-(3-thienyl)imidazo[1,2-a]pyrazine, 6-phenyl-3-(3-thienyl)imidazo[1,2-a]pyrazine, [4-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]phenyl]methanol, 4-[3-(4-methoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]phenol, 6-(3-pyridyl)-3-(3-thienyl)imidazo[1,2-a]pyrazine, 3-(4-pyridyl)-6-(2-thienyl)imidazo[1,2-a]pyrazine, 4-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]phenol, 6-(2-thienyl)-3-(3-thienyl)imidazo[1,2-a]pyrazine, N-[3-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]phenyl]acetamide, N-[3-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]phenyl]methanesulfonamide, 6-(2-furyl)-3-(3-thienyl)imidazo[1,2-a]pyrazine, 3-(6-phenylimidazo[1,2-a]pyrazin-3-yl)phenol, 3-[3-(3-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[6-(3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]phenol, [4-[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]phenyl]methanol, 4-[6-(4-chlorophenyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 3-[6-(2-thienyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 6-(1-methylpyrazol-4-yl)-3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazine, 3-[6-(2-furyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[6-(6-methoxy-3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 3-[6-[4-(hydroxymethyl)phenyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 3-[6-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[6-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyrazin-3-yl]phenol, 6-[6-(4-methylpiperazin-1-yl)-3-pyridyl]-3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazine, N-(2-hydroxyethyl)-3-[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, N-(2-dimethylaminoethyl)-4-[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, N-(2-hydroxyethyl)-4-[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[3-(3-chlorophenyl)imidazo[1,2-a]pyrazin-6-yl]-N-[3-(dimethylamino)propyl]benzamide, 5-[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]pyridin-2-amine, N-[3-(dimethylamino)propyl]-4-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 3-(4-methoxyphenyl)-6-[4-(4-methylpiperazin-1-yl)phenyl]imidazo[1,2-a]pyrazine, N-(2-hydroxyethyl)-3-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 6-[6-(4-methylpiperazin-1-yl)-3-pyridyl]-3-(3-thienyl)imidazo[1,2-a]pyrazine, 5-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]pyridin-2-amine, 3,6-bis(3-thienyl)imidazo[1,2-a]pyrazine, N-(2-dimethylaminoethyl)-4-[3-(3-thienyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 3-(1-methylpyrazol-4-yl)-6-(2-phenoxyphenyl)imidazo[1,2-a]pyrazine, 3-[6-[6-(4-methylpiperazin-1-yl)-3-pyridyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 3-[[5-[3-(1,3-benzodioxol-5-yl)imidazo[1,2-a]pyrazin-6-yl]-2-pyridyl]oxy]-N,N-dimethyl-propan-1-amine, 3-[6-(3-ethoxyphenyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 3-(1,3-benzodioxol-5-yl)-6-[4-(4-methylpiperazin-1-yl)phenyl]imidazo[1,2-a]pyrazine, 3-[6-(3-thienyl)imidazo[1,2-a]pyrazin-3-yl]phenol, 3-[6-[4-(4-methylpiperazin-1-yl)phenyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[3-(4-chlorophenyl)imidazo[1,2-a]pyrazin-6-yl]-N-[3-(dimethylamino)propyl]benzamide, 4-[3-(1,3-benzodioxol-5-yl)imidazo[1,2-a]pyrazin-6-yl]-N-(2-dimethylaminoethyl)benzamide, 3-[6-(6-amino-3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]phenol, N-(2-dimethylaminoethyl)-4-[3-(3-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[3-(4-chlorophenyl)imidazo[1,2-a]pyrazin-6-yl]-N-(2-dimethylaminoethyl)benzamide, 3-[6-[6-(2-morpholinoethylamino)-3-pyridyl]imidazo[1,2-a]pyrazin-3-yl]phenol, N-[3-(dimethylamino)propyl]-4-[3-(3-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, N-(2-hydroxyethyl)-4-[3-(3-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, 4-[3-(1,3-benzodioxol-5-yl)imidazo[1,2-a]pyrazin-6-yl]-N-[3-(dimethylamino)propyl]benzamide, 6-[6-(4-methylpiperazin-1-yl)-3-pyridyl]-3-phenyl-imidazo[1,2-a]pyrazine, 3-[6-[4-(4-isopropylpiperazin-1-yl)phenyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 5-[3-(1,3-benzodioxol-5-yl)imidazo[1,2-a]pyrazin-6-yl]pyridin-2-amine, 4-[6-[6-[3-(dimethylamino)propoxy]-3-pyridyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[6-[6-(2-morpholinoethylamino)-3-pyridyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 4-[6-[6-(4-methylpiperazin-1-yl)-3-pyridyl]imidazo[1,2-a]pyrazin-3-yl]phenol, 3-[2-(cyclohexylamino)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-N,N-dimethyl-benzamide, N-[2-(dimethylamino)ethyl]-4-[3-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, N-[2-(dimethylamino)ethyl]-4-[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, N-[3-(dimethylamino)propyl]-4-[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, N-[2-(dimethylamino)ethyl]-4-[3-(4-hydroxy-3-methoxy-phenyl)imidazo[1,2-a]pyrazin-6-yl]benzamide, and 4-[6-[[(1S)-1-(hydroxymethyl)-2-methyl-propyl]amino]imidazo[1,2-b]pyridazin-3-yl]-2-methoxy-phenol.
7-23. (canceled)
24. A method of ameliorating or preventing a disorder associated with Fyn kinase, said method comprising administering a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt or solvate of the compound to a patient in need thereof, wherein the compound is selected from the group consisting of compounds comprising an SFK40 pharmacore or an SFK43 pharamcore.
25. The method of claim 24, wherein the disease associated with Fyn kinase is selected from the group of disorders consisting of Type I diabetes, Type II diabetes, pre-diabetes, breast cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric cancer, liver cancer, bowel cancer, melanoma, Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease.
26-28. (canceled)
29. A method for ameliorating and improving physiologic functions associated with Fyn kinase, said method comprising administering an effective amount of at least one compound, or pharmaceutically acceptable salt or solvate of the compound to a subject in need thereof, wherein the compound is selected from the group consisting of compounds comprising an SFK40 pharmacore or an SFK43 pharamcore.
US18/328,364 2015-09-09 2023-06-02 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors Pending US20240041868A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/328,364 US20240041868A1 (en) 2015-09-09 2023-06-02 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562216349P 2015-09-09 2015-09-09
PCT/US2016/050776 WO2017044623A1 (en) 2015-09-09 2016-09-08 Methods, compositions, and uses of novel fyn kinase inhibitors
US201815758274A 2018-03-07 2018-03-07
US16/896,663 US11701353B2 (en) 2015-09-09 2020-06-09 Methods, compositions, and uses of novel FYN kinase inhibitors
US18/328,364 US20240041868A1 (en) 2015-09-09 2023-06-02 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16/896,663 Continuation US11701353B2 (en) 2015-09-09 2020-06-09 Methods, compositions, and uses of novel FYN kinase inhibitors

Publications (1)

Publication Number Publication Date
US20240041868A1 true US20240041868A1 (en) 2024-02-08

Family

ID=58240846

Family Applications (3)

Application Number Title Priority Date Filing Date
US15/758,274 Active US10688093B2 (en) 2015-09-09 2016-09-08 Methods, compositions, and uses of novel Fyn kinase inhibitors
US16/896,663 Active US11701353B2 (en) 2015-09-09 2020-06-09 Methods, compositions, and uses of novel FYN kinase inhibitors
US18/328,364 Pending US20240041868A1 (en) 2015-09-09 2023-06-02 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US15/758,274 Active US10688093B2 (en) 2015-09-09 2016-09-08 Methods, compositions, and uses of novel Fyn kinase inhibitors
US16/896,663 Active US11701353B2 (en) 2015-09-09 2020-06-09 Methods, compositions, and uses of novel FYN kinase inhibitors

Country Status (11)

Country Link
US (3) US10688093B2 (en)
EP (1) EP3347462A4 (en)
JP (1) JP2018531916A (en)
KR (1) KR20180064403A (en)
CN (1) CN108368494A (en)
AU (1) AU2016321218A1 (en)
BR (1) BR112018004585A2 (en)
CA (1) CA2998397A1 (en)
HK (1) HK1258996A1 (en)
MX (1) MX2018002916A (en)
WO (1) WO2017044623A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
WO2020047037A1 (en) * 2018-08-31 2020-03-05 Nivien Therapeutics Company Novel heteroaromatic compounds as potent modulators of the hippo-yap signaling pathway lats1/2 kinases
WO2021115560A1 (en) * 2019-12-09 2021-06-17 Rottapharm Biotech S.R.L. New fyn and vegfr2 kinase inhibitors
CN115087657A (en) * 2019-12-18 2022-09-20 加利福尼亚大学董事会 LIN28 inhibitor and method of use thereof
CN111171064B (en) * 2020-01-09 2022-09-16 上海健康医学院 Azafluoroborodipyrrole compound, preparation method thereof and application thereof as Fyn kinase inhibitor
KR20220034454A (en) 2020-09-11 2022-03-18 한국과학기술연구원 A pharmaceutical composition for preventing, treating or alleviation of cancer comprising FYN kinase inhibitor and additional kinase inhibitor
EP4210697A1 (en) * 2020-09-14 2023-07-19 The University of Sussex Small molecule inhibitors of lemur tyrosine kinase 3
WO2022132936A1 (en) * 2020-12-15 2022-06-23 Children's Hospital Medical Center Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2022148821A1 (en) * 2021-01-07 2022-07-14 Locki Therapeutics Limited Usp7 binding survival-targeting chimeric (surtac) molecules & uses thereof
WO2023083330A1 (en) * 2021-11-12 2023-05-19 百极优棠(广东)医药科技有限公司 Drak2 inhibitor, and preparation method therefor and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3864040D1 (en) 1987-03-06 1991-09-12 Micro Mega Sa DENTAL HANDPIECE.
MXPA03008560A (en) * 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Single-stage pfc + ballast control circuit/general purpose power converter.
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US7750000B2 (en) * 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
CN101365695A (en) * 2005-09-20 2009-02-11 阿斯利康(瑞典)有限公司 Quinazoline derivatives as anticancer agents
EP2044084B1 (en) 2006-07-13 2016-02-17 Janssen Pharmaceutica NV Mtki quinazoline derivatives
JP5721426B2 (en) * 2007-04-05 2015-05-20 ザ ジェイ．ディヴィッド グラッドストン インスティテューツ How to identify drugs that relieve excessive nerve excitement
CN102159948B (en) 2008-07-22 2014-06-25 普罗美加公司 Adp detection based luminescent phosphotransferase or atp hydrolase determination
US9180127B2 (en) * 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
WO2011119199A1 (en) 2010-03-22 2011-09-29 Albert Einstein College Of Medicine Of Yeshiva University Method of supressing cancer, increasing weight loss and/or increasing insulin sensitivity
PL3597644T3 (en) * 2011-10-18 2022-01-17 Dicerna Pharmaceuticals, Inc. Amine cationic lipids and uses thereof
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5

Also Published As

Publication number Publication date
US20180250297A1 (en) 2018-09-06
AU2016321218A1 (en) 2018-03-29
HK1258996A1 (en) 2019-11-22
EP3347462A1 (en) 2018-07-18
US11701353B2 (en) 2023-07-18
KR20180064403A (en) 2018-06-14
BR112018004585A2 (en) 2018-09-25
CA2998397A1 (en) 2017-03-16
JP2018531916A (en) 2018-11-01
WO2017044623A1 (en) 2017-03-16
EP3347462A4 (en) 2019-08-14
US10688093B2 (en) 2020-06-23
MX2018002916A (en) 2018-09-12
CN108368494A (en) 2018-08-03
US20210030753A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
US11701353B2 (en) Methods, compositions, and uses of novel FYN kinase inhibitors
Preti et al. History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents
US7776865B2 (en) Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US20160113893A1 (en) New therapeutic uses of enzyme inhibitors
US8669259B2 (en) Heterocyclic amide compounds as protein kinase inhibitors
US20150239905A1 (en) Imidazopyridine compounds
US10633369B2 (en) Method of inhibiting DYRK1B
US20070117804A1 (en) Imidazopyrazines as protein kinase inhibitors
US20070105864A1 (en) Methods for inhibiting protein kinases
US20080027063A1 (en) Imidazopyrazines as protein kinase inhibitors
TW201000481A (en) Novel phenylimidazole derivatives as PDE10A enzyme inhibitors
US20090143391A1 (en) Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10
US10744128B2 (en) 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
US20200397764A1 (en) Vap-1 inhibitors for treating pain
KR20120112460A (en) Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors
US20230014445A1 (en) Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
US11466013B2 (en) ERK inhibitor and use thereof
JP2021100972A (en) COMBINATIONS OF TGFβ INHIBITORS AND CDK INHIBITORS FOR THE TREATMENT OF CANCER
Poulsen et al. Designed macrocyclic kinase inhibitors

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: PATHWAYS NEURO PHARMA, INC., TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LAU, WARREN C.;REEL/FRAME:065854/0029

Effective date: 20230522